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Abstract 
 
DEAD-BOX (DDX) RNA helicases are a large family of proteins 
characterized by the presence of a DEAD/H (Asp-Glu-Ala-Asp/His) motif. 
Their main function is to unwind double stranded RNA to promote 
downstream molecular events. They are involved in virtually all steps of 
RNA metabolism such as transcription, translation, RNA export and 
degradation, ribosome biogenesis and pre-mRNA splicing. The aim of my 
work was to investigate the functions of human DDX3X and DDX54 RNA 
helicases, particularly in in vitro cancer models.  
 
To provide insight into their molecular functions, I identified RNAs bound 
by DDX3X and DDX54 in breast cancer (MCF7) cells by performing iCLIP 
experiments. This generated two very distinct RNA binding profiles: 
DDX3X preferentially bound exonic regions of mRNAs encoding 
translational factors, whilst DDX54 preferentially bound non-coding RNAs 
and intronic regions of mRNAs encoding nuclear proteins. Further 
bioinformatic analysis identified a few discrete binding motifs within 
DDX3X target RNAs. One of these, within the human JUND transcript, 
was validated as a DDX3X binding site using electrophoretic mobility shift 
assays.  
 
Notably, the levels of proteins encoded by mRNAs bound by DDX3X were 
altered following knockdown of the helicase. These data highlight the 
importance of DDX3X in maintaining appropriate levels of certain 
 proteins, which in turn may explain at least some of the changes in 
phenotype observed upon DDX3X knockdown. In this regard, I showed 
that knocking down DDX3X or DDX54 in MCF7 cells slowed cell 
proliferation by inducing a G1/S phase arrest. Furthermore, a 
CRISPR/Cas9 dropout screen in a leukaemia cell line (MLL-AF9) showed 
that both helicases are essential for growth of these cells. However, loss of 
DDX3X or DDX54 had little effect on proliferation of immortalized 
NIH3T3 cells indicating that their loss is not generally lethal. In 
subsequent CRISPR/Cas9 dropout screens in various other cancer cell 
lines, including some derived from solid tumours, DDX54 was found to be 
essential for growth of all cell lines. In contrast, DDX3X was required for 
proliferation of only a subset of these. Focusing on DDX3X, I identified 
that the integrity of the helicase's RNA binding domains is essential for 
growth and cell cycle progression of an acute myeloid leukaemia cell line 
(OCI-AML3). 
Overall, my findings shed mechanistic insight upon the role of DDX RNA 
helicases in cancer and identify DDX3X and DDX54 as potential targets 
for therapeutic intervention in certain cancers. 
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 1 
 
1 Chapter 1 - Introduction 
 
 
By integrating intrinsic and external information, cells coordinate 
multiple regulatory mechanisms to modulate gene expression. Control of 
gene expression occurs at two distinct levels: transcriptional and post-
transcriptional. Significant progress has been made in understanding how 
gene transcription is regulated, however much less is known concerning 
post-transcriptional control of RNA molecules. In eukaryotes, 
transcription and translation are two uncoupled processes which take 
place in different subcellular compartments: the nucleus and the 
cytoplasm respectively. This determines a complex network of newly 
transcribed pre-mRNA processing events, all of which constitute different 
steps of gene expression regulation. Post-transcriptional regulation 
includes events such as maturation, export, localization, turnover and 
translation of mRNAs. The regulation of each of these events determines 
the appropriate time and place at which a given protein is produced [1]. 
The overall aim of the work described in this thesis is to provide insight 
into the mechanisms underlying post-transcriptional regulation of gene 
expression. 
As soon as pre-mRNAs emerge from their sites of transcription they are 
targeted by a multiplicity of RNA binding proteins (RBPs) which mediate 
pre-mRNA processing reactions. The central role of RBPs in controlling 
gene expression at the post-transcriptional level, highlights their 
importance to the cell. By regulating post-transcriptional events, RBPs are 
instrumental in determining biological processes ranging from embryo 
development to differentiation [2-5]. 
RBPs bind primary transcripts and mediate processing of their 5’ and 3’ 
ends through addition of a cap structure and a poly(A) tail, respectively. 
They are also essential for assembly of the spliceosome, for intron 
selection and removal, and the joining of appropriate exons. Different 
 2 
RBPs bind RNA within the spliceosome to determine the sequence identity 
of the mature RNA. Transport of mature mRNAs to the cytoplasm for 
translation is also mediated by RBPs containing nuclear export signals 
(NES). In some cases, RBPs contain nuclear localization signals (NLS) as 
well and function as shuttles between the nucleus and the cytoplasm. 
Once in the cytoplasm, an assembly of cytoplasmic mRNA and RBPs 
(messenger ribonucleoproteins - mRNPs) bind to motor proteins. This 
event localizes the transcript at the relevant subcellular region for 
translation. mRNAs are then assembled with translational initiation 
factors and ribosomes and translated or, alternatively, stored in granule 
structures. mRNAs can either exit the storage bodies due to a 
translational activation signal or they can be eventually degraded [6-8] 
(Figure1.1). Thus, RBPs are critically important regulators of every post-
transcriptional step of gene expression. 
In the next sections, I describe the main steps of RNA metabolism from 
the perspective of RNA binding proteins (RBPs) that mediate the 
processes involved.  I will discuss the consequences of dysregulation of 
these processes, many of which have been shown to lead to cancer. 
Focused sections are dedicated to the description of RNA helicases and, in 
particular, two members of the DEAD-box RNA helicase subfamily, 
DDX54 and DDX3X. 
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Figure 1.1. RNA-binding proteins (RBPs) and RNA metabolism.  
RBPs are involved in every step of RNA metabolism from transcription to 
degradation. As soon as RNA is transcribed from DNA (pre-mRNA) (1) it becomes 
the target of maturation protein complexes that recognize sequence motifs within 
the transcript and mediate capping, splicing and polyadenylation events (2-3). 
The resulting mature transcript (mRNA) is then ready to be exported by means 
of other RBPs through the nuclear pores (4). Once in the cytoplasm (5), mRNAs 
are translated into proteins (6), stored (7-8) or degraded (9). Different RBP 
complexes mediate these events. (LSMs proteins are RNA chaperone ring-shaped 
proteins)[9]. 
 
 
  
 4 
1.1 mRNA metabolism: the long path of coding RNAs together with 
their protein partners 
 
1.1.1 pre-mRNA nuclear processing 
As transcription proceeds, nascent transcripts become available to be 
bound by proteins for pre-mRNA maturation. Newly transcribed RNAs 
undergo a series of modifications within the nucleus to produce a mature 
transcript that is ready for export to the cytoplasm and translation. The 
main and immediate pre-mRNA processing events are acquisition of a cap 
structure at the 5¢-end, splicing out of introns and generation of poly(A) 
tail at the 3¢-end. These reactions happen simultaneously with 
transcription [10] as many processing RBPs (such as capping factors 
(CFs), and 3ʹ-end processing/termination factors) are recruited to the 
carboxy-terminal domain (CTD) of transcribing RNA polymerase II 
complexes. As soon as the first 20–30 nucleotides of the pre-mRNA have 
been synthesized, a cap structure is added at its 5¢-end. This process 
requires the action of an RNA 5-triphosphatase (RTP) that hydrolyses the 
triphosphate of the first nucleotide to a diphosphate allowing a 
guanylyltransferase (GT) to catalyze the fusion of a GMP molecule. A 
methyltransferase ultimately methylates the N7 position of the 
transferred GMP. This cap structure is recognized by the cap binding 
complex (CBC) which plays a major role in the stabilization of the mRNA, 
avoiding 5¢-3¢ exonucleases activity [11, 12].  
Nascent transcripts are susceptible to additional modifications, such as 
adenosines to inosines (A-to-I) RNA editing. In this process RNA 
deaminases of the ADAR family (ADAR1, ADAR2 and ADAR3) convert 
specific adenosines to inosines (A-to-I) through hydrolytic deamination. 
The pre-mRNA substrate of editing is a double-stranded RNA (dsRNA) 
usually formed by imperfect base-pairing between an exon that contains 
the adenosine to be edited and an intronic non-coding element [13] [14]. 
The resulting inosine bases are read as guanosines by the translation 
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machinery, which can result in incorporation of an amino acid different to 
the one encoded by the genome. Aberrations of ADAR-dependent RNA 
editing are linked to cancer progression and growth: hyperactivation of 
ADAR1 has been linked to progression of breast and hepatocellular 
cancers, as well as to haematopoietic disorders such as myeloproliferative 
neoplasms (MPN) and chronic myeloid leukaemia (CML) [15-17].  
The addition of a poly(A) tail to the 3’-end of an RNA requires assembly of 
a multimeric and multifunctional RBP complex onto the pre-mRNA. 
Endonucleolytic cleavage occurs 10 – 30 nucleotides downstream of a 
highly conserved signal sequence (the AAUAAA hexamer) that is 
recognized by the cleavage and polyadenylation specificity factor (CPSF) 
[18, 19]. The addition of  a poly(A) tract at the 3’-end of the RNA  is then 
performed by  Poly(A) polymerase (PAP) which is loaded onto the pre-
mRNA together with the CPSF [20]. Poly(A) binding protein (PABP) binds 
the emerging poly(A) tail and in turn enhances the processivity of the 
poly(A) polymerase [21] [12]. Similarly to the 5¢-cap structure, 
polyadenylation of an RNA affects its nuclear transport, translation 
efficiency and stability [12, 22]. Studies have highlighted the importance 
of the poly(A) tail length in gene expression control. A large proportion of 
genes contain more than one polyadenylation site created as part of 
alternative polyadenylation processes. This phenomenon, generates 
mRNA isoforms that differ either in their coding sequence or in the length 
of their 3′ untranslated regions (UTRs). Interestingly, cancer cells express 
mRNA isoforms with shorter 3¢-UTRs [23, 24]. Since the 3¢-UTR is a target 
of predominantly negative regulatory factors, this generally results in 
production of excess of proteins. In gliomas, this phenomenon promotes 
cancer phenotype by causing an accumulation of transcripts encoding 
proteins involved in cellular proliferation [25].  
The next step in pre-mRNA maturation is RNA splicing. More than 90% of 
human coding genes contain multiple exons. The pre-mRNAs transcribed 
from those genes undergo splicing to generate mature mRNAs ready to be 
translated [26]. Splicing is carried out by a large macromolecular 
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machinery known as the spliceosome which consists of five small nuclear 
ribonucleoprotein complexes (snRNPs - U1, U2, U4, U5 and U6) 
responsible for the excision of non-coding introns from the pre-mRNA and 
joining of exons. The premature transcripts contain splicing recognition 
sequences at exon - intron boundaries (the 5′ splice site) and at intron – 
exon boundaries (the 3′ splice site). These are essential for targeting of the 
RNA by proteins within the spliceosome. Assembly of the splicing 
machinery initially requires interaction of U1 and U2 snRNPs with the 5’ 
splice and 3’ splice sites, which then recruits the U4/U6/U5 tri-snRNP to 
start the process [27] (Figure 1.2 A). Splicing can be constitutive or 
alternative depending on whether the splice sites are always or only 
sporadically recognized and spliced into mature mRNA. Although the 
same machinery is involved in both cases, different trans-acting RNA 
binding proteins govern recruitment of the spliceosome to the relevant 
alternative splice sites [28].  Among these RBPs include the 
serine/arginine-rich proteins (SR proteins) and the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) [29]. In general, SR proteins promote 
splicing (exon inclusion) whilst hnRNPs repress it (promote exon 
skipping), although SR proteins can also act as repressors in a context-
dependent manner [30] [31] [32](Figure 1.2 A). Notably, alternative 
splicing is observed on almost all human genes that contain multiple 
exons and this obviously expands the mature transcriptome as well as the 
subsequent proteome [33]. 
 
SR proteins are characterized by the presence of a C-terminal domain 
enriched in arginine (R) and serine (S) amino acids (RS domain) that 
mediate protein-protein interactions determining the recruitment of the 
spliceosome. SR proteins all possess at least one N-terminal RNA 
recognition domain (RRM domain), responsible for protein-RNA 
interaction[30]. RNA binding domains are discussed in the next section 
(Section 1.2) (Figure 1.2 B). 
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Figure 1.2. Constitutive and alternative splicing are performed by different 
RBPs.  
(A) Arrows indicate the protein-RNA interactions across exons, between the cap 
and poly A synthesis factors (CPSF/CstF) (upstream) and the introns (below). U1, 
U2 and U2AF snRNPs bind constitutive splicing recognition sequences at the 
exon/intron boundaries. SR proteins bind ESE positive (+) sites and hnRNP 
proteins bind ESS (-) negative sites of alternative splicing. (hnRNPs; green 
shaded ovals; SR: blue ovals; U1: pink shaded oval; U2 snRNP :yellow shaded 
oval; U2AF :beige shaded oval; ESE :light orange box; ESS : green box;  5′cap: 
dark green small oval; 3′-polyA machinery CPSF/CstF: dark pink ovals; Exons 
are shown as blue shaded boxes, and introns and 5′- and 3′-untranslated regions 
are shown as black lines) (exonic splicing enhancers-ESE; exonic splicing 
suppressors-ESS) [34] (B). SR proteins are responsible for alternative splicing. 
The panel shows the main known SR proteins and their structural domains 
(RRM, RRMH, RS, and Zn) [30]. 
 
 
  
A
B
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Splicing regulation is essential for cell growth, differentiation and 
development.  As a consequence, alterations of the splicing process play a 
role in cancer development. Spliceosomal mutations were initially 
discovered in haematological malignancies, including myelodysplastic 
syndromes (MDS) and chronic lymphocytic leukaemia (CLL) [35] [36, 37]. 
More recently they have also been identified in several solid tumour types 
[38-40]. Furthermore, both hnRNPs and SRs are mutated or deregulated 
in different cancers, including lung, colon and breast cancer and 
haematological malignancies, where they act as either onco-proteins or 
tumour suppressors [41] [35, 37, 40, 42, 43] . 
Upon excisions of introns and conjunction of exons, mature spliced mRNAs 
are bound by the exon junction complex (EJC). The EJC is a multiprotein 
complex organized around a central core of four proteins: eIF4A3 
(eukaryotic initiation factor 4A3), MAGOH, Y14 (also known as RNA-
binding motif 8A) and MLN51 (metastatic lymph node 51) [44]. The EJC is 
loaded onto mRNAs without sequence specificity. However, it does bind to 
a conserved position 24 nucleotides upstream of the spliced junctions [45]. 
The EJCs remain bound to the mRNA during its transport to the 
cytoplasm and until the translational initiation complex assembly causes 
it to dissociate from the mRNA [46]. During this time, the protein 
composition of the the EJC changes with different proteins associating or 
dissociating from it. These proteins are involved in different processes 
including splicing, transport, translation and non-sense mediated decay 
(NMD)[47-49]. This classifies the EJC as a bridging complex containing 
RNA binding proteins determining continuity between nuclear splicing 
and cytoplasmic processes. SR splicing factors 1, 3 and 7 (SRSF1, SRSF3, 
SRSF7) are associated with the EJC in both the nucleus and the 
cytoplasm [50]. The EJC also associates with the mRNP of the mRNA 
nuclear export factor TAP-p15, promoting passage of the newly matured 
mRNA through the nuclear pore towards the cytoplasm [47, 51]. 
Association of EJC with mature mRNA ready for nuclear export is 
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considered a mechanism of mRNA quality control that ensures only 
completely processed transcript can exit the nucleus [52, 53]. 
 
 
1.1.2 mRNA export  
mRNA export is a complex and dynamic process involving many different 
RBPs. The complexes composed by the target mRNA and translocating 
proteins are formed in the nucleus, transported through the nuclear pore 
and then released into the cytoplasm where the mRNA contacts more 
RBPs in order to be translated, degraded or temporarily stored [54].  
The two main pathways that mediate mRNA export across the nuclear 
pore complex (NPC) involve the NXF1-NXT1 (or TAP-p15) heterodimer 
and the exportin CRM1 (or XPO1). NXF1 is an RNA binding protein which 
assembles with the TRanscription-EXport complex 1 (TREX-1) to 
efficiently export mRNAs [55]. CRM1, is an export factor which does not 
possess intrinsic RNA binding domains and therefore needs an adaptor 
RBP in order to export mRNAs. NXF1-TREX1 and CRM1 are export 
receptors and they interact with the nucleoporins within the nuclear pore 
complex. This allows them to mediate translocation of mRNPs [56]. It is 
intuitive to predict that mRNA export is a vital step in regulating gene 
expression and therefore its mis-regulation may contribute to the 
development of cancer [57]. Indeed, deregulation of many components of 
the mRNP export machinery is correlated with different cancers. For 
example, CRM1 expression is elevated in gliomas, cervical and pancreatic 
cancers [58-60]. In addition, expression of components of the export 
complex TREX was found altered in oral, liver, pancreatic, lung, ovarian 
and colon cancers [61-64]. 
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1.1.3 mRNA cytoplasmic fates 
Once in the cytoplasm, the EJC bound to mRNPs is displaced by assembly 
of the translational initiation complex [46]. Persistence of the EJC on an 
mRNA indicates the presence of premature stop codons located up-stream 
of the EJC position [65]. Indeed, the best characterised function of EJC is 
its quality control of translation involving the nonsense mediated decay 
(NMD) pathway [66]. Normally, all EJCs are removed from transcripts 
after the first round of translation. When a transcript harbours premature 
translation termination codons, the presence of at least one EJC 
downstream of the stalled ribosome triggers NMD of the mRNA. 
Interestingly, since the EJC is loaded onto mRNAs within the nucleus 
during splicing, this suggests that mRNAs retaining premature 
termination codons could be marked for degradation even before getting to 
the cytoplasm [66].  
The NMD pathway quality controls transcripts to ensure that faulty 
transcripts are destroyed to prevent accumulation of truncated proteins 
[67]. Assembly of an NMD-activating complex on a premature stop codon-
containing mRNA requires the progressive recruitment of other RBPs 
along with the UPFs proteins, such as exonucleases and de-adenylases at 
the 3’ end, and de-capping factors at the 5’ end (de-capping enhancer Pro-
rich nuclear receptor co-activator 2 -PNRC2). It is unknown whether all of 
these events occur simultaneously or sequentially [68] [69] [70] [71]. 
Cancer can be triggered by non-sense mutations in tumour suppressor 
genes. The NMD pathway has shown its relevance in favouring these 
tumours by mediating degradation of premature termination codon-
containing mRNAs encoding tumour suppressors, such as TP53. [72].  
By engaging protein-protein interaction with the cytoskeletal molecular 
motor factors and binding mRNAs’ 3¢-UTRs at the same time, some RBPs 
can target transcripts to particular subcellular localizations before 
translation [73].  
Translation of mRNAs is probably the post-transcriptional process that 
involves the highest number of RBPs in a dynamic exchange of 
 11 
interactions. Translation can be divided into three phases: initiation, 
elongation and termination. Of all steps, translational initiation is so far, 
the most studied and best understood. Translational initiation is a 
complex multistep process and is the main target of translational control 
mechanisms (Figure 1.3). The first step in the initiation pathway is 
assembly the 43S pre-initiation complex (43S PIC). 43S PIC is a large 
multifactorial complex comprising the 40S ribosomal subunit, eukaryotic 
translation initiation factors (eIFs) eIF1, eIF1A, eIF3, eIF5 and the 
ternary complex (TC). The TC is formed by initiation factor 2, eIF2, the 
initiator methionyl-tRNA (tRNA Met) and GTP. The eIF4F complex, 
consisting of the mRNA 5ʹ-cap-binding subunit (eIF4E), the large 
scaffolding protein (eIF4G) and the DEAD box RNA helicase (eIF4A), is 
responsible for recruiting 43S PIC onto the mRNA via interactions 
between eIF4E–mRNA-cap and eIF4G–eIF3. Through the ATP-dependent 
action of eIF4A, the eIF4F complex assembles on the 5’-cap of the mRNA 
and unwinds secondary structures found in the 5’-UTR. Other factors 
(eIF4G) bridge the complex at the 5’ UTR to the poly-A tail at the 3’ end by 
interacting with the poly(A) binding protein (PABP). This causes mRNA 
circularization which stabilizes the transcript and stimulates translation. 
The 43S PIC complex scans the transcript in a 5¢ to 3¢ direction in search 
of the initiation codon. When the 43S PIC complex encounters an AUG 
codon embedded within a favourable sequence context (the Kozak 
sequence), base pairing between the initiation codon and the initiator 
tRNA in the ternary complex anticodon takes place. This event then 
triggers GTP hydrolysis by eIF2, which causes release of eIFs and joining 
of the large 60S ribosomal subunit to the 40S Met-tRNA-mRNA complex. 
Formation of a translation-competent 80S ribosome ends the translational 
initiation process and triggers subsequent elongation (Figure 1.3). 
During translational elongation, eEF1-aminoacyl-tRNA-GTP complexes 
bind to the ribosomal A site. Several steps involving codon-anticodon base 
pairing between the mRNA and the tRNA ensure that only the correct 
cognate tRNA is selected. Codon-anticodon base pairing induces eEF1-
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GTPase activity which determines release of the aminoacyl tRNA into the 
A site, ready to form a peptide bond. A peptide bond is formed between the 
incoming amino acid and the peptidyl tRNA in the P ribosome site. The 
translocation of the ribosome is catalysed by eIF2 GTP hydrolysis, which 
determines the exit of the deacylated tRNA from the E site, the 
repositioning of the peptidyl tRNA in the P site, and the mRNA movement 
by three nucleotides to place the next codon into the A site. This cycle is 
repeated until a stop codon enters the A ribosomal site. At this stage, the 
completed polypeptide is released following the activity of GTP-ase release 
factors that hydrolyse the ester bond that links the polypeptide chain to 
the P site tRNA [74]. 
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Figure 1.3. Translational initiation complex assembly.  
The ternary complex (TC) assembles by the interaction of its components eIF2-
GTP and the initiator tRNA (1). TC is then recruited to the 40S ribosome subunit 
through cooperative binding of eIFs 1, 1A, 3 and 5. The resulting assembly is the 
pre-initiation complex (PIC) (2). The mRNA is bound at the 5¢end cap by the eIF4 
factors and at the 3¢ end polyA tail by PABP (3a), and recruited to the PIC (3b). 
The PIC complex scans the mRNA in a 5¢ to 3¢ direction up to the location of a 
start codon (AUG) (4). Upon start codon recognition, GTP hydrolysis releases 
eIF1 and arrest the scanning process (5) determining further dissociation of 
eIF2•GDP and eIF5 and allowing association of eIF5B-mediated joining of the 
60S subunit (6). eIF5B-GTP hydrolysis and subsequent release leave the 80S 
initiation complex (IC) ready to mediate attachment of the first methionine (7) 
[75]. 
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The translational apparatus responds to environmental changes and this 
ensures a cell responds to particular conditions such as metabolic stress or 
nutrient uptake. Regulation of translation is therefore very important in 
controlling cell growth and division. This tight control is accomplished by 
the induction of many pathways that ultimately lead to translational 
stimulation or repression [76]. In many cases signals can direct 
translation of selected proteins needed for the cell to respond to a specific 
condition. One pathway that exemplifies such a regulatory mechanism is 
the mTOR signalling pathway. 
Mammalian target of rapamycin (mTOR) is a serine/ threonine kinase 
that exists in two functionally and structurally divergent complexes: 
mTOR complex 1 and 2 (mTORC1- mTORC2). mTORC1 affects cellular 
proliferation, growth, protein synthesis, metabolic programmes and 
autophagy [77, 78], whereas mTORC2 controls glucose and lipid 
metabolism as well as cytoskeletal organization [79]. 
The mTOR pathway integrates extracellular and intracellular growth 
signals, such as nutrients, growth factors or stress conditions, and links 
them to the translation process by regulating it at several levels. In fact, 
mTOR can mediate transcriptional regulation of ribosomal RNA (rRNA) 
and genes encoding ribosomal proteins, as well as control ribosomal 
proteins mRNA stability and regulate their translation. This leads to a 
coordinated response of the translational apparatus to external stimuli 
[80, 81]. 
mTORC1 directly regulates translation mainly by modulating assembly of 
the eIF4F complex. Activation of the mTOR pathway leads to 
phosphorylation of different effector proteins such as 4E-Binding proteins 
(4E-BPs). These are usually associated with eI4FE and inhibit its 
function. Upon mTOR phosphorylation, 4E-BPs dissociate from eIF4E 
which in turn allows eIF4E–eIF4G interaction and eIF4F complex 
assembly [82, 83]. The other main effectors of mTOR are the S6 kinases 1 
and 2 (S6K1, S6K2).  Activated mTORC1 phosphorylates and activates S6 
kinases 1 and 2 [84, 85]. S6Ks in turn phosphorylate various substrates 
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among which are the ribosomal protein S6 [86] and the translation 
initiation factor eIF2 [87].  
The mTOR pathway represents an example of transcript-specific 
regulation of translation. In particular, mTOR stimulates translation of 
mRNAs with a specific 5¢ sequence, the 5¢ terminal oligopyrimidine tract 
(TOPs) [88]. The 5ʹ TOP sequence is a stretch of 4–14 pyrimidines 
preceded by a C nucleotide. Most of the RNAs containing this sequence 
encode components of the translation machinery, including ribosomal 
proteins, eIF2 and poly(A)-binding protein (PABP) [89]. Ribosome profiling 
studies have shown that mTOR stimulates translation of mRNAs with 
TOPs and TOP-like pyrimidine-rich translational element (PRTE) motifs 
through phosphorylation and inactivation of 4E-BPs [90, 91]. 
Interestingly, it was later shown that upon stress conditions, such as 
hypoxia and nutrient deprivation, which inhibit the mTOR signalling, 
translation of TOP mRNAs was suppressed independently of 4E-BPs [92]. 
Different studies, proposed that S6Ks promote translation of the 5¢-TOP- 
mRNAs via stimulation of RPS6 phosphorylation [93, 94]. However, it was 
subsequently shown that neither loss of S6Ks nor the phosphorylation 
status of RPS6 affected translation of 5¢-TOP mRNAs [95]. These 
controversial observations suggest that more unknown effectors mediate 
regulation of translation of TOP mRNAs through mTORC1-dependent 
signalling [96]. 
Growing evidence shows that translation is frequently deregulated in 
cancer. Indeed, tumour cells have a high demand on protein synthesis to 
cope with their prolific growth and this requires higher levels of ribosomes 
and other translational components [97, 98]. The pathways that are often 
found to drive oncogenesis in many cancers, such as PI3K/ AKT/mTOR, 
RAS/MAPK, and Wnt/b-catenin, are typically upstream translational 
regulation pathways. This suggest that mis-regulation of translation is a 
hallmark of cancer and it can be achieved in different ways [85, 98]. One 
recurrent feature is overexpression of eIF4E, which is found in several 
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tumour types including head and neck, bladder, colon, breast, prostate, 
lung and blood cancers [99, 100]. 
Inhibitors targeting translational components or members of signalling 
pathways that activate translation have been considered for cancer 
therapeutic intervention. In particular, inhibition of mTOR has gained 
considerable attention. Rapamycin is a naturally occurring macrolide 
produced by Streptomyces hygroscopicus [101] that inhibits TOR kinases 
[102]. Rapamycin induces conformational changes that weaken the 
interaction between regulatory-associated protein of mTOR (RAPTOR) 
and mTOR [103], within the mTORC1 complex [104, 105].  
Several rapamycin analogues (rapalogues) were generated to improve its 
pharmacodynamic properties, and these exert anti-neoplastic activity in 
cancer cell lines and mouse models [106]. Many of these molecules have 
been used in the clinic, although they have showed lower efficacy than 
hoped [107]. 
Inhibition of translation and consequent disruption of the translational 
machinery can induce formation of RNA-protein cytoplasmic aggregates in 
which untranslated RNAs are stored.  The main types of such subcellular 
structures are the processing bodies (PBs) and the stress granules (SGs) 
[108, 109]. 
While PBs contain components of the mRNA decay machinery, SGs 
contain components of the translation initiation machinery. PBs form in 
unstressed cells during translational inhibition. In general, events that 
reduce the efficiency of translational initiation include disruption of 
interactions between poly(A)-binding protein 1 (PABP1) and the initiation 
complex and dissociation of translating ribosomes. These events lead to 
recruitment of de-adenylation and de-capping factors to the mRNA 
thereby inducing aggregation of mRNPs and decay proteins within PBs 
[108].  
During stress response, eukaryotic translation initiation is reduced and 
this is associated with formation of stress granules triggered by 
aggregation of several RBPs [110]. The translational silencers TIA1 and 
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TIAR are recruited to the mRNP in response to stress, to promote 
assembly of stalled translation initiation complexes and formation of SGs 
[111]. Stress granules typically contain translational factors such as 
poly(A), 40S ribosomal subunits, eIF4E, eIF4G, eIF4A, eIF4B, Poly(A) 
binding protein (PABP), eIF3, and eIF2 [112]. When cells recover from 
stress, SGs disassemble and mRNAs re-enter translation [113] [114]. 
SGs do not mediate an impairment of global translation but rather of 
selected mRNAs. Usually, the mRNAs in SGs are those encoding proteins 
involved in cell cycle and housekeeping functions, the silencing of which 
will slow down cell growth in order to cope with stress [115] [116]. In 
contrast, mRNAs encoding stress-inducible proteins (HSP70 and HSP90) 
are excluded from SGs [117, 118]. This selectivity shows that aggregation 
of SGs is another means by which RBPs post transcriptionally regulate 
gene expression.  
RNA granules affect cancer development mainly by favouring the 
adaptation of cancer cells to stress conditions of the tumour 
microenvironment [119]. Solid tumours are characterized by outgrowth 
due to rapidly proliferating cancer cells. This is often accompanied with 
instauration of deprivation of oxygen and nutrients which exposes the 
cancer cells to hypoxia and nutrient starvation [119]. To cope with such as 
environment, tumours often trigger a stress response which helps cells to 
adapt and survive to the changing conditions [120]. Formation of SGs in 
cancer cells has been shown to be part of this process. SGs can sequester 
and inactivate pro-apoptotic factors (such as RACK1 and TRAF2) [121, 
122] and mRNAs encoding pro-apoptotic proteins that are induced by 
oxidative stress [123]. 
As mentioned earlier, mTOR is a sensor of the metabolic state of the cell. 
In cancer cells under conditions of nutrient starvation and stress, 
mTORC1 stimulates TIA1/TIAR dependent recruitment of 5'-TOP-
containing mRNAs to stress granules, hindering their translation [124, 
125]. Since this subclass of mRNAs predominantly encodes protein 
biosynthesis factors such as translation factors and ribosomal proteins, 
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this activity of mTORC1 represents an integration of the response to the 
stressful tumour microenvironment and an example of transcript specific 
translational regulation essential to cancer cell metabolism. 
 
1.2 RNA binding proteins features 
RNA binding proteins mediate formation of ribonucleoprotein complexes 
(RNPs) that lie at the core of post-transcriptional gene regulation 
processes. In the formation of RNPs, RNA acts as a scaffold guiding the 
protein’s synergistic recruitment through their recognition of RNA 
sequence or structural features. Within RNPs, RNA is remodelled, 
matured, transported and rendered accessible for other RBPs to bind and 
for enzymatic reactions to take place. 
It has been estimated that RBPs comprise 3–11 % of the entire proteome 
of bacteria, archaea and eukaryotes and they are significantly conserved 
throughout evolution [126, 127]. Many RBPs have been identified by the 
existence within of well-characterised RNA-binding domains (RBDs). The 
best-known RBD is the RNA recognition motif (RRM), composed of 80–90 
amino acids, that is found in most RNA binding proteins and that can 
recognize short stretches of four to eight nucleotides without sequence 
specificity. Other known domains include K-homology (KH domain), RGG 
(Arg-Gly-Gly) box, Sm domain, DEAD/DEAH box helicase domain, zinc 
finger (ZnF), double stranded RNA-binding domain (dsRBD); cold-shock 
domain; Pumilio/ FBF (PUF or Pum-HD) domain; and the Piwi/Argonaute/ 
Zwille (PAZ) domain (Figure 1.4 A) [128]. Computational studies have 
revealed that eukaryotic genomes encode a large number of RBPs 
containing one or more of these domains, although recent proteomic 
studies of the RNA interactome in human cells have also identified 
hundreds of proteins previously unrelated to RNA metabolism and lacking 
any known RBDs. This suggests that the number of RNA binding proteins 
and potential RNA binding domains might be substantially higher than 
currently thought (Figure 1.4 B)[129-131].  
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Figure 1.4. RNA binding domains in RBPs.  
(A) shown are the most frequently found RNA-binding domains (RBD), including 
K-homology (KH) domain, RGG (Arg-Gly-Gly) box, double stranded RNA-binding 
domain (dsRBD), Piwi/ Argonaute/Zwille (PAZ) domain, RNA helicase 
DEAD/DEAH box, RNA-binding zinc finger (ZnF) and Puf RNA-binding repeats 
(Puf). All are presented as coloured boxes [1]. (B). RNA interactome capture in 
human cell lines. An RNA interactome experiment identified a total of 1218 
proteins as RNA binders. Most proteins do not contain any known RBD (∼55 %). 
The remaining proteins harbour the most common RBDs, the RNA recognition 
motif (RRM, ∼13 %), DEAD/DEAD box helicase domain (∼4 %) and the K 
homology domain (KH,∼3 %) [130]. 
A
B
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Most RBPs are composed of the combination of different RNA binding 
modules as well as auxiliary domains (Figure 1.4 A). RBPs are able to bind 
RNA with high affinity thanks to the synergistic binding of multiple 
modules, each of which exerts a weak interaction in isolation. Also, the 
spread distribution of RNA binding domains within the RBP structure, 
provides the protein with the ability to bind portions of RNA or regions 
distally rearranged by secondary RNA structures.  
If the affinity of a RBP is mainly due to its modular composition and 
rearrangements, the specificity is also influenced by the ability of the 
proteins domain to also interact with other proteins. The protein-protein 
interactions can cause even small structural alterations that are 
transmitted to the RBD portions and favour the binding of specific RNAs. 
Therefore, the variation of interactions among RBPs determine their 
context-specific functional activity [132]. The alteration of their targets or 
the aberrant assortment of their protein interactions is therefore 
responsible for the role of RBPs in tissue-specific diseases, including 
cancer [133].  
 
1.2.1 RNA helicases 
RNA helicases are the largest class of RNA binding proteins. They are 
involved in all RNA-related processes and especially in translation 
initiation, ribosome biogenesis and pre-mRNA splicing. RNA helicase 
activity in these processes utilizes the energy from ATP hydrolysis to 
remodel RNA or RNA-protein complexes in order to separate RNA 
duplexes, displace proteins from RNA molecules, anneal RNA strands or 
act as RNA clamps to stabilize RNA folding intermediates [134, 135]. 
 
All RNA (and DNA) helicases can be identified by the presence of the 
typical Walker A and B sites for NTP binding and hydrolysis. A high 
number of proteins were structurally identified as helicases and classified 
into six super-families (SF1-6). Within each super-family, the helicases 
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share homology in terms of both sequence of motifs and structural 
arrangement. Proteins of SFs 1 and 2 are characterised by a helicase core 
formed by two structurally almost identical helicase domains, which 
contain all the conserved motifs. Helicases of SFs 3–6 form hexameric 
toroids. These proteins contain only one helicase domain that is distinct 
from helicase domains within enzymes of SFs 1 and 2. 
 
Classification of a protein as a helicase has long being debated. This is 
because the presence of a helicase domain does not necessarily indicate 
that the protein possesses unwinding activity. In fact, while all of them 
are able to hydrolyse ATP in a nucleic-acid-dependent fashion, this 
activity is not necessarily coupled to RNA (or DNA) duplex unwinding. 
Therefore, the name helicase identifies the sequence features more than 
the enzymatic function. Moreover, the mechanism these enzymes use to 
unwind their double stranded nucleic acids is not necessarily common 
among super-families. Some helicases unwind by translocation, others 
translocate without unwinding or unwind without translocating [135-138]. 
In general, the only real common property of helicases, in terms of 
mechanistic and enzymatic activity, is their ability to bind nucleic acid in 
an ATP-dependent fashion. 
 
SFs 1 and 2 contain the largest number of helicases. These proteins 
contain twelve conserved motifs that constitute the helicase core and 
confer similar activities to the different members. The conserved helicase 
core consists of two similar protein domains (domains 1 and 2) named 
recA-like domains after resemblance to the fold of the bacterial recA 
protein, which is a DNA recombination enzyme. Helicases within SFs 1 
and 2 share almost identical folds and extensive structural similarity of 
the cores (Figure 1.5 A) [137]. 
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Figure 1.5. Structural features and functions of SF1 and SF2 RNA helicases. 
(A) Comparison of the conserved sequence domains of SF1 and SF2 RNA 
helicases. 1B and 1C are SF1 specific inserts. (red: ATP binding and hydrolysis, 
blue: RNA binding, yellow: communication between ATP and RNA- binding 
sites). (B) Cellular roles of eukaryotic SF1 and SF2 RNA helicases. White circles 
and names indicate processes of eukaryotic RNA metabolism (NMD, nonsense 
mediated decay). Grey lines mark connections between processes. Coloured 
circles indicate the number and the subtype of individual RNA helicases involved 
in a given process. Yeast and human orthologues are grouped and color-coded 
according to their families (see legend at left lower corner). Coloured lined 
connect more processes for individual helicases and indicate involvement in one 
or more processes of RNA metabolism. Circles with bold lines emphasize the 
three RNA helicases (Prp22p, Prp43p, eIF4A-III) [139]. 
  
A
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Within the helicase core, Motifs I (Walker A) and II (Walker B) are 
required for NTP/ATP binding and catalyze its hydrolysis, Motif III has 
been suggested to couple ATP binding and hydrolysis to helicase activity, 
Motif VI functions in ATP hydrolysis and Motifs Ia, Ib, IV, and V are 
responsible for binding of the substrate RNA. The helicase core is flanked 
by N- and C-terminal extensions. The composition of the extensions vary 
and often contains additional functional RNA-binding domains such as 
RRMs [137].  
Helicases within SF1 are predominantly DNA helicases and are found in 
all kingdoms of life, including many viruses.  
SF2 is the largest helicase superfamily, with members throughout the 
eukaryotic kingdom, most bacteria, archaea, and in several DNA and RNA 
viruses. SF2 is subdivided into at least 10 sub-families. Five of these 
(DEAD-box, DEAH/RHA, Ski2-like, RIG-I-like, and NS3/NPH-II family) 
contain mainly RNA helicases.  
SFs 3–5 contain mainly RNA helicases that appear to have no eukaryotic 
counterparts [136].  
 
 
1.3 DEAD-box RNA helicases 
1.3.1 Structural features of DEAD-box RNA helicases 
DEAD box proteins (DDX) belong to SF2. RNA helicases of the DEAD box 
family are present in all eukaryotic cells and in many bacteria and 
archaea (Figure 1.6 A) [140]. 
 
The DEAD-box is the largest family of RNA helicases with 37 members in 
humans. The motifs of their helicase core are conserved with similar 
positioning in all members of the protein family and they are flanked by 
variable auxiliary domains which are thought to be critical for the diverse 
individual functions of these enzymes [141].  Like the other SF2 members, 
the helicase core is made of two virtually identical recA–like domains 
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within which are distributed twelve characteristic sequence motifs. The 
DEAD (Asp-Glu-Ala-Asp) motif, which gives the name to the protein 
family, is located in Motif II. In the closed conformation of the protein 
monomer, the two helicase domains form a cleft which constitutes the ATP 
binding and hydrolysis site. Motifs I-II-VI and Q create the ATP contacts 
whereas, on the opposite side of the ATP binding pocket, motifs Ia-Ib-Ic-
IV-IVa and V associate with RNA mainly through interactions with the 
sugar phosphate backbone. The Q-motif, whose name reflects a highly 
conserved glutamine residue, is located upstream of motif I [142] and was 
proposed to function as a sensor to determine the state of the bound ATP 
thereby regulating ATP binding and hydrolysis [143]. Motifs III and IVa 
are thought to mediate communication between the RNA binding site and 
the ATP binding and hydrolysis site, although this aspect is still not 
mechanistically clear [144]. 
 
The N- and C-terminal flanking domains of the helicase core vary in 
length and amino acid composition from one member of the family to 
another. Information about the structural features of these domains are 
limited, because most of the studies have focused on the isolated helicase 
core [145]. 
 
The conventional helicase mechanism is characterized by a directional 
movement of the protein along one nucleic acid strand of the duplex. This 
translocation needs the unwinding activity since progression of the protein 
along the nucleic acid strand displaces the complementary strand [146]. 
DEAD-box proteins are relatively poor “unwindases” and may be more 
appropriately considered as ATP-dependent RNA binding proteins. DEAD-
box proteins use a non-conventional non-processive unwinding mechanism 
that is only effective on approximately two helical turns of duplex, which 
include fewer than 10 or 12 base pairs. This mechanism is known as local 
strand separation: DEAD box helicases load directly on a duplex RNA, 
assisted by a single strand extending either at the 3’ or 5’ end of the 
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double strand. These single strand regions have to be proximal but not 
necessarily covalently connected to the target double helix. Some DEAD-
box helicases can perform unwinding as monomers but in many cases 
multiple protomers of a helicase are actually required and the single 
stranded extensions provide binding sites for additional monomers. 
Loading onto an RNA helix is not directional and can occur at either end 
of an RNA molecule, or internally, and on either strand. A DEAD-box 
helicase loaded on its target RNA duplex can then interact with other 
proteins for further molecular functions and begin to catalyse strand 
separation. This action requires binding of ATP but not its hydrolysis. As 
a consequence of conformational changes due to the RNA-binding, the 
helicase destabilises the helix locally over just a few base pairs, causing 
the immediate neighbour double strand to unwind, without any further 
enzymatic action. ATP and RNA are bound cooperatively by DEAD-box 
helicases and this determines the closure of the two recA-like domains and 
the unwinding of the two RNA strands. It is this closure that stimulates 
ATP hydrolysis. The ADP generated upon hydrolysis has reduced affinity 
for the DEAD box helicase cleft, causing release of both the tightly bound 
RNA strand and the protein. The enzyme is then recycled for unwinding of 
other RNA substrates [147, 148] (Figure 1.6 B). 
 
In physiological mRNPs assemblies, RNAs rarely exceed one helical turn. 
Therefore, the mechanism of unwinding by local strand separation is well 
suited for the biological function DEAD box proteins exert in the cell [135], 
especially in order to promote rapid assembly/disassembly of different 
protein complexes on various transcripts [149].  
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Figure 1.6. Conservation of DEAD box helicases across organisms and their 
mechanism of action.  
(A) Representation of DEAD-box proteins from the three kingdoms of life. The 
phylogram was constructed by Rocak et al 2004 [140]. The numbers for Homo 
sapiens, Arabidopsis thaliana and Saccharomyces cerevisiae are from published 
reports [150-152] whereas the numbers for the remaining organisms were 
obtained by BLAST searches using the yeast eIF4A as reference sequence [140]. 
(B) Schematic representation of DEAD box RNA helicases unwinding mechanism 
by local strand separation. The RNA helicase in its ATP-bound (red star) closed 
conformation is loaded directly onto the RNA duplex without polarity or position 
preference. Loading of protomers is facilitated by single strand ends of the target 
RNA. Upon binding, the RNA duplex is locally destabilized, determining 
dissociation of the double strand. ATP hydrolysis determines release and 
recycling of the RNA helicase [146]. 
 
 
  
BA
 27 
1.3.2 Biological functions of DEAD-box RNA helicases  
DEAD-box RNA helicases are generally defined as RNA unwindases. 
However, their unwinding activity is only one of the several biochemical 
functions of these proteins. DDX helicases are able to unwind local 
secondary structures however, if the release of inorganic phosphate after 
ATP hydrolysis is inefficient the helicase can also function as an RNA 
clamp. As RNA clamps, DDXs can act as nucleation centres for the 
formation of RNA–protein complexes. Some can also mediate RNA-
annealing activity alternatively to their RNA-unwinding activity, which 
gives DEAD-box proteins a wide ability to promote RNA rearrangements. 
DEAD-box RNA helicases can regulate RNA structures and RNA–RNA 
and protein–RNA interactions. They can also function as RNA chaperones 
by remodelling RNPs and modulating RNA–protein 
association/dissociation. DEAD-box proteins can remove proteins from 
RNA in an ATP-dependent reaction. Since DDXs do not translocate on 
their target RNAs, they can remodel RNA locally by displacing proteins 
from limited structured RNA [153]. 
 
As with all RNA binding proteins, DEAD box helicases are usually part of 
larger multi-component complexes, such as spliceosomes and ribosomes. It 
is intriguing to notice how, despite a very high structural conservation of 
their functional helicase core, these proteins perform very different 
functions in RNA metabolism, all of which require multi-step 
association/dissociation of large RNP complexes and modulation of RNA 
structures (Figure 1.7A).  
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Figure 1.7. DEAD box RNA helicases perform many cellular functions and are 
associated with cancer.  
(A) Human DDXs are involved in many steps of RNA metabolism as indicated. 
RNA helicases of the DEAD box family are widely involved in post-
transcriptional regulation of gene expression (DDX, DEADbox; RISC, RNA 
induced silencing complex; snRNP, small nuclear ribonucleoprotein) [145]. (B) 
The figure groups DDXs reported to participate in the onset of various solid 
cancers or leukaemia subtypes. Adapted from [154].   
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DEAD-box proteins have been linked to transcription regulation, 
functioning as either co-activators or co-repressors (DDX1, DDX5, DDX17, 
DDX20, DDX2) through their interaction with key components of the 
transcriptional machinery [155]. Furthermore, many DEAD box helicases 
are involved in alternative splicing through interaction with either the 
exon junction complex (DDX48) [66] or the spliceosome (DDX41-DDX42) 
[156, 157]. 
 
Numerous DDX RNA helicases are also required for ribosome biogenesis 
(Figure 1.7A). This is a very dynamic process that requires processing of a 
ribosomal RNA (rRNA) precursor and further modification of the resulting 
18S and 25S rRNAs that takes place in the nucleolus. The modifications 
(e.g. pseudouridylation and methylation) are performed by enzymes 
coupled to a class of small guide RNAs, called small nucleolar RNAs 
(snoRNA), that match the rRNA target sequence [140, 145]. It has been 
suggested that DEAD-box proteins are required for the unwinding of short 
duplexes of snoRNA–rRNA or rRNA–rRNA interactions to allow new and 
mutually exclusive RNA–RNA interactions to occur [158]. 
 
Different DEAD-box proteins mediate the export (DDX39A, DDX39B) 
[159] and translation (DDX48) [160] of selected mRNAs. DDXs play 
various roles at different steps of general translation: DDX2A and DDX2B 
(also known as eIFA1 and 2) constitute canonical translational initiation 
factors (Section 1.13), whereas other DDXs are required at later stages for 
recognition of stop codons and recruitment of translation termination 
complexes (e.g DDX19B) [161]. DDXs can also mediate mRNA degradation 
by stimulating de-capping enzymes (DDX6)[162]. 
 
The activities of these helicases on their target RNAs do not always 
strictly require their helicase function, which suggests that other 
functional domains are involved. Also, the outcome of DDX activity can 
either promote gene expression or repress it. By considering all of the 
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different functions these proteins can exert, the emerging concept is that a 
specific DDX may interlink more steps of RNA metabolism by performing 
different activities and recruiting functionally different protein partners to 
the same selected target RNAs. In fact, DEAD-BOX proteins are thought 
to function as adaptors or bridging factors in the many steps of RNA 
metabolism in which they are involved. This notion agrees with the 
observation that highly specific regions of individual proteins that lie in 
the N- and C-terminal regions flanking the conserved core, are also the 
ones that interact with other factors. These interactions could determine 
their activity in different cell types and/or in response to different signals 
[134]. Interacting cofactors can stimulate the ATPase and helicase 
activities, as well as modulate the affinity of the helicase toward specific 
substrates. In some cases, this interaction has also been shown to be 
inhibitory [144, 163]. 
 
The mechanism by which DDXs recognise their targets is mostly 
unknown. However, a few studies have shown that they can be selectively 
recruited through direct binding to specific RNA secondary structures 
[164, 165]. Intriguingly, DDXs have been found to be recruited to a large 
number of target RNAs but only appear to affect a subset of them [166]. A 
major challenge in the field is to identify the substrates that are 
selectively regulated by each RNA helicase at each step of gene 
expression. Biochemical approaches including UV crosslinking-based 
techniques like CLIP (UV-crosslinking and Immunoprecipitation) can 
improve our understanding of the selectivity of DDX RNA helicases. 
  
Given the widespread activity of DEAD box helicases in regulating gene 
expression at different levels, and the numerous studies reporting their 
involvement in cellular growth, it is not surprising that alterations in 
their expression or function can potentially affect normal cellular 
homeostasis and contribute to cancer development and progression. DEAD 
box proteins are mutated or deregulated in multiple cancers (Figure 1.7B).  
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These proteins have been suggested to exert both oncogenic and tumour-
suppressive roles, in a context- and cancer- dependent fashion and 
through different mechanisms that affect a wide range of molecular 
events, from transcription to translation. This evidence makes DDX 
enzymes potential candidates for therapeutic development as well as 
disease biomarkers [154]. Inhibitors that affect RNA binding and helicase 
activity of DEAD-box proteins, have already been designed, tested and 
shown to possess anticancer potential [167]. 
A major strategy has involved the design of small molecule inhibitors 
targeting the NTPase activity (e.g. nucleoside analogues), small molecules 
affecting RNA binding and helicase activity, as well as compounds able to 
interfere with specific protein- protein interactions involving the helicases 
or specifically directed against post-transaltionally modified DDXs [167, 
168]. 
Cancer cells are often dependent on certain cellular pathways more than 
normal cells, which makes cancer vulnerable to the targeting of factors 
that act in specific pathways. This is the case of the translation machinery 
(as already discussed in Section 1.1.3), to which cancer cells are addicted 
for both elevated levels of proteins synthesis and expression of specific 
oncogenes [98]. Among the most prominent examples of targeting the 
translational machinery, are the inhibitors designed against DDX2 (e.g 
eIF4A). Many of these compounds have shown anti-tumorigenic ability 
[169-171] and have now reached the preclinical study stage.  
Another interesting case is the one of DDX5, whose phosphorylation at 
tyrosine residues was shown to mediate oncogenic phenotypes in cancer 
cells [172-175]. This led to the development of a phospho-DDX5 specific 
compound whose action is therefore minimally toxic in normal cells and 
directed to cancer cells were phosphorylation of DDX5 is present and 
indispensable for overgrowth [176-179] . 
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1.4 DDX54:  a transcriptional and splicing regulator 
The DEAD box RNA helicase DDX54 is one of the least characterised 
members of the of DDX protein family. In humans, DDX54 is mainly found 
in the nervous system, gastrointestinal tract organs, female breast and 
placenta (The Human Protein Atlas-
https://www.proteinatlas.org/ENSG00000123064-DDX54/tissue). In most 
tissues DDX54 has both nuclear and nucleolar sub-localization.  
 
In addition to the common and conserved domains of the DEAD box 
protein family, DDX54 contains two bipartite nuclear localization signals 
and three nuclear receptor boxes (LXXLL motifs). DDX54 was first 
identified as an interactor of Estrogen Receptor a (ERa). In fact, DDX54 
interacts in vitro with ERa and represses estrogen-bound ERa 
transcriptional activity through a small region (amino acids 589 – 631) 
that has homology to functional domains of other corepressor proteins 
(NCoR2/SMRTe) (Figure 1.8). The co-repressive activity of DDX54 was 
also found to target other nuclear hormone receptors such as progesterone 
receptor (PR), glucocorticoid receptor (GR) and retinoic acid receptor 
(RAR) [180]. 
 
 
Figure 1.8. DDX54/DP97 structural features and homology with nuclear co-
repressors.  
Protein BLAST analysis of aa 413– 656 region of DP97 (yeast homolog of DDX54) 
showed significant sequence similarity to two repressor domains (RD) in co-
repressor NCoR2. Asterisks (*) indicate the same amino acid in DP97 and both 
RDs of NCoR2; bold dots (•) indicate same amino acid in DP97 and one of the 
RDs in NCoR2. (ID, receptor interaction domain) [180]. 
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Conversely, another study showed that DDX54 acts as a co-activator of the 
constitutive androstane receptor (CAR). Direct interaction of DDX54 and 
CAR selectively enhances expression of CAR target genes, which mainly 
encode enzymes involved in drug metabolism. Suppression of CAR target 
genes was observed in DDX54-depleted human hepatoma cells (HepG2), 
whereas expression of the same genes was enhanced upon over-expression 
of DDX54 in the same cell line [181]. 
The presence of DDX54 in the nucleolus of cells suggests regulatory roles 
in rRNA processing and ribosome biosynthesis. In fact, a screen for pre-
rRNA processing factors identified DDX54 as a determinant factor in 
ribosome biogenesis [182]. Consistent with previously reported nucleolar 
localization and function in pre-rRNAs processing, DDX54 was shown to 
be essential for the early stages of 18S rRNA maturation [183].  
More recently, DDX54 was found to regulate alternative splicing of pre-
mRNAs of genes up-regulated upon DNA damage. Specifically, upon 
exposure to ionising radiation, DDX54 is relocated from the nucleolus to 
the nucleoplasm where it interacts with spliceosome-associated proteins, 
including U2AF1. DDX54 binds to introns of DNA damage responsive 
newly transcribed pre-mRNAs and regulates effective splicing of these 
transcripts. Indeed, DDX54 was required for efficient post-transcriptional 
gene expression regulation upon DNA damage [183] 
 
1.5 DDX3X: a multifunctional DEAD box RNA helicase 
1.5.1 Conservation and structure of the Ded1/DDX3 subfamily of DEAD-
box RNA helicases 
Ded1/DDX3 is one of the most widely studied DEAD-box RNA helicase 
subfamilies. Ded1/DDX3 proteins are conserved in eukaryotic organisms 
from yeast to human and regulate several different aspects of RNA 
metabolism [146, 184].  
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The mouse genome encodes three homologues, namely Ddx3x, Ddx3y and 
the autosomic homolog Pl10 [185]. The human genome encodes two DDX3 
homologues: DDX3X and DDX3Y. DDX3X (or DBX) is an X chromosome-
linked gene located in the Xp11.3-11.23 region that escapes X-inactivation 
and encodes a 662- or 661-amino acid polypeptide, depending on 
alternative splicing. DDX3Y (or DBY) is located in the AZoospermia 
Factor a (AZFa) region of the Y-chromosome [186]. The intron–exon 
structure of the human Ded1/DDX3 subfamily of genes is largely 
conserved throughout higher eukaryotes, suggesting a common ancestor 
[186, 187]. 
  
The mouse and human DDX3 homologues possess non-redundant 
functions, as suggested from the different expression pattern of these 
proteins. In humans, DDX3X is ubiquitously transcribed in all tissues 
whereas DDX3Y is only expressed in male germ cells [188]. In contrast, 
amongst the three mouse homologs, Ddx3x and Ddx3y are expressed in all 
analyzed tissues whereas the autosomic homolog Pl10, located on 
chromosome 1, is only expressed in testis [189]. 
 
The characteristic motifs of the helicase core are highly conserved from 
yeast to human among the members of the Ded1p/DDX3 subfamily and 
are divided into the two recA-like helicase core domains. Among others, 
human homologues contain an additional 10 amino acid insertion (aa 250– 
259) that is not found in other eukaryotes (Caenorhabditis elegans, 
Drosophila melanogaster and Saccharomyces cerevisiae) and is important 
for ATP binding, ATPase activity, nucleic acid binding and unwinding. 
Indeed, this insertion is located between motifs I (ATP-binding) and Ia 
(RNA-binding) and it is thought to play a role in positioning the 3¢ end of 
the RNA substrate close to a region of positively charged groups (Figure 
1.9 A-C) [146, 190]. 
As shown in Figure 1.9D, in addition to the recA-like core domains, other 
regions of sequence conservation are also found within members of this 
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family. Regions immediately adjacent to the helicase core are conserved 
between DDX3, Ded1, and Vasa/DDX4. The N-terminal extension (NTE; 
residues 132–168) is predicted to form a short-helix from residues 145 to 
151, whereas the C-terminal extension (CTE; residues 582– 607) has no 
predicted structure but is highly positively charged. In the latest DDX3 
crystal structure, Floor and colleagues have included the N- and C-
terminal conserved extension of the helicase core domain (NTE and CTE). 
Interestingly, they showed that the DDX3 crystal structure, including 
NTE and CTE portions, has a unique closed conformation forming an 
interdomain interface which involves the helicase core, and clashes with 
the RNA-binding surface. This conformation of the DDX3 monomer bound 
to AMP, suggests that the protein is normally in an auto-inhibitory state 
and refractory to RNA binding (Figure 1.9E). In fact, mutation of residues 
in this interface increased the duplex unwinding rate in vitro. This 
suggested that the RNA-dependent rearrangement of the N- and C-
terminal flanking tails is needed for full DDX3 ATPase activity [191]. 
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Figure 1.9. DDX3 sequence conservation and functional domains. 
(A) Schematic representation of DDX3 domains. The two recA-like domains 
(domain 1 and domain 2) contain the SF2 conserved motifs involved in ATP 
binding (blue), RNA binding (brown), and linking of ATP and RNA binding 
functions (green). The variable N- and the C-terminus regions are also indicated. 
(B) Human DDX3 sequence (AAC34298.1) was aligned with chicken 
(NP_001025971.1), frog (An3, NP_001095245.1), zebrafish (CAQ14635.1), fruit 
fly (belle, AAF54262.1), worm (LAF-1, CCG28150.1), and yeast (Ded1, 
CAA99419.1). DDX3 orthologue sequences were aligned. The conserved catalytic 
motifs in the helicase core are indicated with the colour code as in A. 
Additionally, the highly conserved eIF4E-binding motif (green brackets) and the 
less conserved 10-amino acid insertion (red brackets), are also indicated [146]. (C) 
Sequence alignment of 32 different human DEAD-box helicases covering the 
conserved region between motifs I and Ia (amino acid residues 229–279 in 
DDX3X). Conserved residues are shown in green. Red box shows the DDX3X/Y-
specific 10 amino acid insertion (between residues 250 and 259) [190]. 
B C
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Figure 1.9. DDX3 sequence conservation and functional domains.  
 (D) Sequence alignments of Vasa/DDX4 (D. melanogaster), Vasa/DDX4 (H. 
sapiens), DDX3X (H. sapiens), Ddx3x (M. musculus), Ded1p (S. cerevisiae), Sum3 
(S. pombe) showing the N- and C-terminal extensions found in the Ded1/DDX3 
family and indicating construct boundaries used for the crystal structure. 
Numbers correspond to human DDX3X. 
(E) The 2.2 Å crystal structure includes the conserved core of wild-type DDX3 
and the CTE and NTE conserved extensions. The structure of DDX3 (132– 607) 
bound to AMP (blue) is in a partially closed state and clashes with the RNA-
binding site shown in the overlapping structure of the DEAD-box protein Vasa 
bound to RNA (Vasa: pink; RNA: grey; DDX3: blue) [191]. 
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In fact, the authors further showed that removal of the CTE region 
strongly suppresses duplex unwinding in vitro. Since Ded1 
oligomerization in vitro was shown to depend on the C-terminal tail of 
Ded1 [192], the authors speculated that removal of CTE negatively affects 
hDDX3 ability to interact with other proteins. These interactors are likely 
required to open DDX3 conformation and allow RNA binding. 
 
The N-terminal tail of DDX3 contains a CRM1-dependent nuclear export 
sequence [193] and an eIF4E-binding motif [194], whereas the C-terminal 
tail contains an RDYR motif, an invariant WW dipeptide motif conserved 
sequences and an RS-like domain, all of mostly unknown function [186].  
 
1.5.2 Roles of DDX3X in RNA metabolism 
Functional studies on human DDX3 proteins have almost exclusively 
focused on DDX3X implicating this protein in multiple processes of 
cellular RNA metabolism. Despite the predominantly cytoplasmic 
localization of DDX3X, which is consistent with a translational regulation 
function, there is also evidence for nuclear functions of the helicase, 
including roles in transcription, pre-mRNA splicing, mRNP assembly, as 
well as mRNA export [146, 186]. In the following sections, I summarise 
the current knowledge concerning the roles of DDX3X in post-
transcriptional processes.  
 
(i) Pre-mRNA splicing. The role of DDX3X in pre-mRNA splicing was 
indicated by proteomic studies that identified DDX3X in purified human 
spliceosomes [195]. Moreover, DDX3X was found to associate with spliced 
mRNPs in a exon-junction complex (EJC)-dependent manner [196]. It has 
been hypothesized that DDX3X might play a role in pre-mRNA processing 
at splicing junctions but evidence for the importance of DDX3X in splicing 
regulation is still lacking, since no altered splicing events have been 
reported as a consequence of DDX3X depletion. 
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(ii) Nuclear RNA export. DDX3X has been associated with mRNA nuclear 
export involving RNA export factors NFX1 and CRM1, although there is 
no conclusive evidence about DDX3X's role in this process. The RS-like 
domain in the C-terminal region of DDX3X is involved in the interaction of 
DDX3X with the nuclear export factor NFX1 [197]. This interaction 
persists during shuttling between the nucleus and the cytoplasm since 
DDX3X was found associated with NXF1 in both of these cellular 
compartments.  However, since depletion of DDX3X does not affect the 
distribution of NXF1-dependent mRNAs, the relevance of DDX3X's role in 
mRNA export is uncertain. 
DDX3X has also been implicated in CRM1-dependent export in the context 
of viral mRNA export. However, data involving DDX3X-dependent export 
of HIV1 mRNAs are so far controversial. In fact, DDX3X was initially 
reported to be required for RNA export through interaction with both 
CRM-1 and the HIV1 protein Rev, which recognizes the Rev responsive 
element (RRE) on HIV1 intron containing transcripts. But this result was 
questioned by a later study showing that DDX3X knock down does not 
affect Rev dependent export of HIV1 mRNAs [193, 198]. 
 
(iii) Translation. DDX3X has been shown to interact with members of the 
translation initiation complex eIF4F [199]. In particular, it was shown to 
directly interact with eIF4G, eIF4E and PABP in co-immunoprecipitation 
experiments, as well as in in vitro pull-down assays [200, 201]. 
Interestingly, both DDX3X-mediated repressive and activating 
translational activities have been reported. Interaction of DDX3X with 
eIF4A was required for repression of cap-dependent translation of reporter 
constructs [201]. Conversely, interaction between DDX3X and eIF4G 
promotes translation of a subset of viral RNAs that harbour a stem-loop 
secondary structure in their 5’ UTR [198]. 
 Moreover, evidence for DDX3X activity in translational regulation of 
selected cellular mRNAs has been reported. Notably, human cyclin E1 
mRNA translation is specifically dependent upon DDX3X binding to the 
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5’-UTR of the cyclin E1 transcript. This was demonstrated in both 
polysome-associated mRNA analyses as well as in in vitro assays [202]. 
Depletion of DDX3X from HeLa cells decreased the level of cyclin E1 
protein but not the level of other cyclins [202]. 
 
The notion of selective translational activity of DDX3X was challenged by 
reports showing that DDX3X catalytic mutations actually impact global 
translation. DDX3X catalytic mutations (occurring in medulloblastomas) 
do not affect the ability of the protein to bind its target mRNAs but cause 
impairment of translation of DDX3X target and non-target transcripts, as 
shown in ribosome profiling studies [203]. Interestingly, this global 
translational impairment was associated with abnormal formation of 
stress granules in which translationally repressed mRNAs were 
sequestered through DDX3X binding [203].  
 
All of the above lines of evidence, implicating DDX3X in translational 
regulation, leave many open questions: does DDX3X stimulate rather than 
repress translational processes? Does DDX3X act preferentially as a 
general translation factor rather than being targeted to specific structures 
or sequences in specific transcripts? Is DDX3X specifically required for 
translation initiation or is it involved in elongation as well?   
These are non-mutually exclusive possibilities and at present none can be 
ruled out. It is therefore legitimate to speculate that the molecular 
function of DDX3X in translation could respond to the cellular context and 
act differently within different signalling pathways. 
 
(iv) Cytoplasmic mRNA granules. DDX3X is found within stress granules 
(SGs) formed upon environmental stress and DDX3X depletion reduces 
assembly of SGs [203]. DDX3X-dependent stress granule aggregation does 
not require the catalytic domain of DDX3X but instead requires the N-
terminal domain involved in interaction with eIF4E. Based on this 
observation, DDX3X is believed to be located to SGs through interaction 
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with members of the translation initiation machinery (eIF4E and PABP1) 
rather than acting as a SG nucleating factor itself [200]. 
 
1.5.3 Multifunctional biological activity of human DDX3 proteins: 
relevance of DDX3X to cancer biology 
As described earlier, the human genome encodes two DDX3 genes, one on 
each of the sex chromosomes. DDX3Y is located in the AZoospermia Factor 
a (AZFa) region of the Y-chromosome and appears to be critical in 
spermatogenesis and required for early stages of testis development in 
human foetal germ cells. In fact, deletions in the AZFa region of the 
genome cause a condition called Sertoli Cell-Only Syndrome (SCOS) 
characterized by a complete loss of germ cells in the testis that leads to 
male infertility [204, 205]. Deregulated expression of DDX3Y has also 
been linked to testicular tumours [205]. 
 
Most research on the biological functions of the DDX3 human subfamily 
has concentrated on the DDX3X homologue. As highlighted above, DDX3X 
regulates RNA metabolism at many levels. Moreover, DDX3X plays 
important roles in many cellular processes in cancer cells including 
hypoxia, apoptosis, cell cycle regulation and epithelial to mesenchymal 
transition [206]. Altered expression of DDX3X, or mutations at the DDX3X 
locus, are associated with several different tumours. These findings have 
led DDX3X to be described as both a tumour suppressor and an oncogene, 
making it complex to consider DDX3X as a target for cancer therapy [207]. 
 
The role of DDX3X in cancer biology has been studied in numerous 
different cancer models. The mechanisms through which DDX3X regulates 
cell growth, cell cycle progression and cell motility pathways have only 
been partially uncovered since most of the available evidence is limited to 
correlations between expression of DDX3X, or mutations in the DDX3X 
locus, and different types of cancer [206]. 
 42 
In the next two sections, I summarise the available knowledge concerning 
the tumour suppressive and oncogenic role of DDX3X in different cancers. 
 
(i) DDX3X as a tumour suppressor.  Loss of function mutations due to 
missense and nonsense substitutions in the DDX3X gene are associated 
with head and neck squamous cell carcinomas [208]. Furthermore, low 
expression of DDX3X at both the RNA and protein level, correlates with 
poor prognosis and metastasis formation in colorectal cancer, human 
papilloma virus (HPV)-associated lung cancer and Hepatitis B virus 
(HBV)-positive hepatocellular carcinoma (HCC) patient samples, 
compared to the corresponding non-tumour tissues [209-211].  
 
In in vitro studies, forced expression of DDX3X suppresses colony 
formation ability of HCC, cervical carcinoma and colon cancer cells 
through up regulation of the p21 cell cycle inhibitor [212].  
 
(ii) DDX3X as an oncogene. DDX3X has mainly been shown to act as an 
oncogene in many cancer cell lines. This activity has been related to 
different biological processes, especially cell cycle progression and cell 
motility. 
 
Gain of function mutations have been identified in medulloblastoma 
subtypes. In fact, DDX3X is mutated in 50% and 11% of pediatric WNT- 
and SHH-subtypes, respectively [213] and in 54% of adult SHH-subtype 
[214]. All medulloblastomas- associated DDX3X mutations reported so far, 
are nonsynonymous single nucleotide substitutions localized in the 
helicase core and predicted to alter the normal function of the protein 
rather than inactivating it [203]. For example, missense mutations 
localized across the RNA binding domain and the DEAD-BOX domain of 
DDX3X, were found in WNT-subgroup medulloblastomas and predicted to 
alter the specificity or affinity of the protein for its target RNAs [215].  
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High levels of DDX3X protein expression correlate with shorter overall 
survival and metastasis formation in patient samples from different 
histological subtypes of lung cancer and in colorectal cancer patients [216, 
217]. 
In in vitro studies, knockdown of DDX3X significantly reduces colony 
formation and proliferation of lung cancer cells, as well as causing cell 
cycle arrest of these cells in G1. The same phenotypic consequences are 
observed upon DDX3X knockdown in colorectal cancer cell lines [216, 217]. 
Knockdown of DDX3X in Ewing sarcoma cells results in impaired 
oncogenic activity as shown by slowed proliferation. In in vivo studies, 
where control and DDX3X knockdown Ewing sarcoma’s cells were 
implanted subcutaneously in recipient mice, tumour volumes were 
significantly smaller in knockdown cells implants compared to control 
cells implants [218]. 
 
Thus, data concerning DDX3X function in cancer are conflicting. The 
multifunctional biological activity of DDX3X may explain why this protein 
could exert very different functions in different cell types and/or in 
different conditions. 
 
1.6 Role of DDX54 and DDX3X in breast cancer and leukaemia 
The following sections are focused on DDX54 and DDX3X function in 
breast cancer and leukaemia cells, which are the tumour systems relevant 
to the experimental work described in this thesis.  
 
1.6.1 Role in breast cancer 
Breast carcinoma is a very heterogeneous disease classified on the basis of 
histopathological and genetic features that affect both the prognosis and 
the choice of the therapy [219].  Most breast cancers derive from the 
epithelium of the breast with different subtypes showing variable degrees 
of invasiveness and metastatic potential.  
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Expression of certain surface, cytoplasmic or nuclear receptors is one of 
the discriminants of breast cancer subtypes. Breast cancer cells may or 
may not express three important receptors: oestrogen receptor a (ERa), 
progesterone receptor (PR) and human epidermal growth factor 2 (HER2) 
[219]. Most breast cancer in vitro studies involve the use of cell lines of 
different tissue of origin and properties. The most widely used are (i) 
MCF7 cells, which are human breast epithelial cancer cells characterized 
by ERa expression and oestrogen growth-dependence, (ii) MDA-MB-231 
cells, which are human breast epithelial cancer cells characterized by high 
invasiveness, and (iii) MCF10A cells, which are immortalized non-
tumorigenic human breast epithelial cells commonly used as a reference 
cell line.  
 
As described earlier (Section 1.3), DDX54 interacts with ERa in MCF7 
cells when the receptor binds oestrogen. Binding of ERa to oestrogen 
determines DDX54 activity as a transcriptional repressor. The expression 
of genes activated by oestrogen-bound ERa is enhanced by DDX54 
depletion whereas the repression of genes inhibited by oestrogen-bound 
ERa genes was attenuated. Although DDX54 represses the transcriptional 
activity of ERa on a variety of promoters, it does not interfere with ERa 
binding to oestrogen responsive elements on DNA [180]. In MCF7 cells, 
DDX54 is essential for cell survival upon DNA damage as it ensures 
efficient splicing of DNA damage responsive transcripts [183]. 
 
Over-expression of DDX3X in MCF10A cells results in increased invasive 
properties [220]. Conversely, knockdown of DDX3X decreases cell 
proliferation and clonogenic cell capacity in MCF-7 and MDA-MB-231 
cells. In addition, decreased metastasis formation was observed in a 
preclinical breast cancer xenograft mouse model in which DDX3X 
knockdown MDA-MB-231 cells were transplanted [221]. 
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Hypoxia is a major characteristic of solid tumours, which greatly impacts 
cellular and tumour metabolism. Gene expression changes underlying 
tumour adaptation to hypoxic conditions are mainly due to the activity of 
hypoxia inducible factors (HIFs). DDX3X expression contributes to the 
survival of breast cancer cells when they are subjected to hypoxic 
conditions. Indeed, the DDX3X promoter is a direct target of HIF-
1a dependent transcriptional activation [222]. Moreover, DDX3X is 
overexpressed in breast cancer patient samples, and this correlates with 
over-expression of HIF-1a and its downstream genes [223]. 
The role of DDX3X in breast cancer cells during DNA damage has also 
been investigated. In p53 wild type breast cancer cells, such as MCF7, 
DDX3X associates with p53 and stabilises it during the DNA damage 
response [224]. This interaction is necessary for induction of p21 
expression and the downstream cascade that leads to apoptosis. 
Interestingly, in the same conditions, but in p53 mutant cells, such as 
MDA-MB-231 cells, DDX3X inhibits apoptosis and is essential for survival 
[224]. This links the action of DDX3X during DNA damage response to the 
p53 expression status of the cells.   
Another study identified high expression levels of cytoplasmic DDX3X in 
distant breast cancer metastases, especially in brain lesions. This 
correlated with a worse overall patient survival [225]. 
 
The majority of DDX3X is found in the cytoplasm, but a subset of tumours 
has distinct nuclear DDX3X localization. In a very recent study, DDX3X 
was detected in the nucleus in breast cancer patient samples and was 
particularly high in the nucleolus. Nuclear DDX3X correlated with worse 
overall patient survival. Moreover, nuclear DDX3X localization is due to 
decreased CRM1-mediated export which requires interaction of CRM1 
with the nuclear export signal (NES) located in the DDX3X N-terminal 
domain [226]. 
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1.6.2 Role in leukaemia 
Leukaemia is a progressive malignant disease that affects the blood, bone 
marrow, lymphatic system, the haematopoietic and lymphoid tissues. It is 
characterized by abnormal proliferation of dysfunctional and 
undifferentiated leukocytes, resulting in an unbalanced production of 
blood cells. Different subtypes of leukaemia affect different blood cells and 
can be broadly grouped into four types: acute lymphoblastic leukaemia 
(ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia 
(CLL), and chronic myeloid leukaemia (CML) [227-230]. Whilst no 
evidence for a role of DDX54 in any type of leukaemia has been reported 
so far, DDX3X has been found mutated, or involved in chromosomal 
translocations, in different subtypes of leukaemia [231-234]. 
 
Truncating mutations (either nonsense mutations or frameshift indels) in 
DDX3X have been associated with CLL cases and reported to cause loss of 
the protein expression [231]. Recurrent inactivating mutations (nonsense, 
frameshift and copy-loss mutations) localized in the helicase core and 
leading to truncation or loss of DDX3X protein, were found in natural 
killer/T-cell lymphoma patients [232]. Both the previous cases would 
account for a tumour suppressor role of DDX3X in these leukaemia 
subtypes. 
Moreover, DDX3X is involved in the MLLT10-DDX3X gene fusion 
associated with paediatric T-ALL. Interestingly, the fusion causes loss of 
DDX3X's DEAD-box domain [233, 234]. More recently, a CRISPR/Cas9 
screen showed a subset of AML cell lines are vulnerable to DDX3X 
knockout [235].  
 
During my PhD, I focused on the two human DEAD-box helicases DDX54 
and DDX3X and aimed to investigate the role of these proteins in cancer 
cells. The main biological system I chose for my research was the breast 
cancer cell line MCF7. As mentioned, both DDX54 and DDX3X have 
documented roles in breast cancer cells, particularly MCF7 cells. 
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Specifically, the role of DDX54 has only been superficially studied in this 
cell line and, although evidence concerning DDX3X's role in breast cancer 
indicates an oncogenic function, a deep understanding of the molecular 
and mechanistic processes underlying the described phenotypes is 
currently absent. 
 
In the final stages of my research I investigated the role of DDX54 and 
DDX3X in AML mouse and human cell lines. A role for DDX54 and 
DDX3X in AML is currently not known. 
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Chapter 2 - Materials and Methods 
2  
2.1 General materials 
2.1.1 Standard solutions 
Table 2.1 shows the composition of bacterial media and stock solutions 
used.  
 
Name Composition per litre 
LB 5 g NaCl, 5g yeast extract, 10 g bacto-tryptone 
TE 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
TBE 90 Tris-borate, 2 mM EDTA, pH 6.5 
TBS 150 mM NaCl, 20 mM Tris-HCl pH 7.6 
PBS 150 mM NaCl, 2.5 KCl, 10 Mm Na2HPO4, 2 mM K2HPO4 
SSC 20X 0.3 M sodium citrate pH 7,3 M NaCl  
Table 2.1. Stock solutions used. 
 
2.1.2 Vectors 
The following plasmids were used in various applications: 
pPB-CAG-hKLF4-pA-pgk-Hygro and pGG131 were a kind gift from Dr 
Meng Amy Li and Dr Ge Guo (Cambridge Stem Cell Institute). U6-sgRNA-
EFS-GFP plasmid was a kind gift of Jungwei Shi (Cold Spring Harbor 
Laboratory), the pKLV2-U6gRNA5 (BbsI)-PKGpuro2ABFP-W was a gift 
from Konstantinos Tzelepis (Wellcome Trust Sanger Institute). pCMV-
VSVg and psPAX2 were purchased from Addgene. 
 
 
2.2 Bacterial strains and transformation 
2.2.1 Escherichia coli strain. 
DH5a: competent strain for maximized transformation efficiency.   
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2.2.2 Growth of bacterial cultures 
Plated cultures were grown at 37° C overnight on LB plates (LB with 20g 
bacto-agar per litre). Bacterial suspension cultures were grown in LB at 
37° C overnight. To allow the selection of bacteria transformed with 
plasmid DNA expressing the gene of interest, ampicillin (100 µg/ml) was 
included in the media. 
 
2.2.3 Transformation of E. coli by heat shock. 
For the transformation of E. coli, 0.1 µg of DNA was added to 100 µl of 
competent bacteria and incubated on ice for 30 minutes. Samples were 
placed for 45 seconds at 42° C, returned to ice for 1 minute following which 
1 ml of LB was added. This was incubated at 37° C for 1 hour. Bacteria 
were then plated immediately.  
 
 
2.3 Preparation of DNA 
The QIAGEN Maxi-prep and Mini-prep kits were used according to the 
manufacturer’s instructions for large and small scale plasmid DNA 
preparation, respectively. 
 
 
2.4 Cloning of target guide sequences (sgRNA) for CRISPR/Cas9. 
The mouse sgRNAs (table 2.2) were designed by Isaia Barbieri 
(Kouzarides Lab-University of Cambridge) and Jungwei Shi (Vakoc Lab-
Cold Spring Harbor Laboratory); the human sgRNAs (table 2.2) were 
designed by Konstantinos Tzelepis (Wellcome Trust Sanger Institute), 
using the CRISPR design tool at http://crispr.mit.edu/. sgRNAs were 
cloned into the plenti-U6-sgRNA-EFS-GFP vector (mouse sgRNAs) or 
pKLV2-U6gRNA5-(BbsI)-PKGpuro2ABFP-W vector (human sgRNAs) 
following standard target guide sequence cloning protocol. 
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Briefly, the vector was digested with BsmBI (GFP vector) or BbsI (BFP 
vector) for 30 minutes at 37° C, with the addition of FastAP alkaline 
phosphatase for 5’ ends dephosphorylation. Digested vectors were run on a 
1% agarose gel and purified by excising the relevant gel band and 
purification using QIAquick Gel Extraction kit following the 
manufacturer’s instructions.  
sgRNA oligo pairs (Table 2.2) were phosphorylated and annealed in the 
following reaction: 
• 1 µl 100 µM oligo1 
• 1 µl 100 µM oligo2 
• 1 µl 10X T4 Ligation Buffer (NEB) 
• 6.5 µl ddH2O 
• 0.5 µl T4 PNK (10,000 units/ml NEB) 
 
Reaction samples were run with the following parameters: 
37° C for 30 minutes  
95° C for 5 minutes – ramp down to 25°C at 5° C /min. 
 
Annealed oligos were used at a 1:200 dilution for ligation reactions with 
digested/dephosphorylated vector, using the Quick Ligase kit (NEB) 
following manufacturer’s instructions.  
Ligated constructs were transformed into DH5a bacteria for plasmid 
amplification and extraction (Section 2.3). 
 
sgRNA target gene  sgRNA oligos sequences (5’à3’) 
Ddx54 #1 Forward: caccGTCAGCCGCTCAAACATCGGG 
Reverse: aaacCCCGATGTTTGAGCGGCTGAC 
Ddx54 #2 Forward: caccGCACATGCACCAGACGCCCAG 
Reverse: aaacCTGGGCGTCTGGTGCATGTGC 
Ddx3x #1  Forward: caccGCGCAAGGACGGACTCTAGAT 
Reverse: aaacATCTAGAGTCCGTCCTTGCGC 
Ddx3x #2 Forward: caccGCAGATTCGAGACTTAGAACG 
Reverse aaacCGTTCTAAGTCTCGAATCTGC 
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Rpa3  Forward: caccGGCTGGCGTTGACGCGCGCTT 
Reverse aaacAAGCGCGCGTCAACGCCAGCC  
Rosa26 Forward: caccGGAAGATGGGCGGGAGTCTTC 
Reverse: aaacGAAGACTCCCGCCCATCTTCC 
DDX3X Exon 2 Forward: caccGATCTGAAGAGTTCAGGTCT  
Reverse: aaacAGACCTGAACTCTTCAGATC 
DDX3X Exon 3 Forward: caccGCTCGGTTCCTTAAATGAGG 
Reverse aaacCCTCATTTAAGGAACCGAGC 
DDX3X N-terminal domain #1 Forward: caccGGTGGACGGAGTGATTACGA  
Reverse: aaacTCGTAATCACTCCGTCCACC 
DDX3X N-terminal domain #2 Forward:  caccGGGAGTGATTACGATGGCAT 
Reverse aaacATGCCATCGTAATCACTCCC 
DDX3X ATP binding loop #1 Forward: caccGTGAGGGAACTCTTTTCTGG 
Reverse aaacCCAGAAAAGAGTTCCCTCAC 
DDX3X ATP binding loop #2 Forward: caccGCTCCCACCAAGTGAACGCT 
Reverse: aaacAGCGTTCACTTGGTGGGAGC 
DDX3X ATP binding and hydrolysis site #1 Forward: caccGATGCTTTTGCACTGGAGTT 
Reverse aaacAACTCCAGTGCAAAAGCATC 
DDX3X ATP binding and hydrolysis site #2 Forward:  caccGGAATAGCATGCTTTTGCAC 
Reverse  aaacGTGCAAAAGCATGCTATTCC 
DDX3X RNA binding domain (portion A) #1 Forward: caccGTTGGCAGTACAGATCTACG 
Reverse: aaacCGTAGATCTGTACTGCCAAC 
DDX3X RNA binding domain (portion A) #2 Forward: caccGCACCACCATAAACCACGCA 
Reverse: aaacTGCGTGGTTTATGGTGGTGC 
DDX3X RNA binding domain (portion B) #1 Forward: caccGAAGGGTGCAGATTCTCTGG 
Reverse: aaacCCAGAGAATCTGCACCCTTC 
DDX3X RNA binding domain (portion B) #2 Forward: caccGCCATGGAGACCGTTCTCAG 
Reverse: aaacCTGAGAACGGTCTCCATGGC 
DDX3X RS-like domain #1 Forward: caccGACTACAAGGGTAGCAGTCG 
Reverse: aaacCGACTGCTACCCTTGTAGTC 
DDX3X RS-like domain #2 Forward: caccGGAGACTACCGACAAAGTAG 
Reverse: aaacCTACTTTGTCGGTAGTCTCC 
AURKB #1 Forward: caccGAAAATAGTTGTAGAGACGC 
Reverse aaacGCGTCTCTACAACTATTTTC 
AURKB #2 Forward: caccGATGCTCTAATGTACTGCCA 
Reverse: aaacTGGCAGTACATTAGAGCATC 
Table 2.2. sgRNAs sequences and target genes.  
The listed sgRNAs were cloned in the relevant vectors to perform CRISPR/Cas9. 
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DNA oligonucleotides were synthesized by IDT (Integrated DNA 
technologies). Automated DNA sequencing was performed by Source 
Bioscience in Cambridge (UK). 
 
 
2.5 RNA purification and mRNA quantification  
2.5.1 RNA purification 
Total RNA was purified from cells using the miRNeasy Mini Kit (Qiagen) 
following manufacturer instructions. Excess of contaminating DNA was 
removed by On-Column DNase Digestion with the RNase-Free DNase Set 
(Qiagen), following manufacturer’s instructions. 
 
2.5.2 First strand cDNA synthesis 
The Superscript III Reverse Transcriptase kit (Invitrogen) was used 
according to manufacturer’s instructions to synthesise first strand cDNA. 
Briefly, RNA was mixed with 1 µl hexanucleotide primers (100 ng/µl), 1 µl 
dNTP (10 mM) and 12 µl H2O. Samples were heated for 5 minutes at 65°C 
then mixed with 4 µl 5x first strand buffer, 1 µl 0.1 M DTT, 1 µl of RNAse 
out (a recombinant ribonuclease inhibitor at 40 U/µl) and 1 µl Superscript 
III RT for 5 minutes at 25°C. cDNA was synthesised by incubating 
samples at 50°C for 30-60 minutes. Reactions were inactivated for 15 
minutes at 70°C.  
 
2.5.3 Quantitative real-time RT-PCR 
cDNA purified as described (2.5.2) was used to quantify mRNA levels. 
Quantitative real-time PCR was performed with the ABI Prism 7300 
(Applied Biosystems) sequence detection system using SYBRGreen as the 
detector.   A 10 µl reaction was used on 96 well plates (5 µl of SYBRGreen 
master-mix, 2 µl of 1 µM forward and reverse primer mix, 3 µl of 1:20 
diluted cDNA). Used primers are listed in Table 2.3.  
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PCR amplification was performed with an initial step of 2 minutes at 
95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.  
Relative quantification was obtained calculating ∆∆Ct as follows: 
Fold change of normalized target gene expression = 2-∆∆Ct  
Where: 
∆Ct1 = Ct (Target gene in	treated) – Ct (Ref gene in treated)  
∆Ct2 = Ct (Target gene in control) – Ct (Ref gene in control)  
∆∆Ct = ∆Ct1 (treated) – ∆Ct2 (control)  
GAPDH expression was used as reference gene. Standard deviation (error 
bars) and P-values were calculated using the Prism 7 statistical tool. 
 
Primer for cDNA analysis Sequences (5’à3’) 
NEAT1 lncRNA isoform e and b Forward: GTGGCTGTTGGAGTCGGTAT   
Reverse: ATTCACTCCCCACCCTCTCT   
PVT  Forward: CTTCCTTTGGGTCTCCCTATG 
Reverse: AAGGCTCCAGGGAGTATGGT 
TET2 Forward: GCAGCACACCCTCTCAAGAT 
Reverse: TCCCTTACTGCTCTTCCTGGA 
NCOA1 Forward: TCCTGCCAGCTTCACTTCAG 
Reverse: CTGATCGCCTGTTCCTGGTT 
MYB Forward: GCAGGTGCTACCAACACAGA       
Reverse: GGTGTTCTCCCAAACAGGAA       
MTA3 Forward: CCCGAGACATCACCTTGTTT       
Reverse: ACAGGTCCTCCGAGTGGTACT      
TFF1 Forward:  TTTGGAGCAGAGAGGAGGCAATGG 
Reverse:  TGGTATTAGGATAGAAGCACCAGGG 
GREB1 Forward:  CACCGGTGTGCACAAGTTAC 
Reverse:  GTGCCTCCGTGTCTAGCTTC 
RPS24 Forward: AGAAAGCAACGAAAGGAACGC 
Reverse: AGCACCTTTACTCCTTCGGC 
DDX54 Forward: TGGGACAGTCAGGACAGGAA 
Reverse: CCCTTCTTCGTCCGAGTCAC 
DDX3X Forward: ACTATGCCTCCAAAGGGTGTCC 
Reverse: AGAGCCAACTCTTCCTACAGCC 
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SOX4 Forward: ACTTTGAGAGCATGTCCCTGG 
Reverse: GTGCAGTAGTCCGGGAACTC 
CALR Forward: CCTGCCGTCTACTTCAAGGAG 
Reverse: CCGTAGAACTTGCCGGAACT 
JUND Forward: GAAGACCCTCAAGAGTCAGAACA 
Reverse: TGTTGACGTGGCTGAGGA 
PUS1 Forward: TGGTGAGGACATGAGGAAAATG 
Reverse:	GAATGTGAGAGGGAAGGTGG 
RPS2 Forward: CCCACACTGTCCCTTGCAA 
Reverse: AGCAGCTTCTTAGGCACAGG 
RPS3 Forward: ATGCTGAAAAGGTGGCCACT 
Reverse: ATGAACCGCAGCACACCATA 
RPS6 Forward: ACGCTCTGGGTGAAGAATGG 
Reverse: CTCAGTAGCAGGCGGACAC 
CCNA2 Forward: CATGGACCTTCACCAGACCT         
Reverse: GATTTAGTGTCTCTGGTGGGTTG      
CDK2 Forward: CATTCCTCTTCCCCTCATCA         
Reverse: GCCCCCTCTGTGTTAATAAGC        
KLF4 Forward: CCATCCTTCCTGCCCGATC 
Reverse: CGTCTTCCCCTCTTTGGCTT 
CCNE1 Forward: CAGATGAAGAAATGGCCAAAA       
Reverse: TTTGGGTAAACCCGGTCAT         
GAPDH Forward: TGCACCACCAACTGCTTAGC 
Reverse: GGCATGGACTGTGGTCATGAG 
Table 2.3. Primers used in qPCR. 
 
 
2.6 Protein purification, detection and analysis 
2.6.1 SDS polyacrylamide gel electrophoresis (PAGE) 
Proteins were separated in 10% acrylamide gels according to size, by the 
standard Laemmli procedure of one-dimensional gel electrophoresis under 
denaturing conditions. Protein samples were denatured by boiling in 1X 
SDS loading buffer (200mM Tris-HCl pH6.8, 20% [v/v] b-mercaptoethanol, 
2% [v/v] SDS, 0.1% [w/v] bromophenol blue, 40% [v/v] glycerol) for 5 
minutes, and then loaded onto the gel. The gel was separated by 
electrophoresis in Tris-glycine running buffer (25mM Tris-HCl, 250mM 
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glycine, 0.1% [v/v] SDS) at 150-200V. Pre-stained high molecular weight 
protein markers were run alongside the samples (PageRuler from 
ThermoFisher Scientific).  
 
2.6.2 Western blotting 
Proteins were transferred from polyacrylamide gels to nitrocellulose 
membranes using the mini-trans blot cell (BIO-RAD). Following 
electrophoresis, gels were transferred in transfer buffer (50mM Tris, 
500mM glycine, 20% [v/v] methanol) to a nitrocellulose membrane 
(Schleicher and Schuell) by applying a constant current (0.4A) for 45 min. 
After the transfer, the nitrocellulose membrane was stained with Ponceau 
S to ensure equal transfer and then placed either in milk blocking buffer 
(TBS with 0.5% [v/v] Tween-20, 5% [w/v] non-fat milk powder) or BSA 
blocking buffer (TBS with 0.5% [v/v] Tween-20, 5% BSA), for a minimum 
of 30 minutes at room temperature. The membranes were then probed 
with primary antibody diluted in blocking buffer, and incubated on a 
rocking table overnight at 4°C. The next day membranes were washed 
three times with TBS with 0.5% [v/v] Tween-20 with gentle agitation at 
room temperature and then probed with secondary antibody (conjugated 
to horse-radish peroxidase) dilution in blocking buffer at room 
temperature for 1 hour. Membranes were then washed three times for 10 
minutes with TBS with 0.5% [v/v] Tween-20. Detection of protein bands 
was carried out using the ECL system (Amersham) according to the 
manufacturer’s instructions. The membranes were then exposed to X-ray 
film (Fuji) or imaged by Chemicdoc (Imaging systems –BIORAD). 
Antibodies used are listed in Table 2.4. 
In some cases membranes were stripped in order to be re-probed with 
different antibodies. For stripping, membranes were incubated for 1 hour 
in stripping solution (2% SDS, 62.5 mM Tris-HCl Ph 6.8, 0.8% ß-
mercaptoethanol) in gentle shaking. Membranes were then washed twice 
in TBS with 0.5% [v/v] Tween-20 for 20 minutes in gentle shaking and 
blocked as previously described. 
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2.6.3 Preparation of mammalian cell samples for Western blotting 
Cells were lysed by the addition of 1X SDS loading buffer. The lysed cells 
were transferred to an eppendorf tube and sonicated with a VibraCell 
probe sonicator (Sonics) for 20 seconds at 22% amplitude. The samples 
were then boiled for 5 minutes. 5-30µl of whole cell extracts were analysed 
by SDS-PAGE and western blotting.  
 
2.6.4 Antibodies 
The following antibodies were used in the listed concentrations for 
western blot, immunoprecipitation and immunofluorescence assays. 
 
Antibody Description Concentration 
  WB IP 
(µg/mg of 
lysate) 
IF 
DDX54 Rabbit polyclonal-Abcam- ab76947 1:1000 3-5  
DDX54 Mouse monoclonal –Abcam-ab57711 
 
1:1000  1:500 
Fibrillarin Rabbit polyclonal-Nucleolar Marker 
Abcam-ab5821 
 
  1:200 
DDX3 Mouse monoclonal -Abcam-ab196032 1:1000 3-5  
b-tubulin Rabbit polyclonal-Abcam-ab6046 1:1000   
DDX1 Rabbit polyclonal -Abcam - ab70252  3-5  
DDX24 Rabbit polyclonal -Abcam-ab70463  3-5  
GAPDH Rabbit Polyclonal Abcam ab9483 1:1000   
ERa Rabbit monoclonal -Abcam -ab32063 
 
1:1000 3-5  
RPS2 Rabbit monoclonal -Abcam ab155961 
 
1:1000   
RPS3 Rabbit monoclonal -Abcam ab181992 
 
1:1000   
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RPS6 Rabbit monoclonal -Abcam ab137826 
 
1:1000   
RPS6-(phospho S240 + 
S244) 
Rabbit polyclonal -Abcam-ab53024 
 
1:1000   
JUND Rabbit polyclonal-Abcam-ab181615 1:1000   
CDK2 Mouse monoclonal –Santa Cruz- sc-
6248  
 
1:500   
KLF4 Rabbit polyclonal-Abcam-ab106629 1:1000   
H3 (tri methyl K4)  
 
Rabbit polyclonal –Abcam-ab8580 
 
 3-5  
b-tubulin Rabbit polyclonal - Loading Control 
Abcam-ab6046 
1:500   
GAPDH Rabbit Polyclonal -Abcam -ab9485 1:2000   
Mouse Control IgG2a  
 
Mouse IgG2a Isotype Control 
Abcam-ab18413 
 
 3-5  
Rabbit IgG, polyclonal - 
Isotype Control 
 
Rabbit IgG, polyclonal - Isotype Control 
Abcam-ab27478 
 
 3-5  
Alexa594-conjugated IgG. 
 
Rabbit polyclonal, Invitrogen   1:250 
Alexa488-conjugated 
IgG2A 
Mouse polyclonal, Invitrogen   1:250 
Table 2.4. Antibodies used for immunoprecipitation (IP), western blot (WB) or 
confocal immunofluorescence (IF) 
 
2.6.5 Co-Immunoprecipitation from mammalian cell extracts (Co-IP). 
Cells were washed once in PBS and pelleted by micro-centrifugation 
(4,000 rpm, 4 min), resuspended in ice-cold IPH lysis buffer (150mM NaCl, 
50mM Tris-HCl pH 8.0, 5mM EDTA, 0.5% NP-40) with protease inhibitor 
cocktail (CompleteTM, Roche) and incubated on ice for 30 minutes. Extracts 
were cleared of debris by micro-centrifugation (15 minutes, 13,000rpm, 
4°C). Extracts were then incubated with 3µg of antibody, on a rotating 
wheel at 4°C for a minimum of 2 hours. 20µl protein A or protein G 
sepharose beads (1:1 mix) were added and the incubation continued for 4-
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14 hours. The sepharose beads were pelleted in a cooled micro-centrifuge 
(4,000 rpm, 1 min, 4°C) and washed 3 times with ice-cold IPH. After the 
final centrifugation, the beads were resuspended in 1X SDS loading buffer 
analysed by SDS-PAGE and western blotting.    
 
2.6.6 Fractionation of mammalian cells. 
Subcellular fractions were obtained following the REAP fractionation 
protocol [236]. Briefly cells grown as monolayers in 10 cm diameter dishes 
were washed in ice-cold phosphate buffer saline (PBS) pH 7.4, scraped 
from culture dishes on ice using a plastic cell scraper and collected in 1.5 
ml micro-centrifuge tubes in 1 mL of ice-cold PBS. After a “pop-spin” 
centrifugation (for 10 seconds in an Eppendorf table-top micro-centrifuge 
13,000 rpm), supernatants were removed from each sample and cell 
pellets were resuspended in 900 µL of ice-cold 0.1% NP40 (Calbiochem, 
CA, USA) in PBS and triturated 5 times using a p1000 micropipette 
(Gilson, WI, USA). 300 µL of the lysate were removed as “whole cell 
lysate” and 100 µL of 4 × Laemmli sample buffer were added to it, then 
kept on ice until the sonication step. The remaining (600 µL) material was 
collected by centrifugation for 10 seconds in 1.5 ml micro-centrifuge tubes 
and 300 µl of the supernatant were removed as the “cytosolic fraction”. 
100 µL of 4 × Laemmli sample buffer were added to this fraction and 
boiled for 1 min. After the remaining supernatant was removed, the pellet 
was resuspended in 1 ml of ice-cold 0.1% NP40 in PBS and centrifuged as 
above for 10 seconds and the supernatant was discarded. The pellet (~20 
µL) was resuspended with 180 µL of 1 × Laemmli sample buffer and 
designated as “nuclear fraction”. Nuclear fractions and whole cell lysates 
that contained DNA were sonicated with a VibraCell probe sonicator 
(Sonics) for 20 seconds at 22% amplitude, and boiled for 1 min. 10 µL, 10 
µL and 5 µL of whole cell lysate, cytoplasmic and nuclear fractions, 
respectively, were loaded and separated by electrophoresis using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  
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2.7 Electrophoretic Mobility Shift Assay (EMSA)  
2.7.1 Preparation of protein extracts 
Cultured adherent cells (MCF7) were washed twice with ice-cold PBS 1X, 
collected by scraping in 1 ml of ice-cold PBS1X and transferred into a 1.5 
ml  micro-centrifuge tube. The cell suspension was collected by 
centrifugation in a micro-centrifuge for 5 min at 700 x g, at 4°C and pellets 
were lysed in 200 µl of lysis buffer (1% Triton X100, 25Mm Tris-HCl (pH 
7.4), 40 mM KCl) supplemented with protease inhibitor cocktail 
(CompleteTM, Roche). Lysates were incubated for 20 minutes on ice and 
then collected by centrifugation at full speed at 4°C. Supernatants were 
transferred to a new micro-centrifuge tube and kept on ice. Protein 
content was quantified with a BCA protein assay Kit (ThermoFisher 
Scientific), following manufacturer’s instructions  
 
2.7.2 Preparation of radiolabelled JUND RNA probes. 
RNA oligonucleotides in Table 2.5 were synthetized by IDT (Integrated 
DNA technologies). To generate 5’ radiolabelled probe, the following T4 
polynucleotide kinase reactions were set up: 
• 20 pmol of RNA probe 
• 1X T4 kinase buffer  
• T4 PNK (2 µl - 10,000 units/ml)  
• 100pmol ATP, [γ-32P]- 3000Ci/mmol 10mCi/ml  
 
Reactions were incubated for 1h at 37°C with gentle shaking and stopped 
by adding EDTA, pH8 to a final concentration of 50mM. Labelled probes 
were purified with RNA Clean & Concentrator™-5, according to 
manufacturer’s instructions. Finally, probes were diluted in RNase-free 
water (1:10) and quantified by scintillation counter. 
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2.7.3 Protein extract-RNA probe binding reactions. 
30µg of protein extract were combined with 50000cpm/µl labelled RNA 
probe. Lysis buffer supplemented with 5 U/µl of RNaseOUT Recombinant 
Ribonuclease Inhibitor (Invitrogen) was used to dilute the protein extracts 
to the appropriate amount. In the supershift condition, 1.5 µg of anti-
DDX3 antibody were added to the reaction. Binding reactions were carried 
out at room temperature for 20 minutes. After this time, heparin was 
added to a concentration of 500 µg/ml and the reaction was allowed to 
continue for 10 more minutes.  
 
2.7.4 Separation of protein extracts-RNA probes complexes by 
electrophoresis 
Glycerol was added to all samples to a final concentration of 20% (v/v) and 
samples were run on a 6% TBE gel (Novex- ThermoFisher Scientific) at 60 
V for 30 minutes. 
Gels were fixed in fixing solution (Methanol 10%, Acetic Acid 20% in H2O) 
for 10 minutes at room temperature, then placed into an autoradiography 
exposure cassette and exposed to film at -80°C for variable exposure times 
(30 mins to 48h). 
 
 
 
RNA probe 
name 
RNA probe sequence (5’à3’) 
hJUND  
Wild Type  
DDX3X Binding Motif 
 
5’-AGCUGGUUCUGCUUGUGUAAAUCCUCCAGGGCCUUGACGAAGCCCUCGGCGA-
3’ 
hJUND  
Mutant  
DDX3X Binding Motif 
 
5’-AGCUGGUUCUGCUUGUGUAAAUCGAGCAGGGCCUUGACGAAGCCCUCGGCGA-
3’ 
Table 2.5. RNA oligo probes used in EMSA. 
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2.8 Cell lines and mammalian tissue culture. 
2.8.1 Cell culture media, reagents and maintenance 
 
Name Cell type Other information 
MCF7 Human transformed 
breast epithelial cancer 
cell line 
Estrogen Receptor a + 
MCF10A Human immortalized 
non-tumorigenic breast 
epithelial cell line 
 
OCI AML2/CAS9 Human Acute Myeloid 
Leukaemia cell line 
Stably expressing Cas9. 
OCI AML3/CAS9 Human Acute Myeloid 
Leukaemia cell line 
Type A NPM1 gene mutation 
(NPM1c). 
Stably expressing Cas9. 
RN2c   Mouse acute myeloid 
leukaemia cell line 
MLL-AF9/NrasG12D; 
Stably expressing Cas9 
NIH 3T3/Cas9 Mouse embryonic 
fibroblasts 
Stably expressing Cas9 
HEK293T Human embryonic 
kidney epithelial cell line 
SV40 T-antigen 
 
Table 2.6. Cell lines used. 
 
 
All tissue culture manipulations were carried out under sterile conditions 
in a standard laminar flow hood. All cell lines used are listed in Table 2.6. 
MCF7, NIH-3T3 and 293T cells were cultured in DMEM (Invitrogen), 
supplemented with 10% FBS and 1% penicillin/streptomycin/glutamine. 
MCF10A cells were cultured in DMEM/F12 (Invitrogen) supplemented 
with 5% Horse serum, 20ng/ml EGF, 0.5 mg/ml Hydrocortisone, 100ng/ml 
cholera toxin, 10 µg/ml Insulin and 1% penicillin/streptomycin. OCI-
AML2/Cas9 and OCI-AML3/Cas9 cells were cultured in Alpha-MEM 
 62 
supplemented with 20% FBS, 1% penicillin/streptomycin/glutamine and 
1µg/ml blasticidin. 
RN2c cells were cultured in RPMI1640 (Invitrogen) supplemented with 
10% FBS and 1% penicillin/streptomycin/glutamine. All cell cultures were 
stored in incubators at 37°C at 5 %CO2 (100% humidity) and passaged 
between 1:3 and 1:5 every 3-4 days to maintain a sub-confluent cell 
density. Cells were passaged using conventional cell culture techniques. 
To detach adherent cells, culture medium, and cells were washed in PBS 
1X and detached by addition of 1ml/10cm plate Trypsin/EDTA solution 
(0.025% trypsin and 0.01% EDTA in PBS). 
RN2c and NIH-3T3/Cas9 cells were a kind gift from the Vacok lab. These 
cell lines were derived by retroviral transduction of a murine MLL-
AF9/NrasG12D acute myeloid leukemia cell line (RN2)  and murine 
fibroblasts NIH-3T3 with MSCV-hCas9-PGK-Puro, followed by puromycin 
selection and serial dilution to derive single cell-derived clones. OCI-
AML2/Cas9 and OCI-AML3/Cas9 were a kind gift from Konstantinos 
Tzelepis (Wellcome Trust Sanger Institute). These cell lines were 
generated by lentiviral transduction using pKLV2-EF1aBsd2ACas9-W, 
followed by blasticidin selection and serial dilution to derive single cell-
derived clones.  
 
2.8.2 Cell proliferation assay  
Cells were seeded at 3 x 105 in 2 ml of complete medium in three biological 
replicates. Cells were counted every 2 days after plating using the 
Countess II cell counter. Proliferation curves and standard deviation were 
generated using the Prism 7 statistical tool. 
 
2.8.3 Transient transfection of cells using FuGENE 6. 
MCF7 and MCF10A cells were plated in a 6-well tissue culture dish in the 
relevant culture media without antibiotics for 24h reaching 60-80% 
confluency. Media was replaced with 2ml of Opti-MEM. 6µl of FuGENETM 
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was mixed with 74µl of Opti-MEMTM (Gibco), 2µg of total DNA was then 
added to the mix and incubated for 30 minutes at room temperature. 
Increasing amount of pPB-CAG-hKLF4-pA-pgk-Hygro were transfected (0 
µg, 0.5 µg, 1 ug, 2µg) and combined with decreasing amount of pGG131 
control plasmid in order to transfect a final amount of 2µg of DNA in all 
conditions. 
The transfection mix was added in droplets to the cells which were left at 
37°C, 5%CO2 for 6-16 hours. After this time, transfection media was 
replaced by 3 ml of normal media. Cells were harvested 48h after 
transfection for RNA extraction or processed for cell cycle analysis (Section 
2.10.2). 
 
2.8.4 Transient knock down by RNA interference (RNAi). 
MCF7 and MCF10A cells were plated in a 6-well tissue culture dish in the 
relevant culture media without antibiotics for 24h reaching 60-80% 
confluency.  Then, cells were transfected with small interfering RNA 
oligonucleotides (100 nM final concentration) and Dharmafect I to knock 
down DDX3X or DDX54 according to manufacturer’s instructions (4µl of 
Dharmafect I were combined with 96µl of Opti-MEM; 10µl of 20µM siRNA 
were combined with 90µl of Opti-MEM). The siRNA used are listed in 
Table 2.7. 
Target  siRNA name 
hDDX3X J-006874-06 
 
hDDX3X J-006874-08 
 
hDDX54 J-017128-09 
 
hDDX54 J-017128-10 
 
hDDX54 J-017128-12 
 
hKLF4  J-005089-08 
 
(Non-targeting siRNA)  Scramble sequence     D-001810-01  
Table 2.7. siRNAs used. 
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Cells were harvested 72h after transfection for RNA or protein extraction 
and several downstream assays. All ON-TARGET plus human siRNA and 
Dharmafect I reagent were purchased from DharmaconTM. 
 
2.8.5 Lentiviral Particles production 
For each plasmid to be transfected, HEK293T cells were plated in DMEM 
+ 10% FBS without antibiotics (no penicillin or streptomycin) in a 10 cm 
tissue culture plate previously coated with poly-D-lysine (Sigma), and cells 
incubated at 37°C, 5% CO2 overnight. 
A mixture of the 3 transfection plasmids was prepared in a 2:1:0.5 ratio as 
follows:  
• 3 µg pLKO.1 shRNA plasmid/sgRNA containing plasmid 
• 1.5 µg psPAX2 packaging plasmid 
• 750 ng pVsVg envelope plasmid 
and OPTI-MEM medium was added to a final volume of 60 µl. 
 
For each reaction 18 µL FuGENE 6 were mixed with 222 µL OPTI-MEM 
and 240µl of Fugene mix were added to each DNA mix and incubated for 
30 minutes at room temperature. The DNA:FuGENE mix was added 
dropwise to the cells and medium was replaced with 6 ml of normal fresh 
DMEM after 16h incubation at 37°C, 5% CO2.  24h and 48h hours later 
virus-containing media was harvested from cells, filtered through a 0.45 
µm filter to remove the cells and used to infect cells or stored at -80°C. 
 
2.8.6 Generation of stable knock down cell lines through shRNA lentiviral 
transduction. 
Stable DDX3X and DDX54 knock-down MCF7 cells were obtained by 
transduction of lentiviral particles bearing pLKO.1 plasmids expressing 
the relevant shRNA and the puromycin selection cassette. The pLKO.1 
constructs used are shown in Table 2.8. 
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Target  pLKO.1-puro ID 
hDDX3X TRCN0000000001 
hDDX54 TRCN0000288991 
pLKO.1-puro Non-
Mammalian shRNA 
Control Plasmid DNA 
 
SHC002 
 
Table 2.8. shRNAs used. 
 
 
MCF7 cells were plated in normal DMEM in 10 cm plate to reach 70% 
confluency the next day. The viral suspension (~ 6 ml) was supplemented 
with 8 µg/ml human polybrene (Millipore) and added to MCF7 target 
cells. Cells were left at 37°C, 5% CO2 overnight.  Virus containing media 
was changed for fresh media 24 hours after infection and to 1µg/ml 
puromycin-containing media 48h after infection. After three days of 
selection in puromycin, cells were harvested for RNA or protein extraction. 
 
2.8.7 Generation of DDX54 and DDX3X CRISPR/Cas9 knockout or 
DDX3X CRISPR/Cas9 domain targeted cell lines. 
Lentiviral sgRNA expressing vector (U6-sgRNA-EFS-GFP and pKLV2-
U6gRNA5 (BbsI)-PKGpuro2ABFP-W) together with the packaging 
plasmids PAX2 and VSVg were transfected at a 2:1:0.5 ratio into 
HEK293T cells for lentiviral production (as described in Section 2.8.5). 
Supernatant was harvested 48h and 72h after transfection. 1x 106 RN2c, 
OCI-AML2/Cas9 or OCI-AML3/Cas9 cells and viral supernatant were 
mixed in 2 ml of culture medium supplemented with 8 µg/ml (human) or 4 
µg/ml (mouse) polybrene (Millipore), followed by spinfenction (60 min, 900 
g, 37 °C). NIH-3T3/Cas9 cells were plated in 6 well plates and infected 
with the same ratio of culture medium:viral supernatant. All cells were 
further incubated overnight at 37°C. The medium was refreshed on the 
following day and the transduced cells were cultured further.  
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For competition assays, a serial dilution of relevant virus in correlation 
with the GFP+ or BFP+ cell population was used to estimate the viral titre 
to use. To ensure sub-optimal infection, a 1:3 dilution of the first viral 
collection (Section 2.8.5) was used under all conditions. 
 
2.9 Immunofluorescence, RNA FISH and confocal microscopy 
MCF7 wild type cells or MCF7 cells transfected with either scramble 
siRNA or DDX54 targeting siRNAs (#9 or 12) at 48h after transfection, 
were seeded in 12 well culture dishes containing glass coverslips 
(previously coated with poly-L-lysine and let to attach overnight). The 
next day cells were washed twice in 1 X PBS then fixed with 4% 
paraformaldehyde in PBS, pH 7.4 for 15 min at room temperature then 
washed twice with 1 X PBS. The next steps were diversified to perform 
either immunofluorescence, RNA FISH or a combination of the two 
techniques. 
 
2.9.1 Double immunofluorescence 
Fixed cells were permeabilized for 10 min at room temperature incubation 
in 1X PBS containing 0.25% Triton X-100. Cells were washed three times 
in 1X PBS and then blocked with 1% BSA in PBS-0.1% Tween for 30 min 
at room temperature. A mixture of anti-DDX54 and anti-Fibrillarin 
primary antibodies diluted in block solution was added to cells for 1h at 
room temperature. After primary antibody incubation, cells were washed 
three times in 1X PBS-0.1% Tween and a mixture of Alexa-Fluor 488 
conjugated anti-mouse and Alexa-Fluor 594 conjugated anti-Rabbit 
secondary antibody diluted in blocking solution was added to cells in the 
dark for 1h at room temperature. Cells were washed three times with 1X 
PBS- 0.1% Tween.  
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2.9.2 RNA Fluorescence In Situ Hybridization (RNA-FISH). 
Fixed cells were permeabilised by 1h incubation in 70% ethanol at 4°C, 
then washed twice in 1X PBS and twice in FISH wash buffer (2X SCC, 
10% v/v formammide in Nuclease-free water) for 5 minutes per wash. 
Next, coverslips were placed cell-side down onto a 100ul drop of 
hybridization buffer (10% w/v dextran in wash buffer) containing 1:1000 
diluted Quasar 570-conjungated NEAT1 lncRNA probes (StellarisTM-LGC) 
in a humidified chamber. The humidified chambers were sealed and 
incubated in the dark at 37°C overnight. The next day coverslips were 
incubated in fresh hybridization buffer in the dark for 30 min at 37°C, to 
reduce the background, then washed once in wash buffer and twice in 1X 
PBS.  
 
2.9.3 Immunofluorescence and RNA FISH combined  
Fixed cells were permeabilised and blocked as in Section 2.9.2, then 
washed in 1X PBS and in FISH wash buffer as described in Section 2.9.2 
then hybridized overnight with 100µl of hybridization buffer (2.10.2) 
containing NEAT1 lncRNA probes (1:1000), 0.25% Triton X100 and anti-
DDX54 primary antibody. The next day coverslips were washed as 
described (Section 2.9.2), incubated 1h at room temperature in the dark 
with anti-mouse Alexa Fluor 488 conjugated secondary antibody solution 
(Section 2.9.1) and finally washed three times with 1X PBS- 0.1% Tween.  
In all cases (Sections 2.9.1-2-3) coverslips were mounted on microscope 
slides using DAPI-containing mounting medium (Vectashield- Vector 
Laboratories). Samples were then analysed by confocal microscopy. 
Confocal laser images were captured with an Olympus Fluoview FV1000 
microscope equipped with a 40X oil lens. Image processing was carried out 
using ImageJ software.  
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2.10 Flow cytometry 
2.10.1 BFP and GFP detection 
For detection of GFP or BFP, RN2c, OCI AML2 and OCI AML3 
suspension cells were washed and resuspended in 1X PBS at room 
temperature. For detection of GFP, NIH-3T3 cells were detached by 
trypsinization, washed and resuspended in 1X PBS at room temperature. 
Cells were then analysed with a FACSCalibur cytometer (BD) (for GFP 
detection) or SONY Cell Sorter (for BFP detection). At least 25,000 events 
per sample were collected. Data were processed with  
FlowJo software. Standard deviation (error bars) and p-values were 
calculated using the Prism 7 statistical tool. 
 
2.10.2 Cell cycle assessment 
MCF7 cells transfected with either scramble siRNA or DDX54 targeting 
siRNAs (#9 or 12), or DDX3X targeting siRNA (#6 or #8) were treated with 
50ng/ml nocodazole for 16 h (overnight) at 72h after transfection. Cells 
were detached by trypsinization. OCI-AML2/Cas9 and OCI-AML3/Cas9 
cells in which CRISPR/Cas9-mediated excision was performed against the 
DDX3X RNA binding domain or no target (empty vector) were treated 
with 50ng/ml nocodazole for 16 h (overnight) at day 8 after infection (day 4 
after puromycin selection).  
All cells were washed in 1X PBS 10mM EDTA and pellets were 
resuspended in 100µl 1X PBS 10mM EDTA 1% BSA. 200µl of Propidium 
Iodide (PI) staining solution (1% NP40, PI 20 µg/ml, RNaseA 0.1 mg/ml in 
1X PBS, 10mM EDTA, 1%BSA) were added to resuspended pellets. 
Samples were kept on ice and measured by a FACSCalibur Cytometer 
(BD). 
At least 25,000 events per sample were collected. Data were processed 
with FlowJo software. Standard deviation (error bars) and p-values were 
calculated using the Prism 7 statistical tool. 
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2.11 RNA-seq 
2.11.1 RNA-seq library preparation. 
Total RNA was extracted as described (Section 2.5) from MCF7 cells 
transfected with either scramble siRNA or DDX54 targeting siRNAs (#9 or 
12), or DDX3X targeting siRNA (#6 or #8) harvested 72 h after 
transfection and OCI-AML2/Cas9 and OCI-AML3/Cas9 cells in which 
CRISPR/Cas9-mediated excision of DDX3X RNA binding domain (A and B 
portions) or no target (empty vector) harvested at day 8 after infection 
(day 4 after puromycin selection). All conditions were produced in three 
independent biological replicates. 
Ribosomal RNA was depleted with Ribo-Zero rRNA Removal Kit 
(Human/Mouse/Rat) from Illumina(R), following manufacturer’s 
instructions. RNA seq libraries were produced with the NEXTflex™ RNA-
Seq Kit from Bioo Scientific, following manufacturer’s instructions. Before 
multiplexing, excess primer was removed with AMPure XP beads (Beckam 
Coulter). Before and after multiplexing, libraries were tested for both size 
and quantity of DNA using the Qubit™ dsDNA HS Assay Kit and High 
Sensitivity D1000 ScreenTape system following manufacturer’s 
instructions. 
 
2.11.2 RNA-seq bioinformatic analysis 
RNA-seq bioinformatic analysis was performed as follows. 
 
(i)For differential gene expression in DDX3X and DDX54 knock down 
MCF7 cells (Section 2.84):  
Trimmed reads were mapped in paired end mode to the h38 human 
genome using tophat [237] with the following parameters (--no-coverage-
search --max-multihits 300 --report-secondary-alignments --read-
mismatches 2 --library-type fr-firststrand). Multihits (reads mapping to 
multi loci) were filtered, along with reads mapping with quality score less 
 70 
than 20. Reads were counted across gene models taken from the Ensembl 
v86 gtf gene model list using the summarizeOverlaps function from 
the GenomicAlignments package in R [238]. The strand of each read was 
inverted prior to counting to account for the fact that libraries represent 
the first strand of synthesised cDNA. Read counts were converted into 
normalised fragments per kilobase mapped (FPKM) values for quality 
control plots. Differential expression analysis was conducted on the raw 
count data using the DESeq2 package in R [239]. P values were corrected 
for multiple testing using the Benjamini and Hochberg FDR correction. 
Significantly changing genes were identified based on a fold change 
greater than 2-fold (up or down) and an adjusted p value less than 0.05. In 
addition, significant genes were filtered to remove genes where both the 
control and mutant samples had an average FPKM score less than 1. 
(ii)For differential gene expression in OCI-AML2/Cas9 and OCI-
AML3/Cas9 cells upon CRIPSR/Cas9-mediated excision of DDX3X RNA 
binding domain (Section 2.8.7):  
Fastqc files were mapped against the reference genome sequence 
(GRCh38) using STAR [240] (v2.5.0) with indexes built with the Ensembl 
[241] reference transcriptome GTF file. The number of reads mapping to 
each Ensembl annotated gene were counted with STAR and then imported 
into DESeq2 [239] for differential expression analysis. The DESeq2 
workflow was run with default parameters using a one-factor design 
representing the treatment condition. The resulting p-values were 
corrected using the Benjamini-Hochberg method as impelemented in 
DESeq2. 
 
In both cases, Gene Ontology analysis was performed by using default 
settings of the DAVID tool (DAVID Bioinformatics Resources 6.8 - 
https://david.ncifcrf.gov - P-values < 0.01). 
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2.12 Chromatin immunoprecipitation (ChIP)-sequencing. 
DNA was cross-linked with 1% (v/v) formaldehyde for 15 minutes at room 
temperature and cross-linking was stopped by the addition of 0.125M 
glycine. Cells were then lysed in 1% [v/v] SDS, 10mM EDTA, 50mM Tris-
HCL pH8.0, and 1mM protease inhibitors. Cells were sonicated in a 
QSONICA sonicator (1h cycle 5 secs ON/5 secs OFF) to achieve a mean 
DNA fragment size of 500bp.  
Acceptable fragmentation was checked as follows: 
3 times the volume of Elution Buffer (1%SDS, 0.1M NaHCO3) was added 
to aliquots of non-sonicated and sonicated samples, and samples were 
boiled at 95°C for 5 minutes 
1 volume of phenol:chloroform:isocyamil (25:24:1) was added and samples 
were vortexed for 20 seconds and collected by centrifugation at RT, 5 min, 
13.5 K. 
The supernatant was transferred to a fresh tube and DNA was 
precipitated by addition of 1µl glycogen, 1:10 3M NaAcetate, pH 5.2, 
adding 2.5 volumes of EtOH 100%, for 1h at -80°C. 
Samples were collected by centrifugation for 30 mins, max speed at 4°C, 
and pellets were washed with 70% EtOH and finally resuspended in H20. 
Samples were incubated with 2µl RNase A with shaking at 37°C for 10 
minutes and then run on a 1.5% agarose gel followed by post-staining with 
EtBr . 
An equal volume of protein A and G dynabeads magnetic beads (Thermo 
Scientific), were equilibrated in modified RIPA buffer (1% [v/v] Triton-X-
100, 0.1% deoxycholate, 0.1% SDS, 90mM NaCl, 10mM Tris-HCL pH8.0, 
and EDTA-free protease inhibitors) and used to pre-clear chromatin under 
rotation at 4°C for 2 hours prior to immunoprecipitation. After pre-
clearing, 100µl of chromatin was mixed with 100µl of lysis buffer and 
stored as input material. Immunoprecipitation was performed for a 
minimum of 12 hours at 4°C in modified RIPA buffer with anti-DDX3, 
anti-DDX54, anti-ERa, anti-H3K4me3 or anti-IgG Rb isotype control 
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antibodies. All IPs were performed in triplicate. Protein A (for rabbit 
antibodies) and G (for mouse antibodies) previously equilibrated in 
modified RIPA buffer, were used to bind the antibody and associated 
chromatin for a minimum of 2 hours. The beads were then washed twice 
with wash buffer (0.1% [v/v] SDS, 1% [v/v] Triton-X-100, 2mM EDTA, 
20mM Tris pH8.0, 150mM NaCl) and once with final wash buffer (0.1% 
[v/v] SDS, 1% [v/v] Triton-X-100, 2mM EDTA, 20mM Tris pH8.0, 500mM 
NaCl). DNA was then eluted with 200µl of elution buffer (1% [v/v] SDS, 
100mM NaHCO3) for 15 minutes rotating at room temperature. The input 
and immunoprecipitated samples were then mixed with 2µl of RNase 
(DNase free-Roche) for a minimum of 5 hours at 65°C to reverse the 
crosslinks. DNA purification was performed using the ChIP DNA ZYMO 
purification kit.  Purified DNA was used for preparation of ChIP seq 
libraries with NEXTflex® ChIP-Seq Library Prep Kit for 
Illumina® Sequencing from Bio Scientific, following manufacturer 
instructions. Before multiplexing, excess primers were removed with 
AMPure XP beads (Beckam Coulter). Libraries were quantified with the 
Qubit® dsDNA HS Assay and the High Sensitivity D1000 ScreenTape 
system, following manufacturer’s instructions. 
 
2.12.1 ChIP seq bioinformatic analysis. 
Trimmed reads were mapped against the hg38 build of the human genome 
using BWA v0.7.12 [242] [PMID: 19451168] with default 
parameters. Peaks were called for each replicate IP condition against a 
reference condition made by combining the data from the Input replicates. 
Peaks were called using MACS v1.4.2 (Zhang et al. Model-based Analysis 
of ChIP-Seq (MACS) [243]. Pairwise overlaps between the replicates were 
taken and the union was used as the final peak set such that a peak exists 
in the final data set if it is present in at least 2 of the 3 replicates. 
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2.13 iCLIP (Individual Cross-Linking ImmunoPrecipitation) 
iCLIP was performed following the protocol in Huppertz et al 2014 [244].  
 
2.13.1 Cells UVC irradiation and immunoprecipitation, 3’ end adapter 
ligation and 5’ end radioactive labelling 
MCF7 cells were cultured in 10 cm diameter dishes. When cells reached 
confluence, media was removed and cells were washed twice with ice-cold 
PBS 1X. 6ml of ice cold PBS 1X were added, plates were placed on ice and 
irradiated once at 150 mJ/cm2, 254 nm. Cells were scraped and harvested 
into eppendorf tubes and spun at top speed for 10 seconds at 4°C. Pellets 
were resuspended in CLIP lysis buffer (50 mM Tris–HCl, pH 7.4, 100 mM 
NaCl, 1% Igepal CA-630, 0.1% SDS, 0.5% sodium deoxycholate) 
supplemented with protease inhibitor cocktail (CompleteTM, Roche) and 
sonicated once at VibraCell probe sonicator (Sonics) for 20 seconds at 22% 
amplitude. Lysates were treated with 10µl of either high RNase I (Life 
Technologies) (1:10) or low RNase I (1:500) together with 2µl of Turbo 
DNase (Life Technologies) for 3 minutes at 37°C shaking at 1,100 rpm and 
then immediately placed on ice. Samples were then collected by 
centrifugation for 10 min at 22,000 g at 4°C to clear the lysate. The 
supernatant was collected and quantified with a BCA assay. Protein A (for 
rabbit antibodies) or protein G (for mouse antibodies) Dynabeads were 
previously washed twice in lysis buffer and then resuspendend with 100 µl 
lysis buffer with the relevant antibody dilution and incubated under 
rotation at room temperature for 1h. The lysates were added to the 
antibody/bead mix and incubated overnight under rotation at 4°C. 
 
The next day beads were washed 4 times in High Salt buffer (50 mM Tris–
HCl, pH 7.4,1 M NaCl, 1 mM EDTA 1%, Igepal CA-630, 0.1% SDS, 0.5% 
sodium deoxycholate) and twice in PNK buffer (20 mM Tris–HCl, pH 
7.4, 10 mM MgCl2,0.2% Tween-20). Then 3¢ends of protein-bound RNA 
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fragments were dephosphorylated by resuspending the beads in 20 µl 
PNK mix (15 µl water; 4 µl 5x PNK pH 6.5 buffer [350 mM Tris-HCl, pH 
6.5; 50 mM MgCl2; 25 mM dithiothreitol]; 0.5 µl PNK enzyme; 0.5 µl 
RNasin [Promega]) and incubating for 20 min at 37°C with shaking at 
1,100 rpm. Beads were then washed once in high-salt buffer and twice 
with PNK buffer. Next the L3 adapter linker was ligated to RNAs 3¢ends 
by resuspending the beads in 20 µl ligation mix (9 µl water; 4 µl 4x 
ligation buffer [200 mM Tris-HCl; 40 mM MgCl2; 40 mM dithiothreitol]; 1 
µl RNA ligase [NEB]; 0.5 µl RNasin [Promega]; 1.5 µl pre-adenylated 
linker L3 [20 µM]; 4 µl PEG400 [81170, Sigma]) and incubating overnight 
at 16°C with shaking at 1,100 rpm shaking. The next day protein-bound 
RNAs were radiolabelled at their 5¢ends: beads were washed in high-salt 
buffer and PNK buffer, resupended in 8 µl of hot PNK mix (0.4 µl PNK 
[NEB]; 0.8 µl 32P-γ-ATP; 0.8 µl 10x PNK buffer [NEB]; 6 µl water) and 
incubated for 5 min at 37°C at 1,100 rpm shaking. After removal of the hot 
PNK mix, beads were resuspended in 20 µl 1X Nupage loading buffer 
(Invitrogen) and incubated at 70°C for 10 min to elute protein-RNA 
complexes. Supernatants were loaded on a 4-12% NuPAGE Bis-Tris gel 
(Invitrogen) together with a pre-stained protein size marker. The gel was 
run for 50 minutes at 180 V. and the protein-RNA complexes were then 
transferred to a nitrocellulose membrane using Novex wet transfer 
apparatus (Invitrogen) for 1 h at 30 V. The membranes were rinsed in 
PBS buffer, wrapped in saran wrap and exposed to a Fuji film at -80°C for 
30 min, 1 hour or overnight. 
 
2.13.2 iCLIP library preparation   
Protein-RNA complexes were isolated from the low-RNase treated samples 
by cutting the membranes at the right size range (20-80 kDa above protein 
size) indicated by the autoradiograph. To digest the protein covalently 
bound to the RNAs and release peptide-RNA complexes, membranes were 
cut into small slices and incubated with 200 µl PK buffer (100 mM Tris-
HCl pH 7.4; 50 mM NaCl; 10 mM EDTA) and 10 µl proteinase K (Roche, 
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03115828001) by shaking at 1,100 rpm for 20 min at 37°C.  200 µl of PK-
Urea buffer (100 mM Tris-HCl pH 7.4; 50 mM NaCl; 10 mM EDTA; 7 M 
urea) was then added, and incubation was carried out for 20 more minutes 
at 37°C. The peptide-RNA complexes containing solution was added to an 
equal volume of RNA phenol/chloroform (acid phenol/chloroform) and 
added to a 2 ml Phase Lock Gel Heavy tube, incubated for 5 min at 30°C 
with shaking at 1,100 rpm collected by centrifugation for 5 min at 13,000 
rpm at room temperature. The peptide-RNA complexes were precipitated 
from the aqueous solution by addition of 1:10 3M sodium acetate pH 5.5, 
0.5 µl glycoblue (Ambion, 9510) and 2.5 volumes of 100% ethanol, over-
night at -20°C.  After washing in 80% ethanol, the primer mix (6.25 µl 
water; 0.5 µl RTclip primer [0.5pmol/µl]; 0.5 µl dNTP mix [10mM]) was 
added to the resuspended RNAs (primers listed in Table 2.10), and retro-
transcription was carried out with SuperScriptIII (Invitrogen) as 
described (Section 2.5.2). cDNAs were precipitated in ethanol, as described 
earlier, resuspended in 2X TBE-urea loading buffer (Invitrogen)  and then 
loaded on a 2X TBE-urea gel (Invitrogen) together with a low molecular 
weight marker. The gel was run for 40 min at 180 V and then three bands 
were cut at 120-200 nucleotides (high), 85-120 nucleotides (medium) and 
70-85 nucleotides (low).  cDNAs were recovered from the gel slices by 
crushing them in TE buffer with a syringe plunger and incubation with 
shaking at 1,100 rpm for 2 h at 37°C, then purified using Costar SpinX 
column (Corning Incorporated, 8161), and precipitated as described 
earlier.  
The cDNAs were circularised by resuspending the pellets in 8 µl 
CircLigase mix (6.5 µl water; 0.8 µl 10x CircLigase Buffer II; 0.4 µl 50 mM 
MnCl2; 0.3 µl; Circligase II [Epicentre]) and incubating for 1 h at 60°C. An 
oligo containing the BamHI digestion site was annealed to the circularized 
cDNAs by adding oligo annealing mix (26 µl water; 3 µl FastDigest Buffer 
[Fermentas]; 1 µl cut_oligo [10 µM]) and incubating the samples for 1 min 
at 95°C. The temperature was decreased by 1°C/20sec until reaching 25°C, 
then cDNAs were digested by adding 2 µl BamHI (Fast Fermentas) and 
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incubating the samples for 30 min at 37°C.  cDNAs were precipitated as 
described earlier and amplified by PCR by adding primer mix (Illumina 
P3/P7 primers – Table 2.10), Accuprime Supermix 1 enzyme (Invitrogen) 
and running the following PCR programme:  
• 94°C for 2 min,  
• [94°C for 15 sec, 65°C for 30 sec, 68°C for 30 sec] 28 cycles,  
• 68°C for 3 min    
An aliquot of the PCR product was loaded onto a precast 6% TBE gel 
(Invitrogen) which was then stained with Sybrgreen I DNA stain 
(Invitrogen) to check the extent of amplification of the three cDNA 
fractions of each sample before multiplexing.  
Before multiplexing, excess primer was removed with AMPure XP beads 
(Beckam Coulter). Libraries were quantified with the Qubit® dsDNA HS 
Assay and High Sensitivity D1000 ScreenTape system following 
manufacturer’s instructions. 
All oligos used are listed in Table 2.10. 
 
2.13.3 CLIP-qPCR variation 
CLIP-qPCR was performed applying the following variations to the iCLIP 
protocol: 
RNAs were not fragmented, therefore upon sonication the samples were 
incubated with only 2 µl TurboDNase for DNA degradation. No 3¢ end 
adapter ligation and 5¢ end radioactive labelling were perfomed. 
Protein-RNA complexes were digested with proteinase K as described 
(Section 2.13.2) but using a final volume of 50µl. RNA was extracted from 
the sample as described in Section 2.5.1. cDNA synthesis and qPCR were 
performed as described (Section 2.5.2). 
RNA enrichment was quantified as follows: 
Percentage of Input (% of Input) = 100*2 - delta (Ct-IP - Ct-input) =2-Δ Ct 
Standard deviations and p-values were calculated using the Prism 7 
statistical tool. 
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2.13.4 iCLIP bioinformatic analysis. 
Reads were designed with a sample-specific adapter sequence immediately 
following the P7 adapter. These barcodes were 9-mers of the 
format NNNXXXXNN, where XXXX was a fixed 4 bp barcode for each 
sample (chosen to ensure adequate complexity across all samples), and the 
Ns were randomly incorporated bases. Samples were demultiplexed based 
on the 4 bp barcode allowing zero mismatches, and PCR duplicates were 
identified based on identical sequence of the random barcode, using an in-
house perl script. Trimmed reads were mapped in single end mode to the 
hg38 human genome using tophat [237] with the following parameters (--
no-coverage-search --max-multihits 20 --report-secondary-alignments --
read-mismatches 2). Multihits (reads mapping to multi loci) were filtered, 
along with reads mapping with quality score less than 20.  
To identify cross-linking sites, Dr Namshik Han developed a 
computational pipeline which identifies and analyses iCLIP cross-linking 
sites.  The pipeline takes advantage of combining a peak-finding approach 
(PIPE-CLIP [PMID: 24451213]) and a differential binding detection 
analysis approach (dCLIP [PMID: 24398258]) using RNA-seq Input as 
reference and IgG peaks as background. This allows the pipeline to 
identify both biologically and statistically significant enriched truncation 
sites. The pipeline then annotates the identified cross-linking sites with a 
given Gencode reference annotation. The pipeline also analyses the 
pattern of localization and genomic features (e.g., 5’UTR, exon, intron, 
etc.) associated with the cross-linked sites. The genomic categories of 
iCLIP peak location were searched by using PAVIS [PMID: 24008416] 
with default settings. 
To determine which regulatory motifs are over-represented in iCLIP peak 
regions, we identified all possible ungapped 8-mers in the regions and 
computed their frequency. iCLIP provides single base-pair resolution of 
binding position, so we needed to extend this precise peak location to allow 
a search of the enriched motifs. We extended +/-100 bp centred by iCLIP 
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peak to make 200 bp windows around the peaks. An 8-mer is considered 
over-represented if its frequency in the windows is significant. We found 
the presence of repeats that consist of a single nucleotide or dimer 
repeated for the entire 8-mer. This phenomenon is common in genomic 
sequences and generally is associated with non-functional components, 
and thus, these were filtered out. 
To assess the statistical significance of the computed frequency for the 
over-represented motifs, we generated scrambled sequences according to 
the nucleotide composition of the original sets of sequences in the 
extended windows centred by iCLIP peaks. The frequencies for the 
random 8-mers were computed, and the distribution of the frequencies 
was approximated by the extreme value distribution. We used the 
MATLAB function gevfit to compute the maximum likelihood estimation 
of the extreme value distribution. We then overlaid a scaled version of its 
probability density function, computed using MATLAB function gevpdf, 
with the histogram of the frequency of the random 8-mer sequences. We 
repeated this process 100 times for bootstrapping and calculated the p-
value. We concluded that the over-representation of the 8-mer motifs in 
the iCLIP peak-centered window is statistically significant if the p-value 
estimate is less than 1.0e-4. 
To identify consensus motifs, enriched 8-mers were phylogenetically 
clustered into 10 groups. We used the MATLAB function seqlinkage to 
construct phylogenetic trees from pairwise distances. We checked the 
codon usage in the extended windows centred by iCLIP peaks. We used 
MATLAB codoncount that counts the codons in a given set of nucleotide 
sequences and returns the codon counts in Codons. We used the MATLAB 
function seqlogo to identify consensus motifs and their weight matrix for 
the clustered 8-mer(s) in each group.  
The gene ontology enrichment of iCLIP bound genes was obtained using 
the DAVID functional annotation tool or Ingenuity pathway analysis (IPA) 
with default settings.  
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oligo oligo sequence (5’à3’) 
Pre-adenylated 
adapter L3-
App 
rAppAGATCGGAAGAGCG GTTCAG/ddC/ 
Cut_oligo 
(BamHI site 
containing 
oligo) 
GTTCAGGATCCACGACGCTCT TCaaaa  
 
iCLIP RT oligo  iCLIP RT oligo sequence (5’à3’) 
Rt8clip  
(DDX3X rep1) 
/5Phos/NNCATTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt9clip  
(DDX3X rep2) 
/5Phos/NNGCCANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt11clip  
(DDX54 rep1) 
/5Phos/NNGGTTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt13clip  
(DDX54 rep2) 
/5Phos/NNTCCGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt6clip (Rb 
IgG) 
/5Phos/NNCCGGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt10clip (Ms 
IgG) 
/5Phos/NNGACCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Primer primer sequence (5’à3’) 
P5 Illumina AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGA 
CGCTCTTCCGATCT 
P7 Illumina  CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTG  
CTGAACCGCTCTTCCGATCT 
Table 2.9. Oligos used in iCLIP. Barcodes are highlighted. 
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2.14 Bioinformatic quality control analysis. 
For all high throughput sequencing data (Sections 2.11.2;2.12.1;2.13.4) 
read quality was assessed using fastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were 
trimmed using trim_galore 
( https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to 
remove adapter contamination. 
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3 Chapter 3 - Identification of DDX54 target RNAs 
through iCLIP technology 
 
 
 
3.1 Introduction  
The pathways in which DDX RNA helicases are involved and the protein 
complexes in which they are found largely define their overall function. 
However, knowing the identity of their target RNAs is essential in order to 
understand their specific activities and roles in cells. Moreover, mapping 
protein–RNA interactions is essential to dissect RNA regulatory processes. 
In the recent years, genome-wide tools have been developed to investigate 
protein–RNA interactions in vivo, revealing binding features of many 
RBPs.  
The first attempts included approaches like RNA immunoprecipitation 
(RIP) coupled with microarrays or sequencing (RIP-Chip/RIP-Seq), which 
showed a series of limitations particularly regarding the high detection of 
non-specific interactions and the low resolution of RBP binding sites. 
Overcoming these limitations was the aim of developing UV cross linking-
based techniques (CLIP - cross-linking immunoprecipitation). The demand 
of improving the resolution of this techniques is particularly important 
since most RBPs bind short length portions of RNAs and are therefore 
often attached to more than one site per RNA molecule. 
UV-crosslinking a wavelength of 254 nm creates a covalent bond between 
an amino acid residue and an RNA base only if they are in very close 
proximity due to a direct interaction. Because of the UV cross linking step, 
CLIP-based protocols use higher stringency washes which disrupt 
protein–protein interactions and reduce the probability of recovery 
unspecific RNA. RNAs are digested to create short RBP-protected RNA 
fragments. This allows the identification of RBP binding sites 
transcriptome-wide, at high resolution. UV-crosslinking leaves an 
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aminoacid residue bound to the nucleotide at the protein-RNA 
crosslinking site. In the first version of CLIP (HITS-CLIP) the RNAs were 
reverse transcribed after ligation of both a 5′ adaptor a 3’ adapter and the 
resulting cDNAs were subjected to high-throughput sequencing. Since 
retro-transcription enzymes are prone to termination at the crosslinking 
site, it has been estimated that up to 80% of the resulting cDNA products 
lacked the 5¢ adapter. These sequences fail to be amplified by PCR and are 
thus lost from the sequencing library, resulting in considerable loss of 
information about the binding site [245]. 
Individual nucleotide resolution CLIP (iCLIP) addresses the issue of low 
crosslinking site identification with a strategy that includes an 
intramolecular circularization step: reverse transcription is primed with 
an oligonucleotide that contains the 3′, as well as the 5′, adaptor region. 
The cDNA is isolated through size selection, circularized, then linearized 
by enzymatic digestion and amplified by PCR (Section 2.13; Figure 3.1A). 
Truncated cDNAs represent over 80% of the iCLIP cDNA library. Once the 
sequence is mapped to the genome the cross-linking site is identified by 
the nucleotide upstream of the truncation site. This strategy largely 
improved the definition of RBP binding sites [244].  
iCLIP profiles can provide both biological and mechanistic insights into 
the function of the relevant RNA binding protein. Furthermore, when 
coupled with focused bioinformatic motif searches, this technique can also 
help to identify discrete nucleotide sequences within RNAs which are 
bound by the protein of interest. Since binding to a protein can also 
involve secondary structure of the RNAs, a bioinformatic structural 
prediction analysis may also reveal RNA folding patterns common to the 
target RNAs of a specific protein. 
  
Although DDX helicases are related members of a broad protein family 
with many members thought to perform redundant functions, these 
proteins can show specificity with respect to the RNAs they target 
(Section1.3).  In this chapter, and in the next, I set out to characterize the 
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RNA binding profiles of two members of the DDX helicase family, namely 
DDX54 and DDX3X. Although much is known about the cellular functions 
of both of these helicases, the identities of RNAs bound by these proteins 
were unknown at the beginning of this project.  
 
 
3.2 Aims of this chapter 
The aims of the work described in this chapter were: 
• To determine RNA binding profiles of DDX54 in the MCF7 breast 
cancer cell line. 
• To identify and validate individual target RNAs of the helicase. 
• To identify specific RNA sequences and/or secondary structures to 
which the helicase binds. 
• To investigate the molecular function and biological relevance of 
DDX54 binding to specific target RNAs. 
 
 
3.3 iCLIP in-house library preparation and computational analysis 
of derived data 
A schematic flow diagram of the iCLIP procedure is shown in Figure 3.1A. 
UV cross-linking and immunoprecipitation is followed by adapter ligation 
and radioactive labeling. When protein-RNA complexes are resolved by 
SDS-PAGE a radioactive smear should be visible above the molecular 
weight of the protein (step 8, Figure 3.1A). I performed iCLIP using highly 
efficient immunoprecipitation antibodies against DDX54 (Figure 3.1B) to 
precipitate protein-RNA complexes from UV irradiated MCF7 cells. The 
immunoprecipitation produced a smear within the correct size range 
(about 20-80 kDa above the predicted size of DDX54) (Figure 3.1C) which 
corresponds to the protein binding to 32P-labeled RNA fragments of about 
50 to 100 nucleotides, obtained by mild (+) RNase treatment. As shown in 
Figure 3.1C, high concentration (+++) RNase treatment leads to the 
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formation of protein-RNA complexes of lower molecular weights because 
the higher RNase activity digests protein-bound RNAs into smaller 
fragments. As negative controls, immunoprecipitations were performed 
using (i) anti IgG isotype control antibody in UV cross-linked lysates and 
(ii) anti-DDX54 antibodies in non-UV cross-linked lysates. For each of 
these conditions, no precipitation of protein-RNA complexes occurred 
(Figure 3.1C). This testifies to the high specificity of the protein-RNA 
complexes precipitated by the anti-DDX54 antibody. These complexes 
were used in subsequent library preparations (Section 2.13): the RNA 
retrieved from the DDX54 and IgG complexes was used to generate iCLIP 
libraries within a 150 to 300 nucleotide optimal size range (Figure 3.1D). 
 
iCLIP detects protein-RNA binding sites at a single nucleotide resolution 
thanks to an intramolecular ligation step that captures cDNAs truncated 
at the protein binding site (steps 10 to 16 in Figure 3.1A). In order to 
identify these sites, we developed a computational pipeline that combines 
a peak-calling approach and a differential binding analysis approach 
(Section 2.13.4). The pipeline then annotates the identified cross-linking 
sites with a given Gencode reference and further analyses the pattern of 
localization and genomic features (e.g., 5’UTR, exon, intron, 3’UTR etc.) 
associated with the cross-linked sites. An enriched motif search provides 
an opportunity to discover specific sequential patterns of nucleotides at 
the cross-linked sites or in user-defined search regions. The pipeline 
annotates the enriched motifs with known binding motifs and generates a 
density plot in order to visualize the localization pattern of the motifs. 
Although it would be interesting to analyse possible common structural 
features in all target RNAs identified by iCLIP, the comparative 
prediction of such a high number of targets is too demanding for the 
ability of available computational tools. However, it is still possible to 
select a subset of target RNAs, on the basis of biological common 
relevance, to compare discrete regions of interest surrounding the binding 
sites. 
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Figure 3.1. iCLIP of endogenous DDX54 in MCF7 breast cancer cells. 
(A) Workflow of the iCLIP procedure from [244] (see Section 2.13 for description). 
(B) Western blot analysis of immunoprecipitated DDX54 in MCF7 whole cell 
lysate: cells were lysed in CLIP lysis buffer and DDX54 immunoprecipitation was 
A
B C
 anti-IgG IP
M
H M LHM LH M L
anti-DDX54 IP
50 nt -
75 nt -
100 nt -
150 nt -
200 nt -
250 nt -
300 nt -
350 nt -
500 nt -
766 nt -
D
NO
UV CL
+++ + + + +Rnase I :
100 -
55 -
130 -
kDa
UV Crosslinking
kDa
100 -
IP FT
DDX54
99 kDa
Rb
IgGInput
anti-DDX54 IP
anti-DDX54
       IP
anti-IgG
     IP
 86 
performed. (IP= immunoprecipitation; FT= flow through). (C) Autoradiography of 
DDX54 –32P fragmented RNA complexes migrating 20-80 kDa above the size of 
the protein (indicated by the blue box in the second and third lanes). Whole 
lysates from MCF7 cells exposed to 254 nm UV crosslinking at 150mJ/cm2 were 
subjected to immunoprecipitation using an anti-DDX54 antibody in the presence 
of high RNase (+++) treatment (single sample), or low (+) RNase treatment (in 
duplicate) or anti-IgG antibody immunoprecipitation in the presence of mild 
RNase treatment (+) (single sample). Whole lysate from MCF7 cells not exposed 
to UV crosslinking was used for anti-DDX54 immunoprecipitation in the 
presence of low (+) RNase treatment (single sample). (D) DDX54 iCLIP libraries: 
RNA was recovered from immunoprecipitated material and size-selected 
DDX54:RNA complexes shown in (C). cDNA was divided into three size ranges 
and libraries were produced as described (Section 2.13.2). Shown are the PCR 
amplified libraries obtained for each size range for both biological replicates of 
DDX54 immunoprecipitation and the single IgG control immunoprecipitation 
(H=high; M=medium; L=low nucleotide size range). 
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Using our pipeline, we identified numerous DDX54 target RNAs and some 
potential protein binding sites within their sequences (Appendix Figure 1). 
These results are presented and discussed in the following sections. 
 
 
3.4 DDX54 binds to introns of nuclear protein mRNAs and to non-
coding RNAs  
As shown in Figure 3.2A-C, bioinformatic analysis of the DDX54 iCLIP 
showed localization of truncation sites within introns towards the 3¢ end of 
coding transcripts as well as in non-coding RNAs, including long non-
coding RNAs. To validate these DDX54 binding data, I performed CLIP-
qPCR on four putative targets (NEAT1, PVT1, TET2 and NCOA1: Figure 
3.3) and one negative control unbound mRNA (PUS1). CLIP-qPCR was 
performed with an anti-DDX54 antibody, as well as with antibodies 
against others DDX helicases and an IgG control. Target RNAs were 
specifically and significantly enriched by DDX54 antibody and the control 
non-binding RNA, PUS1, was unspecific in DDX54 CLIP-qPCR (Figure 
3.3).  
 
A DAVID gene ontology analysis of DDX54 target RNAs showed 
enrichment for nucleoplasmic components with transcriptional or 
chromatin related functions (Figure 3.4A-B). Cell fractionation analysis 
and immunofluorescence assay showed DDX54 to be localized in the 
nucleolus and in the nucleoplasm of MCF7 cells (Figure 3.5A-B). Results 
of pathways analysis highlighted that many DDX54 target RNAs are part 
of “upstream regulators” enriched groups, such as Estrogen Receptor 
alpha (ESR1) and p53 (TP53) (Figure 3.4C). 
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Figure 3.2. DDX54 iCLIP truncation sites localize preferentially to intronic 
regions and at the 3’end of transcripts. 
(A) Pie chart indicating location of iCLIP peaks in transcripts. Shown are the 
percentages of DDX54 iCLIP truncation sites found in the indicated category. 
The genomic categories of iCLIP peak location were searched for using PAVIS 
[PMID: 24008416] with default settings. 
(B) Density plot of iCLIP localisation on a scaled gene body (metaplot). The 
transcripts that have iCLIP peaks of DDX54 were scaled to the same length and 
also extend by 20% up- and down-stream. Then, iCLIP peaks for each gene were 
accumulated on the scaled gene to visualise the distribution of iCLIP truncation 
sites localisation. The scaled gene body represents three indicative regions: 5’-
end, middle, and 3’-end. Y axis = counts of iCLIP sites; X axis = scaled gene body 
localization. (C) Bar graph of gene types containing iCLIP peaks. Shown are the 
number of DDX54 iCLIP truncation sites in each gene type category. Y axis = 
counts of iCLIP sites; X axis = gene type category.  
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Figure 3.3. CLIP-qPCR validation of DDX54 iCLIP targets. 
CLIP-qPCR was performed as described (Section 2.13.3) to validate the binding 
of NEAT1 lncRNA, PVT1, NCOA1, TET2 and PUS1 mRNAs to DDX54. 
Antibodies against DDX1 and DDX24, and against IgG, were controls, as was 
analysis of PUS1, an RNA not identified as binding DDX54. cDNA obtained from 
each immunoprecipitation was analysed by qPCR to test for enrichment of the 
indicated targets. Results represent the average of three biological replicates. 
Error bars indicate standard deviation.  
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I next analyzed the sequence features of DDX54 binding sites and 
observed enrichment of A- and T- (i.e. U- in RNA) rich triplets in both 200 
base-pair and 30 base-pair windows centred around truncation sites 
(Figure 3.6). To investigate whether these triplets could be part of a 
sequence binding motif, I performed a motif search analysis and identified 
ten subgroups of related motifs to which most DDX54 targets could be 
assigned (Figure 3.7A). The motif search surrounding DDX54 binding 
sites showed a good extent of overlap between the motifs and the 
localization of the truncation sites (Figure 3.7B), which suggests that 
DDX54 most likely binds to target RNAs via specific motifs. 
Examples in Figure 3.8A-C show the enrichment of poly A and poly T (i.e. 
poly U in RNA) sequences at the RNA binding sites of DDX54, which was 
predicted already by the triplet usage analysis (Figure 3.6). Among the 
motifs found, one T-rich (i.e. U-rich in RNA) motif showed homology with 
the splicing factors U2AF2 and USAF50 RNA recognition sequence 
(Figure 3.8C). This is consistent with a role for DDX54 in splicing, recently 
shown by others [183]. 
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Figure 3.4. Gene ontology analysis of DDX54 iCLIP target RNAs. 
DAVID gene ontology (GO) search of cellular components (A) and molecular 
function (B) enriched terms. The GO enrichment of DDX54 iCLIP bound 
transcripts was obtained using the DAVID functional annotation tool with 
default settings [PMID: 19131956]. P-values were calculated using the “default” 
method of DAVID. 
(A-B) The scatter plot was generated with REVIGO [PMID: 21789182] to 
visualise the GO term analysis result for cellular components (A) and molecular 
function (B). The scatter plot shows GO term cluster representatives in a two-
dimensional space. X-axis indicates the frequency of the GO term in the 
underlying GO analysis database (i.e. bubbles that are closer to the end of x-axis 
(lager values) are more general terms). Y-axis and bubble colour/size indicates 
the log transformed p-value of GO terms.  
(C) Bar graph shows Upstream regulators term enrichment generated with IPA 
tool (IPA (Ingenuity® Systems) GO search of DDX54 iCLIP targets. P-values 
were calculated using default settings of Ingenuity. The Y-axis shows the GO 
terms related to upstream regulators. X-axis shows –log10 p-values of each GO 
term. The group with highest significance was ESR1 (Estrogen Receptor a). 
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Figure 3.5. DDX54 is localized in the nuclei of MCF7 cells. 
(A) Western blot detection of DDX54 and b-tubulin in whole cell (W), cytoplasmic 
(C) and nuclear (N) fractions of MCF7 cells.  
(B) DDX54 immunofluorescence in MCF7 cells. Cells were fixed and probed with 
anti-DDX54 mouse antibody (ab57711) and anti-Fibrillarin rabbit antibody.  
Nuclei were stained with DAPI; DDX54 was detected with Alexa488-conjugated 
goat anti-mouse IgG2A; Fibrillarin was detected with Alexa594-conjugated goat 
anti-rabbit IgG. Scale bar length: 50 pixel; Scale bar width: 0.12 µm or 0.18 µm 
(as indicated).  
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Figure 3.6. Motif search on DDX54 iCLIP binding sites: a poly A binder. 
Heatmap of triplet usage in 200 base-pair and 30 bp windows centered by DDX54 
iCLIP peak. Shown is the enrichment of triplets found in a 200 bp (upper panel) 
and 30 bp (lower panel) extended window centred on iCLIP peaks. MATLAB 
codoncount was used to generate the heatmap (Section 2.13.5). Scale indicates 
counts of triplets found in the considered window and associated hub. 
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Figure 3.7. Motif search on DDX54 iCLIP binding sites.  
(A) Phylogenetic tree of highly enriched 8-mer motifs in 200 base-pair windows 
centered on DDX54 iCLIP peak. 8-mers enriched in an extended +/-100bp centred 
by iCLIP were found as (Section 2.13.5). To identify consensus motifs, enriched 8-
mers were phylogenetically clustered into 10 groups. MATLAB function 
seqlinkage was used to construct the phylogenetic tree shown (Section 2.13.5). 
(B) Density plot of highly enriched motifs localised within a scaled gene body. 
The distribution of the motifs within a scaled gene are shown. The transcripts 
that have the enriched motifs in the +/-100bp extended windows centred by 
DDX54 iCLIP peaks were scaled to the same length and also extended by 20% 
up- and down-stream. Then, the enriched motifs for each gene were accumulated 
on the scaled gene to visualise the distribution of DDX54 binding motif 
localisation. The scaled gene body represents three indicative regions: 5’-end, 
middle, and 3’-end. Y axis = counts of iCLIP motifs; X axis = scaled gene body 
localization.  
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Figure 3.8. Examples of enriched motifs at DDX54 iCLIP binding sites. 
Enriched motifs at DDX54 binding sites. Density plot of a motif's location within 
a scaled gene body. The scaled gene body represents three indicative regions: 5’-
end, middle, and 3’-end. Y axis indicates the frequency (actual count) of the motif; 
X axis = scaled gene body localization. Consensus motifs for the clustered 8-
mer(s) in each phylogenetic group were found with MATLAB function seqlogo 
(Section 2.13.5). The sequence logos of two different phylogenetic groups (A and 
B) are shown (Y axis = Bits; X axis =sequence position). (C) The motif is matched 
to known RNA binding motif. The table shows the known RNA binding proteins 
that recognize a similar sequence motif and relative p-values indicating the 
significance of homology.   
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3.5 Investigations into DDX54 binding NEAT1 lncRNA 
NEAT1 lncRNA was one of the strongest DDX54 validated targets (Figure 
3.3). I further confirmed the specificity of this reaction by performing 
CLIP-qPCR analysis in MCF7 cell extracts depleted of DDX54 using 
shRNA (Figure 3.9A-B). 
NEAT1 lncRNA is localized within discrete subnuclear structures called 
paraspeckles [246]. I therefore investigated whether binding of DDX54 
affects formation of NEAT1 lncRNA-dependent paraspeckles. For this 
purpose, I performed RNA FISH to localize NEAT1 RNA in MCF7 cells 
transfected with either scrambled siRNA or two different DDX54 specific 
siRNAs. DDX54 protein level was efficiently reduced by both siRNAs (#9 
and #12) (Figure 3.10A), but no significant depletion of paraspeckles was 
observed in MCF7 cells transfected with these siRNAs, compared to MCF7 
cells transfected with scrambled siRNA (Figure 3.10C). 
Importantly, by combining RNA FISH for NEAT1 lncRNA detection and 
immunofluorescence for DDX54 detection, I did not observe co-localization 
of DDX54 and NEAT1 lncRNA in wild type MCF7 cells (Figure 3.10D). 
Also, the expression levels of NEAT1 lncRNA was not consistently affected 
by DDX54 knock down using the two different siRNAs (Figure 3.10B). 
This discrepancy could be partially explained by the different efficacy of 
the two siRNAs. In fact, the higher depletion of DDX54 when siRNA #12 
was used led to a significant change in NEAT1 lncRNA levels, not 
observed with siRNA #9-mediated DDX54 knock down (Figure 3.10A-B). 
Taken together, these data do not support my hypothesis that DDX54 is 
involved in formation of NEAT1 paraspeckles. 
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Figure 3.9. NEAT1 lncRNA binding validation in DDX54 knock down MCF7 
cells. 
(A) Western blot shows the levels of DDX54 and ß-tubulin in MCF7 cells 
transduced with scrambled or DDX54 targeting shRNA, 72 h after transfection. 
(B) DDX54 and IgG CLIP-qPCR were performed as described (Section 2.13.3) in 
MCF7 cells transduced with scrambled or DDX54 targeting shRNAs. Results 
represent the average of three biological replicates.	Error bars indicate standard 
deviation. P-values represent statistical significance calculated with unpaired t 
test compared to scramble shRNA (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 
0.001;**** ≤ 0.0001). 
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Figure 3.10. Knock down of DDX54 does not affect NEAT1 lncRNA. 
(A) A western blot shows the level of DDX54 and ß-tubulin in MCF7 cells 
transfected with either scrambled siRNA or three different DDX54 targeting 
siRNAs (#9, #10 or #12), alternatively.  
For all conditions, cells were harvested 72h after transduction/transfection. 
(B)NEAT1 lncRNA levels in MCF7 cells transfected with either scramble siRNA 
or two different DDX54 targeting siRNAs (#9 or #12), measured by qPCR. 
Results represent the average of three biological replicates (Section 2.5.3). Error 
bars indicate standard deviation. P-values represent statistical significance 
calculated with unpaired t test compared to scramble (P-values: ns. > 0.05; * ≤ 
0.05; ** ≤ 0.01; *** ≤ 0.001;**** ≤ 0.0001). (C) RNA FISH was performed as 
described (Section 2.9.2) in MCF7 cells transfected with either scramble siRNA 
or two different DDX54 targeting siRNAs (#9 or #12). Images show cell nuclei 
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stained with DAPI. Human NEAT1 lncRNA stellaris probes were conjugated 
with Quasar 570 fluorescent dye. (D) DDX54 immunofluorescence and NEAT1 
lncRNA FISH in wild type MCF7 cells. Cells were fixed as described (Section 
2.9.3) and probed with anti-DDX54 mouse antibody (ab57711) and anti-
Fibrillarin rabbit antibody. Nuclei were stained with DAPI; DDX54 was detected 
with Alexa488-conjugated goat anti-mouse IgG2A; Fibrillarin was detected with 
Alexa594-conjugated goat anti-rabbit IgG.  
Scale bar length: 50 pixels; Scale bar width: 0.18 µm or 0.10 µm (as indicated). 
All images were taken with an Olympus FV1000 upright microscope.  
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3.6 Contradictory evidence of DDX54’s Oestrogen Receptor a co-
transcriptional regulation activity 
As previously described (Section 1.4), DDX54 is a co-transcriptional 
regulator of several nuclear receptors. In particular, it co-represses 
estrogen receptor a (ERa)-dependent transcription [180]. My gene 
ontology analysis of DDX54 iCLIP target RNAs showed significant 
enrichment of genes belonging to the ERa pathway (ESR1 upstream 
regulator - Figure 3.4C). I therefore hypothesized that DDX54 exerts its 
regulatory activity by co-transcriptionally binding to RNAs transcribed 
from ERa target genes. To test this hypothesis, I performed ChIP-seq 
experiments to determine the genomic locations of ERa and DDX54 in 
MCF7 cells (Appendix Figure 2). ERa ChIP-seq analysis revealed regions 
bound by ERa, which were predominantly promoters, whilst DDX54 ChIP-
seq analysis failed to identify any significant binding events. This is 
exemplified in Figure 3.11A that shows ChIP-seq genome tracks 
surrounding two ERa target gene promoters (TFF1 and GREB1).  It 
highlights the absence of peaks in the DDX54 ChIP-seq track. I also 
performed co-immunoprecipitation experiments to investigate whether 
DDX54 and ERa interact in MCF7 cells. Immunoprecipitation of ERa 
resulted in DDX54 pull down but I could not observe the reciprocal pull 
down of ERa in DDX54 immunoprecipitation, even with a longer exposure 
(Figure 3.11B). 
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Figure 3.11. Lack of evidence for DDX54 and ERa co-localization at promoters. 
(A) USCS custom track for TFF1 and GREB1 genes showing ChIP-seq binding 
data for ERa, DDX54 and H3K4me3. H3K4me3 is seen interspersed over the 5’ 
side of the gene body (TFF1) and towards the promoter (GREB1). ERa binding is 
enriched at promoter regions of both genes. DDX54 track shows no peaks. The 
gene is represented below the X-axis and the height of the ChIP-seq read density 
is annotated on the Y-axis and is manually scaled at the same height for all 
tracks. (B) Co-immunoprecipitation of oestrogen receptor a and DDX54 
performed as described (Section 2.6.5). 
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Figure 3.12. DDX54 does not regulate ERa dependent transcription. 
(A) ERa ChIP-seq and DDX54 CLIP targets belonging to the “ESR1 upstream 
regulator” GO term were intersected. Shown is the list of common targets 
between the two data sets. (B) CLIP-qPCR was performed as described (Section 
2.13.3) to validate binding of MTA3 and MYB mRNAs to DDX54, and to DDX1, 
DDX24 and IgG as controls (top panels). DDX54 and IgG CLIP-qPCR were 
performed in MCF7 cells transduced with scrambled or DDX54 targeting shRNA 
(bottom panels). (C) mRNA levels of TFF1, GREB1, RPS24, MYB and MTA3 in 
MCF7 cells transfected with either scramble siRNA or two different DDX54 
targeting siRNAs (#9 or #12), under normal growth conditions. (D) mRNA levels 
of TFF1, GREB1, RPS24, MYB and MTA3 in MCF7 transfected either with 
scrambled siRNA or two different DDX54 targeting siRNAs (#9 or #12). Cells 
were grown in estrogen deprived medium for 72h and treated for 3 hours with 
either 100% ethanol or 100nM b-estradiol. Results represent the average of three 
biological replicates (Section 2.5.3). (E) Western blot (left panel) shows DDX54 
and  b-tubulin proteins levels in MCF7 cells grown in normal condition or in 
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estrogen deprived medium for 72h and treated for 3 hours with either 100% 
ethanol or 100nM b-estradiol; DDX54 mRNA levels in the same conditions in 
cells (middle panel). The right panel shows DDX54 mRNA levels measured in 
qPCR: cells were treated as in D. Results represent the average of three 
biological replicates (Section 2.5.3). Error bars indicate standard deviation. P-
values represent statistical significance calculated with unpaired t test compared 
to scramble siRNA (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001;**** ≤ 
0.0001). 
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These latest results suggested that DDX54 regulation of ERa activity does 
not occur at the chromatin level. Nevertheless, DDX54 binding to ERa 
target genes’ RNA may be involved in the stability or processing of such 
transcripts. Indeed, this form of regulation may be specifically relevant to 
the biology of MCF7 breast cancer cells. To test whether DDX54 is 
required for an efficient and effective response to activation of ERa 
dependent transcription, MCF7 cells were grown in oestrogen-deprived 
media for 72h and then oestrogen receptor signaling was reactivated by 
addition of b-estradiol to the culturing media. This system allows analysis 
of early oestrogen responsive genes thereby distinguishing real targets of 
ERa transcriptional regulation from secondary events. 
Based on published observations that DDX54 co-represses TFF1 (one of 
the main ERa early responsive genes), in oestrogen-stimulated 
transcription [180], I investigated whether DDX54 has a general role in 
regulating ERa target genes. In order to expand the scope of my analysis, 
I included other putative ERa target genes. I intersected the results from 
the ERa ChIP-seq with those from the DDX54 iCLIP to identify DDX54 
target RNAs that are also transcriptional ERa targets (Figure 3.12A). 
Among the genes highlighted by the CLIP/ChIP intersection, I selected 
two candidates to test this hypothesis: MYB and MTA3. Figure 3.12B 
shows validation by CLIP-qPCR of DDX54 binding to MYB and MTA3 
RNAs, performed as previously described in wild type MCF7 cells and in 
MCF7 cells transduced with either scrambled shRNA or DDX54 targeting 
shRNA. I then measured expression of two known ERa transcriptional 
targets (TFF1 and GREB1), MTA3 and MYB and RPS24 (which is not an 
ERa ChIP target and was therefore used as a negative control). In MCF7 
cells under normal growth conditions, TFF1, GREB1, MYB and MTA3 
expression increased to different extents in DDX54 knock down only when 
one of two DDX54 siRNAs was used. RPS24 expression was slightly 
increased in DDX54 knock down using both siRNAs (Figure 3.12C).  
When I tested the same genes in conditions of ERa signalling early 
activation, I found the two main ERa target genes TFF1 and GREB1 were 
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consistently up-regulated upon b-estradiol treatment and their level of b-
estradiol dependent activation showed no change, or only a slight 
reduction, when DDX54 was knocked down with either of the two siRNAs 
(Figure 3.12D). As expected, RPS24 expression did not change irrespective 
of the presence of b-estradiol in the growth medium, whereas MYB and 
MTA3 did not show consistency in their response to neither b-estradiol 
dependent ERa activation nor when comparing the response obtained 
with either of the two siRNAs used to knock down DDX54 in these 
conditions (Figure 3.12D). Figure 3.12E shows the level of DDX54 mRNA 
and protein did not change upon growth in oestrogen-deprived medium 
nor during the b-estradiol treatment.  
Overall, these findings suggest DDX54 does not co-regulate 
transcriptional activity of ERa in MCF7 cells. 
 
 
3.7 Discussion  
DDX54 iCLIP in MCF7 cells was performed following successful quality 
controls steps, as determined by published protocols (Figure 3.1B-D). The 
data generated were used in the development of our iCLIP data analysis 
pipeline. This analysis uncovered some relevant information about the 
RNA binding preferences of DDX54 in MCF7 cells. Nevertheless, 
downstream investigations into the biological role of this helicase were 
inconclusive, probably also due to the low correlation of the iCLIP 
replicates generated (Appendix Figure 1B). The results of this chapter also 
highlight the need to couple iCLIP data to other data sets such as those 
derived from RNA-seq, ribosome profiling or mutant studies, to lead to a 
more comprehensive overview of potential functions of a protein of 
interest. 
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3.7.1 DDX54 shows binding preferences toward A-rich introns and 3’ ends 
One important finding from bioinformatic analysis of DDX54 iCLIP was 
that the DDX54 binding sites preferentially localize toward the 3¢ end of 
target transcripts and correspond to A- and T- (i.e. U- in RNA) rich 
triplets. These observations would suggest preferential binding to mRNA 
tails. Given the fact that DDX54 is a nuclear protein, it is unlikely that 
poly A binding would be related to translational processes. One 
speculation would be that DDX54 could be involved in polyadenylation 
events during or just after transcription. DDX54 was also found to bind 
preferentially to introns. Additionally, one T- (i.e. U- in RNA) rich 
sequence among the enriched motifs found in DDX54 binding sites, 
suggested a probable role in splicing. In fact, this sequence shows 
homology to the RNA sequence recognized by splicing factors (U2AF2, 
U2AF50).  
The DAVID Gene Ontology analysis of DDX54 target RNAs showed 
enrichment for nucleoplasmic components with transcriptional or 
chromatin related functions. This is an interesting observation if linked to 
the subcellular localization of DDX54. I indeed observed that DDX54, 
which is uniquely localized in the nucleus, showed preferential binding to 
nuclear related proteins RNAs. These observations would support the idea 
that proteins regulating RNAs of factors functional in a particular 
subcellular compartment are localized in the same relevant region. 
  
DDX54 is one of the least characterized DDX helicases, however a few 
reports in the literature indicate a role in regulating transcriptional 
activity of nuclear receptors (Section 1.4). Taking advantage of these 
published observations, I tried to expand the supposed ERa co-regulatory 
role of DDX54 in MCF7 breast cancer cells. However, my results did not 
show consistent evidence for a regulatory role of DDX54 on ERa-
dependent transcription. TFF1 and GREB1 are ERa target genes that 
respond early to oestrogen mediated activation of the receptor. These 
genes were not included in the overlap of ERa ChIP-seq targets and 
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DDX54 iCLIP targets. Moreover, I observed inconsistent effects of both 
DDX54 knock down and b-estradiol dependent ERa activation on the 
expression of genes that resulted from the overlap of the two data sets 
(MYB and MTA3). Altogether, these observations suggest DDX54 does not 
affect ERa-dependent transcription and that ERa transcriptional target 
genes are enriched as DDX54 iCLIP targets as a consequence of their 
expression in an ERa-dependent breast cancer cells line (MCF7) but with 
no apparent biological relevance for DDX54 binding their mRNAs.  
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4 Chapter 4 - Identification of DDX3X target RNAs 
through iCLIP technology 
 
 
 
4.1 Introduction 
The aim of Chapter 3 was to identify DDX54 RNA binding targets in order 
to gain novel insights into the biological function of a so-far poorly 
characterised protein. Unfortunately, the outcome of the DDX54 iCLIP 
analysis and the resulting follow-up investigations did not provide 
particularly useful information concerning the function of DDX54 on its 
target RNAs. As this outcome was considered a possibility, and in order to 
widen the scope of my investigation, I also performed in parallel an iCLIP 
experiment in MCF7 cells on a second candidate DEAD-box RNA helicase: 
DDX3X.  
As discussed in Section 1.5, DDX3X is a more well characterized protein 
than DDX54, and it has been shown to perform several molecular 
functions in post-transcriptional events. Although the role of DDX3X in 
breast cancer in vitro models has been partially investigated (Section 
1.6.1), the RNA target-specific activity of this protein in breast cancer cells 
was unexplored. 
 
 
4.2 Aims of this chapter 
Similar to the previous chapter, the aims of the work described in this 
chapter were: 
• To determine the RNA binding profiles of DDX3X in the MCF7 
breast cancer cell line. 
• To identify and validate individual target RNAs. 
• To identify specific RNA sequences and/or secondary structures to 
which the helicase binds. 
 111 
• To investigate molecular function and biological relevance of 
DDX3X binding to specific target RNAs. 
 
 
4.3 DDX3X iCLIP in-house library preparation 
Similarly to that shown for DDX54 in the previous chapter, I performed 
iCLIP using highly efficient immunoprecipitation antibodies against 
DDX3X (Figure 4.1A) to precipitate protein-RNA complexes from UV 
irradiated MCF7 cells. Figure 4.1B show the smear produced by DDX3X 
binding to 32P-labeled RNA fragments bound to DDX3X. These fragments 
of about 50 to 300 nucleotides, were obtained upon mild (+) RNase 
treatment of the RNA cross-linked to DDX3X and following 32P-labelling. 
As with DDX54 immunoprecipitation, high concentration (+++) RNase 
treatment leads to the formation of protein-RNA complexes of lower 
molecular weight. These give a signal just above the size of DDX3X due to 
the protein binding short RNA fragments. Negative control 
immunoprecipitations with (i) anti IgG isotype control antibody in UV 
cross linked lysates or (ii) anti-DDX3X antibodies in non-UV cross linked 
lysates did not precipitate any protein-RNA complexes (B). Protein-RNA 
complexes precipitated by the anti-DDX3X and anti-IgG antibodies were 
then used for subsequent library preparation (Section 2.13). RNA was 
retrieved from the complexes and used to generate iCLIP libraries within 
a 150 to 300 nucleotide optimal size range (Figure 4.1C) 
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Figure 4.1. iCLIP of endogenous DDX3X MCF7 breast cancer cells. 
(A) Western blot analysis of immunoprecipitated DDX3X in MCF7 whole cell 
lysate: cells were lysed in CLIP lysis buffer and DDX3X immunoprecipitation 
was performed. (IP= immunoprecipitation; FT= flow through). (B) 
Autoradiography of DDX3X - 32P fragmented RNA complexes migrating 20-80 
kDa above the size of the protein (indicated by the blue boxes in the second and 
third lanes). Whole cell lysates from MCF7 cells exposed to 254 nm UV 
crosslinking at 150mJ/cm2 were used to immunoprecipitate DDX3X in the 
presence of high (+++) RNase treatment in a single sample and low (+) RNase 
treatment in duplicate and anti-IgG antibody immunoprecipitation in the 
presence of mild RNase treatment in a single sample. Whole lysate from MCF7 
cells not exposed to UV was used for anti-DDX3X immunoprecipitation in the 
presence of low (+) RNase treatment in a single sample. (C) DDX3X iCLIP 
libraries: RNA was retrieved from immunoprecipitated complexes and size-
selected DDX3X-RNA complexes shown in (B). cDNA was divided into three size 
ranges and libraries were produced as described (Section 2.13.2). Shown are the 
PCR amplified libraries obtained for each size range for both biological replicates 
of DDX3X immunoprecipitation and the IgG control immunoprecipitation 
(H=high; M=medium; L=low nucleotide size range).  
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4.4 DDX3X binds exons within translation factors mRNAs 
The same bioinformatic approach used for DDX54 iCLIP was used to 
analyse DDX3X iCLIP data (Appendix Figure 1). This analysis showed 
DDX3X preferentially binds exons of protein coding RNAs (Figure 4.2 A,C) 
and it is preferentially found at 5¢ and 3¢ ends of transcripts with a 
predominant abundance towards the 5¢ end (Figure 4.2B). Interestingly, in 
cell fractionation experiments, DDX3X was localized in both the cytoplasm 
and the nucleus (Figure 4.2D). 
 
To validate binding of DDX3X to target RNAs, I performed CLIP-qPCR 
and analysed four DDX3X iCLIP target RNAs (SOX4, TFF1, CALR, 
JUND) and one RNA (PUS1) not bound by DDX3X (Figure 4.3). CLIP-
qPCR was performed with either an anti-DDX3X antibody, antibodies 
against other DDX helicases (DDX1 and DDX24) or IgG control antibodies. 
Data show that DDX3X target RNAs were specifically and significantly 
enriched by DDX3X antibodies but not by the other antibodies (Figure 
4.3). As expected, the control unbound RNA, PUS1, was unspecific in 
DDX3X CLIP-qPCR (Figure 4.3 bottom panel). These data indicate that 
the identified target RNAs are indeed specifically bound by DDX3X.  
Next, DDX3X bound RNAs were subjected to a gene ontology analysis 
using the DAVID bioinformatics resource. This showed a striking 
predominance of genes encoding ribosomal components (Figure 4.4A-B). 
The human genome contains 80 ribosomal proteins genes of which 32 
encode proteins of the small subunit and 48 encode proteins of the large 
subunit of ribosomes. Amongst the DDX3X target RNAs, I identified 42 
(53% of total) ribosomal protein mRNAs, which constitute approximately 
20% of all DDX3X bound RNAs (Figure 4.4C). 
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Figure 4.2. DDX3X iCLIP truncation sites localize on exonic regions and are 
enriched at 5’ and 3’ end of transcripts.  
(A) Pie chart indicating location of iCLIP peaks in transcripts. The percentages of 
DDX3X iCLIP truncation sites found in the indicated categories are shown. 
Genomic categories of iCLIP peak location were searched for using PAVIS 
[PMID: 24008416] with default settings.  (B) Density plot of iCLIP localisation on 
a scaled gene body (metaplot). The transcripts that have iCLIP peaks of DDX3X 
were scaled to the same length and also extended by 20% up- and down-stream. 
Then, iCLIP peaks for each mRNA were accumulated on the scaled plot to 
visualise the distribution of iCLIP truncation sites localisation. The scaled gene 
body represents three indicative regions: 5’-end, middle, and 3’-end. Y axis = 
counts of iCLIP sites; X axis = scaled gene body localization.  (C) Bar graph of 
gene types with iCLIP peaks. Shown are the enrichments of DDX3X iCLIP 
truncation sites in each gene type category. The genomic categories of iCLIP 
peak location were searched for using PAVIS [PMID: 24008416] with default 
settings. Y axis = counts of iCLIP sites; X axis = gene type category. (D) DDX3X 
is localized in the nucleus and cytoplasm of MCF7 cells. Western blot analysis 
with antibodies against DDX3X and ß-tubulin, as indicated, in whole cell (W), 
cytoplasmic (C) and nuclear (N) fractions of MCF7 cells.  
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Figure 4.3. CLIP qPCR validation of DDX3X iCLIP targets.  
CLIP-qPCR was used to validate binding of SOX4, TFF1, CALR, JUND mRNAs 
to DDX3X. DDX1, DDX24 and IgG were included as negative controls, as was the 
non-bound PUS1 mRNA. cDNA obtained from each immunoprecipitation was run 
in qPCR to determine enrichment of the indicated targets. Results represent the 
average of three biological replicates. Error bars indicate standard deviation. 
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Figure 4.4. DDX3X iCLIP target RNA gene ontology analysis shows enrichment 
of ribosomal components. 
DAVID gene ontology search of cellular component (A) and molecular function 
(B) enriched terms. The GO enrichment of DDX3X iCLIP bound transcripts was 
obtained using the DAVID functional annotation tool with default settings 
[PMID: 19131956]. P-values were calculated using the “default” method of 
DAVID. 
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(A-B) Scatter plots were generated with REVIGO [PMID: 21789182] to visualise 
the GO term analysis result for cellular components (A) and molecular function 
(B). The scatter plots show GO term cluster representatives in two-dimensional 
space. X-axis indicates the frequency of the GO term in the underlying GO 
analysis database (i.e. bubbles that are closer to the end of x-axis (lager values) 
are more general terms). Y-axis and bubble colour/size indicates the log 
transformed p-value of GO terms. (C) Table shows all RNA targets of DDX3X 
iCLIP and highlights ribosomal proteins.   
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As with the RNAs validated above (Figure 4.3), I validated binding of 
DDX3X to specific ribosomal protein mRNAs (RPS2, RPS3 and RPS6) by 
performing CLIP-qPCR (Figure 4.5A). Each of these mRNAs preferentially 
bound to DDX3X.  Importantly, the specificity of the anti-DDX3X antibody 
was corroborated by performing CLIP-qPCR in MCF7 cells that had been 
depleted of DDX3X using shRNA. In these experiments, precipitation of 
each ribosomal protein mRNA was dramatically reduced upon loss of 
DDX3X (Figure 4.5B).  Efficient knock down of DDX3X was confirmed by 
western blotting with the anti-DDX3X antibody (Figure 4.5C). 
To investigate the significance of DDX3X to the synthesis of ribosomal 
proteins, I analysed the levels of RPS2, RPS3 and RPS6 proteins, via 
western blotting with appropriate antibodies upon knock down of DDX3X 
(via shRNA and siRNAs) in MCF7 cells (Figure 4.6A). RPS2 and RPS6 
were depleted upon loss of DDX3X, with the highest effect observed on 
RPS2 protein level, whilst RPS3 and the loading control b-tubulin 
remained unchanged (Figure 4.6A). At the mRNA level, RPS2, RPS3 and 
RPS6 were slightly reduced in both transient siRNA-mediated and stable 
shRNA-mediated DDX3X knocked down MCF7 cells (Figure 4.6B).  
Overall, these results suggest that binding of DDX3X to ribosomal protein 
mRNAs may be required for their efficient translation and for stability of 
RPS2, RPS3 and RPS6 mRNAs. 
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Figure 4.5. CLIP-qPCR validation of DDX3X binding to ribosomal protein 
mRNAs.  
(A) Clip-qPCR was performed to validate binding of RPS2, RPS3, and RPS6 
mRNAs to DDX3X. DDX1, DDX24 and IgG were included as negative controls. 
(B) DDX3X and IgG CLIP-qPCR were performed in MCF7 cells transduced with 
scrambled or DDX3X targeting shRNA. (A-B) cDNA obtained from each 
immunoprecipitation was analysed by qPCR to test for enrichment of the 
indicated targets. Results represent the average of three biological replicates. 
Error bars indicate standard deviation. P-values represent statistical significance 
calculated with unpaired t test compared to scramble (P-values: ns. > 0.05; * ≤ 
0.05; ** ≤ 0.01; *** ≤ 0.001; **** ≤ 0.0001). (C) Western blot analysis shows the 
level of DDX3X and ß-tubulin in whole lysate of MCF7 cells transduced with 
scrambled or DDX3X targeting shRNA, used in B.  
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Figure 4.6. DDX3X knock down affects ribosomal proteins mRNA and protein 
levels. 
(A) Western blot analysis shows the level of RPS2, RPS3, RPS6, DDX3X and ß-
tubulin proteins in whole lysate from MCF7 cells transduced with either 
scrambled shRNA or DDX3X targeting shRNA (left panel) and in cell lysate from 
MCF7 cells transfected with either scrambled siRNA or two different DDX3X 
targeting siRNAs (#6 or #8) (right panel). (B) RPS2, RPS3 and RPS6 mRNA 
levels in MCF7 treated as in A, measured by qPCR. Results represent the 
average of three biological replicates (Section 2.5.3). Error bars indicate standard 
deviation. P-values represent statistical significance calculated with unpaired t 
test compared to scramble controls (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 
0.001**** ≤ 0.0001). 
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4.5 Does DDX3X regulate ribosomal protein mRNAs in mTOR 
signalling? 
In order to find pathways in which DDX3X may function, I ran additional 
gene ontology analysis on pathways enrichment. As expected, my search 
again indicated that most DDX3X target RNAs fall into translational 
regulation pathways. Particularly, mTOR (mechanistic target of 
rapamycin) signalling was one of the top terms (Figure 4.7). Indeed, most 
of the genes listed in the mTOR signalling category were ribosomal 
proteins, amongst which were the validated DDX3X binding targets RPS2, 
RPS3 and RPS6.   
As previously described, mTORC1 is a known regulator of translation and 
is required mainly for translation of translation factors mRNAs, many of 
which encode ribosomal proteins (Section 1.1.3) [77]. Furthermore, DDX3X 
binds mRNA 5¢-caps in an mTOR-dependent manner. DDX3X association 
to the 5¢-cap complex is increased upon insulin dependent mTOR 
signalling activation and reduced upon mTOR signalling chemical 
inhibition [96]. These reports, together with the results from my 
bioinformatic analysis, prompted me to investigate whether DDX3X 
binding to ribosomal protein mRNAs could affect their protein levels in an 
mTOR-dependent manner. I speculated that if mTOR regulates binding of 
DDX3X to its target mRNAs, then inhibition of the mTOR pathway (by 
rapamycin treatment) should affect DDX3X binding to its targets. To test 
this hypothesis, I subjected MCF7 cells to a time-course of rapamycin 
treatment. I first performed a short-term time-course (0-6 h) using 100 nM 
rapamycin. This showed no changes in either the protein or mRNA levels 
of RPS2, RPS3 and RPS6, although the mTOR pathway was efficiently 
inhibited as demonstrated by loss of a signalling marker, namely RPS6 
phosphorylation (Figure 4.8A-B). DDX3X binding to ribosomal proteins 
mRNAs was also unaffected over this short-term time-course of rapamycin 
treatment (Figure 4.8C). 
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Figure 4.7. Pathways enrichment of DDX3X iCLIP targets: mTOR signalling.  
(A). Bar graph showing pathways term enrichment generated with IPA tool (IPA 
Ingenuity® Systems) GO search of DDX3X iCLIP targets. P-values were 
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calculated using default settings of Ingenuity. The X-axis shows GO terms 
related to upstream regulators. Y-axis shows –log10 p-values of each GO term. 
The table shows the components of the mTOR term: mostly ribosomal proteins. 
(B) The mTOR kinase is the core component of two distinct protein complexes 
termed mTORC1 and mTORC2. mTORC1 responds to amino acids, stress, 
oxygen, energy, and growth factors and is acutely sensitive to rapamycin. It 
promotes cell growth by inducing and inhibiting anabolic and catabolic processes, 
respectively, and also drives cell cycle progression. mTORC2 responds to growth 
factors and regulates cell survival and metabolism, as well as the cytoskeleton. 
mTORC2 is insensitive to acute rapamycin treatment but chronic exposure to the 
drug can disrupt its structure. (C) mTOR signaling promotes tumorigenesis. 
Oncogenes (red) or tumor suppressors (green) implicated in the control of mTOR 
signaling are indicated. Adapted from [77] 
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Figure 4.8. Effects of rapamycin inhibition of mTOR pathway at early time points 
on RPS2, RPS3 and RPS6 expression and DDX3X binding of their respective 
mRNAs. 
(A) Western blot shows the level of RPS2, RPS3 RPS6, DDX3X and ß-tubulin at 
the indicated time points upon treatment with 100 nM rapamycin or DMSO 
control. RPS6 phosphorylation (at residues S240/S244) reduction is used as a 
marker of mTOR activity inhibition. (B) mRNA levels of RPS2, RPS3 and RPS6 
in MCF7 cells treated with DMSO or with 100 nM rapamycin at the indicated 
time-points, measured by qPCR. Results represent the average of three biological 
replicates (Section 2.5.3). P-values were n.s. (C) DDX3X and IgG CLIP-qPCR 
performed as previously described to test the binding of RPS2, RPS3 and RPS6 
mRNAs in MCF7 cells treated with DMSO or with 100 nM rapamycin at the 
indicated time points. cDNA obtained from each immunoprecipitation was 
analysed by qPCR to determine enrichment of the indicated targets. Results 
represent the average of three biological replicates. Error bars indicate standard 
deviation. P-values were n.s. 
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Next, I exposed MCF7 cells to rapamycin for 24 hours, and compared the 
effects of this longer treatment on the expression of RPS2, RPS3 and RPS6 
proteins in MCF7 cells in which DDX3X was knocked down or normally 
expressed (Figure 4.9A). The intensity of the bands in these western blots 
were then quantified using ImageLab (Figure 4.9B). Strikingly, after 24 h 
of rapamycin treatment, the level of DDX3X itself was reduced by about 
70% compared to the level in control DMSO treated cells. Interestingly, 
knock down of DDX3X under DMSO control conditions was as effective as 
the rapamycin treatment in reducing the level of DDX3X protein. 
However, rapamycin treatment caused a further reduction of the DDX3X 
protein level in DDX3X knock down cells. A similar trend was observed for 
RPS2 protein. Conversely, RPS3 protein levels were not affected by 
DDX3X knock down but were decreased upon 24 h rapamycin treatment. 
RPS6 protein levels were insensitive to rapamycin treatment but were 
reduced by DDX3X knock down, equally in either DMSO or rapamycin 
treated cells. Interestingly, mRNA levels of RPS2, RPS3 and RPS6 were 
reduced in DDX3X knockdown cells and went slightly up in the presence 
of rapamycin inhibition in cell lines expressing DDX3X as well as in those 
with DDX3X knock down (Figure 4.9C). 
CLIP-qPCR performed in the same conditions showed that after 24 h of 
rapamycin treatment, binding of DDX3X to RPS2 and RPS6 mRNAs was 
almost unchanged, whilst binding to RPS3 mRNA was slightly increased, 
compared to the binding detected in the DMSO controls (Figure 4.9D). 
However, DDX3X protein level is strongly decreased after 24h rapamycin 
treatment (Figure 4.9B). Therefore, assuming an equal efficiency of 
DDX3X immunoprecipitation for all samples, one could speculate that the 
residual DDX3X protein expressed after 24h of rapamycin treatment is 
mostly engaged in binding of its target mRNAs. 
These results show that DDX3X binding to RPS2, RPS3 and RPS6 mRNAs 
is maintained upon inhibition of the mTOR pathway with rapamycin. 
Moreover, the levels of RPS2, RPS3 and RPS6 proteins were differently 
affected by both rapamycin treatment and DDX3X knock down: RPS2 is 
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strongly decreased by DDX3X knock down as well as by rapamycin 
treatment; RPS3 is insensitive to DDX3X knock down but decreased upon 
rapamycin treatment; RPS6 is insensitive to rapamycin and decreased 
upon DDX3X knockdown (although showing less sensitivity than RPS2).   
These observations indicate the complexity of the hypothesized connection 
between DDX3X and the mTOR pathway. 
 
 
 
Figure 4.9. Effects of 24h rapamycin inhibition of the mTOR pathway on RPS2, 
RPS3 and RPS6 expression and DDX3X binding of their respective mRNAs. 
(A) Western blot shows the levels of RPS2, RPS3, RPS6, DDX3X and ß-tubulin 
proteins in MCF7 cells transduced with either scrambled shRNA or DDX3X 
targeting shRNA and treated with DMSO or 100 nM rapamycin for 24 h. 
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Reduction of RPS6 phosphorylation (residues S240/S244) was used as a marker 
of mTOR activity inhibition. (B) protein levels from A were quantified with 
ImageLab. Values were normalized to ß-tubulin levels and expressed as fold over 
DMSO control. 
(C) mRNA levels of RPS2, RPS3 and RPS6 tested under the same conditions as 
in A, measured by qPCR. (D) DDX3X and IgG CLIP-qPCR performed as 
previously described to detect binding of RPS2, RPS3 and RPS6 mRNAs in MCF7 
cells treated with DMSO or 100 nM rapamycin for 24h. cDNA obtained from each 
immunoprecipitation was analysed by qPCR to determine enrichment of the 
indicated targets. (C-D) Results represent the average of three biological 
replicates (Section 2.5.3). Error bars indicate standard deviation. P-values 
represent statistical significance calculated with unpaired t test compared to 
DMSO (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001;**** ≤ 0.0001). 
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4.6 DDX3X binds specific sequences within its target RNAs. 
To further investigate binding specificity of DDX3X, I analysed RNA 
sequences surrounding DDX3X binding sites and observed enrichment of 
CG and CT (i.e. CU in RNA) containing triplets in both 200 base-pair and 
30 base-pair windows around the truncation sites (Figure 4.10A). To ask 
whether these triplets could be part of a more enriched sequence binding 
motif, I ran a motif search and found ten subgroups of related 8-mers to 
which most DDX3X targets could be assigned (Figure 4.10B). All enriched 
motifs were localized towards either the 5¢- or the 3¢-end of transcripts, 
consistent with the truncation site localization previously observed 
(Figure 4.2B and Figure 4.10C), which suggests most target RNAs may be 
bound via a discrete motif. 
Amongst the most enriched motifs were subgroups (Figure 4.11) showing 
high similarity to known binding sites of RNA binding proteins involved in 
different molecular processes (data not shown). Of most relevance, the 
motif called SG2 was found to possess strong sequence homology with the 
binding motif of SR splicing factors 1 and 2 (SRSF1, SRSF2), suggesting 
that DDX3X may be involved in alternative splicing, at least of RNAs 
bearing this motif (Figure 4.11B: SG2). 
 
My analyses also revealed that ribosomal protein RNAs generally bear 
more than one motif spread throughout their mRNA sequence and, 
although belonging to different phylogenetic subgroups, most of the motifs 
present within these RNAs share a CT (i.e. CU in RNA) enrichment 
within the 8-mer sequence, as shown in the examples in Figure 4.11A-D. 
Interestingly, the three validated ribosomal proteins mRNAs (RPS2, RPS3 
and RPS6) bear different binding motifs within their sequences (Figure 
4.12). 
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Figure 4.10. Motif search on DDX3X iCLIP binding sites. 
(A) Heatmap of triplets usage in 200 base-pair and 30 bp windows centred by 
DDX3X iCLIP peak. Shown is the enrichment of triplets found in a 200 bp (left) 
and 30 bp (right) extended window centred on iCLIP peaks. MATLAB codoncount 
was used to generate the heatmap (Section 2.13.5). The colour gradient bar 
indicates counts of triplets found in the considered window and associated hue. 
(B) Phylogenetic tree of highly enriched 8-mer motifs in 200 base-pair windows 
centred by DDX3X iCLIP peak. 8-mers enriched in an extended +/-100bp centred 
by iCLIP were found as described (Section 2.13.5). To identify consensus motifs, 
enriched 8-mers were phylogenetically clustered into 10 groups. MATLAB 
function seqlinkage was used to construct the phylogenetic tree shown (Section 
2.13.5). (C) Density plot of highly enriched motifs localised on scaled gene body. 
Shown is the distribution of the motif localisation. The transcripts that have the 
enriched motifs in the +/-100bp extended windows centred by DDX3X iCLIP 
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peaks were scaled to the same length and also extended by 20% up- and down-
stream. Then, the enriched motifs for each gene were accumulated on the scaled 
gene to visualise the distribution of DDX3X binding motif localisation. The scaled 
gene body represents three indicative regions: 5’-end, middle, and 3’-end. Y axis = 
counts of iCLIP Motifs; X axis = scaled gene body localization.  
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Figure 4.11. Enriched motifs at DDX3X binding sites. 
(A-D) Shown are 4 examples of enriched motifs at DDX3X binding sites together 
with a density plot of the motifs localisation within a scaled gene body. The 
scaled gene body represents three indicative regions: 5’-end, middle, and 3’-end. 
Y axis indicates the frequency (actual count) of the motif; X axis = scaled gene 
body localization. Consensus motifs for the clustered 8-mer(s) in each 
phylogenetic group were found with MATLAB function seqlogo (Section 2.13.5).  
Each density plot represents the localization of the clustered motifs of four 
different phylogenetic groups considered (SG1, SG2, SG3, SG4). The sequence 
logo of the phylogenetic group consensus motif is shown (Y axis = Bits; X axis 
=sequence position). Ribosomal proteins and JUND bearing the motif are listed 
under the corresponding plot at the scaled position where the motif was found in 
their sequence.  (B) The motif is matched to known RNA binding motifs. Table 
shows the known RNA binding proteins that recognize a similar sequence motif. 
P-values represent the significance of homology.  
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Figure 4.12. DDX3X binding motif localization within RPS2, RPS3 and RPS6 
mRNAs.  
Visualization of the USCS custom tracks for DDX3X iCLIP truncation sites and 
motif localization within RPS2, RPS3, and RPS6 mRNA sequences.  
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4.7 DDX3X binds hJUND mRNA at a specific binding motif. 
The JUND transcript was shown to require binding of the DEAH BOX 
RNA helicase DHX9 for efficient translation [247]. In my CLIP-qPCR 
validations, the JUND transcript was one of the most enriched and highly 
reproducible DDX3X target RNAs detected (Figure 4.3). Furthermore, the 
specificity of DDX3X binding to JUND RNA was confirmed by CLIP-qPCR 
experiments in DDX3X knock down cells (Figure 4.13A). 
 
Interestingly, both JUND mRNA and protein levels showed significant 
depletion upon DDX3X knock down in both DDX3X shRNA transduced 
and DDX3X siRNA transfected MCF7 cells (Figure 4.13B-C).  Moreover, 
my motif search analysis identified a CT- (i.e. CU in RNA) rich putative 
DDX3X binding motif within the JUND transcript (Figure 4.14A marked 
with *). These observations, together with published reports, provided the 
rationale to validate the motif search results within the sequence of JUND 
mRNA. For this purpose, I performed electrophoretic mobility shift assays 
(EMSA) using in vitro synthesized RNA oligonucleotides. I designed a wild 
type RNA oligonucleotide that included 52 nucleotides surrounding the 
putative DDX3X binding motif site within JUND mRNA.  I also designed 
a mutant RNA oligonucleotide mapping to the same region but harbouring 
a three-nucleotide substitution within the motif 8-mer (Figure 4.14B). The 
oligonucleotides were then 5'-end labelled with 32P and incubated with 
MCF7 whole cell lysate prepared from cells that had been transduced with 
either scrambled shRNA or DDX3X shRNA. The oligonucleotides and 
bound proteins were then resolved in a polyacrylamide non-denaturing gel 
via standard EMSA procedures (Section 2.7). The autoradiograph of the 
resulting gel showed free probe at the bottom of the gel with a number of 
'shifted' higher molecular weight bands above. The bands with lower 
mobility than free probe represent protein-RNA complexes. 
 
The band with an intermediate mobility (marked with *) was only 
observed with the WT probe and not the mutant probe (Figure 4.14C).  
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Importantly, this band was completely lost when MCF7 cell extracts 
depleted of DDX3X were used (Figure 4.14C, lane IV). This suggests that 
DDX3X is essential for the formation of this protein-RNA complex and this 
signal represents a DDX3X-RNA complex. 
 
The band with the lowest mobility (marked with ^) was present with both 
the wild type probe and mutant probe. Interestingly, this band ran 
slightly faster when the wild type probe was used in binding reactions 
with lysate from DDX3X knock down MCF7 cells (Figure 4.14C – WT 
JUND probe box, lane IV). This suggests that DDX3X is part of a larger 
protein-RNA complex and when it is depleted, other components of the 
complex can still bind to the probe.  
When the mutant JUND probe was used in binding reactions with lysate 
from DDX3X-expressing MCF7 cells, the mobility of this band was 
intermediate compared to the mobility shown when using the wild type 
probe (Figure 4.14C - MUTANT JUND probe box, lanes II) with lysates 
expressing or depleted of DDX3X (Figure 4.14C - WT JUND probe box, 
lanes II and IV). When the mutant JUND probe was used in binding 
reactions with lysate from DDX3X knock down MCF7 cells the intensity of 
this band was reduced (Figure 4.14C - MUTANT JUND probe box, lanes 
IV) but not its mobility. 
Overall, these results suggest that DDX3X binds directly to the identified 
motif within JUND mRNA (* band) and that a multicomponent complex 
containing DDX3X specifically recognizes the motif within the JUND 
sequence (^ band). In addition, other factors within the complex appear 
capable of binding to the probe, outside of the specific DDX3X binding 
motif, independently of DDX3X. Finally, it is likely that DDX3X also binds 
to other regions of the probe and/or interacts with other factors of the 
complex, to mediate co-operative binding of the rest of the complex. 
To test the specificity of DDX3X binding to the JUND oligonucleotides, I 
performed an antibody super-shift experiment by adding an anti-DDX3X 
antibody to the binding reactions (performed as previously described). 
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Unfortunately, no change in band mobility was observed with either wild 
type or mutant JUND probes (Figure 4.14C- lanes III).  
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Figure 4.13. JUND expression is affected by DDX3X knock down. 
(A) DDX3X and IgG CLIP-qPCR were performed to test the binding of JUND 
mRNA in MCF7 cells transduced with either scrambled shRNA or DDX3X 
shRNA. cDNA obtained from each immunoprecipitation was analysed by qPCR to 
determine enrichment of the indicated targets. (B) Western blot shows DDX3X, 
JUND and GAPDH protein levels in whole cell lysates of MCF7 cells transduced 
with either scrambled shRNA or two different DDX3X shRNA (right panels) and 
in MCF7 cells transfected with either scrambled siRNA or two different DDX3X 
targeting siRNAs (#6 or #8) (left panels). (C). mRNA levels of JUND under the  
same conditions as in B measured by qPCR. (A,C) Results represent the average 
of three biological replicates (Section 2.5.3). Error bars indicate standard 
deviation. P-values represent statistical significance calculated with unpaired t 
test compared to scramble controls (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 
0.001; **** ≤ 0.0001).  
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Figure 4.14. DDX3X binds the human JUND transcript on a discrete sequence 
motif. 
(A) DDX3X consensus sequence of the binding motif found in JUND mRNA (left 
panel).  Visualization of the USCS custom tracks for DDX3X iCLIP truncation 
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sites and motif localization on JUND sequence (left panel-validated motif is 
marked with *).  (B) Model of the wild type JUND and mutant JUND RNA motif- 
containing probes used in EMSA assays; Minimum Free Energy (MFE) 
secondary structure of the RNA oligonucleotide probes used in EMSA, predicted 
using RNAfold tool (http://rna.tbi.univie.ac.at//cgi-
bin/RNAWebSuite/RNAfold.cgi) (C) Shown is the autoradiograph of the mobility 
shift assay performed as described (Section 2.7). Briefly, whole cell lysate from 
MCF7 cells transduced with either scrambled shRNA (lanes II and III) or DDX3X 
targeting shRNA (lanes IV) were used to test the binding of either wild type (left 
half) or mutant (right half) JUND probe.  Anti-DDX3X antibody was added (lanes 
III). Probe signal (lanes I). (D) Western blot shows protein level of DDX3X and 
GAPDH in whole lysate of MCF7 cells used in C. 
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4.8 DDX3X binds target RNAs that share similar predicted 
structures. 
It is possible that structural features of target RNAs mediate interactions 
with binding proteins. I therefore decided to investigate whether DDX3X 
target RNAs, so far identified and validated, share common predicted 
structures at the region bound by DDX3X. To do this, I considered an 
extended region of approximately 200 nucleotides surrounding the first 
iCLIP site located at the 5¢-side of the RPS2, RPS3, RPS6 and JUND 
transcripts (marked with * in Figure 4.12).  
I used the locARNA tool to compare the 2D structure of selected RNAs. 
The software first generates a phylogenetic tree based on the alignment of 
the sequences. As shown in Figure 4.15A, RPS6 sequence has lower 
homology when compared to the other RNAs sequences, whereas RPS2, 
RPS3 and JUND show higher homology among them. I therefore decided 
to run comparative structural prediction on RPS2, RPS3 and JUND 
sequences, to improve the quality of the prediction results. LocARNA 
generates a structural prediction combining all potential common 
structures of the aligned RNA sequences. The outputs of locARNA are 
shown in Figure 4.15B (sequence and structure alignment) and C (overlaid 
structure of three RNAs). The sequence and structure of the three RNAs 
are well aligned showing strong conservation in forming stem-loop 
structures (Figure 4.15B). More interestingly, DDX3X iCLIP binding sites 
are located in three consecutive stem-loop structures (highlighted in 
Figure 4.15C). In the case of RPS3 mRNA, the region used in the 
alignment contains two consecutive distal binding sites that both lie on 
different stem loop structures (Figure 4.15C). Importantly, one of the 
RPS3 binding sites is located within the same stem-loop as the two 
consecutive JUND binding sites (Figure 4.15C). These results suggest that 
DDX3X binding to its target RNAs may preferentially occur at stem loop 
RNA secondary structures. 
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Figure 4.15. DDX3X binds its target RNAs with similar secondary structures. 
(A) Phylogenetic tree generated with locRNA [PMCID: PMC3334699] by 
alignment of RPS2, RPS3 and JUND sequences (indicated by the genomic 
coordinates) extended around iCLIP binding sites. 
(B-C) locRNA output of sequence and structure alignment (B) and overlaid 
structure prediction (C) of the three RNA sequences. (B-C) Colour code indicates 
the number of possible base pairs (red=1; yellow=2; green=3); (C) Sequence in the 
overlaid structure is shown in IUPAC. 
  
RPS3 5UTR ExonCD ExonCD chr11 75399415 75399677
JUND ExonCD chr19 18281034 18281245I1
RPS2 ExonCD chr16 1964193 1964397
I2
RPS6 5UTR chr9 19379505 19379708
I3
..............(((....))).......................(((.....))).(
JUND|ExonCD|chr19:18281034-18281245:- C-------------UGCUUGUGUAAAUCCUC----------------CAGGGC-CUUGAC 30
RPS3|5UTR,ExonCD,ExonCD|chr11:75399415-75399677:+ CGUAAAAACUACAUUUCCCAUGAGCACCCACAGGCGUGCACGCAGCGCAGCCC-UCCGUC 59
93CAGUAAACCCGACCC----------CAACCUCCUAAUCGUAGACGGUAA------------:7934691-3914691:61rhc|DCnoxE|2SPR
.........10........20........30........40........50.........
((..((((((.........((((.(((.((......)).(((.((............)))
JUND|ExonCD|chr19:18281034-18281245:- GAAGCCCUCG-----GCGAACUCCUGCUCCUCGCUGGCCGCCACCUU----------GGG 75
RPS3|5UTR,ExonCD,ExonCD|chr11:75399415-75399677:+ GUCGCUCGCGCCCUUUAUACUCACUUCCGCCCGCGAGCCACUUCCUUUCCUUUCAGCGGA 119
29CGGAUAAUUCCAUGCGCAGCCAGCAACCCCGCAACUCGUUCA-------CGCUGGGGCCU-:7934691-3914691:61rhc|DCnoxE|2SPR
.........70........80........90........100.......110........
)).(((((((......)))))))............(((.((((....)))))))....))
JUND|ExonCD|chr19:18281034-18281245:- GUAGAGGAAC-UGUGAGCUCGUC------------GGCGUGGUGGUGACCAGCCCGUUGG 122
RPS3|5UTR,ExonCD,ExonCD|chr11:75399415-75399677:+ GCGCGGCGGCAAGAUGGCAGUGCAAAUAUCCAAGAAGA-GGAAGGUGAGCCUCUGG--GG 176
041GUU--CCUGUACU-UCUAGUU-CAGGGAC--------CUCCUCUAGAUAGAGAAGAGGGA-:7934691-3914691:61rhc|DCnoxE|2SPR
.........130.......140.......150.......160.......170........
).))))))).)))....)))..((((((.((((((.(((..(((.(((((.........)
JUND|ExonCD|chr19:18281034-18281245:- ACUGGAUGAUGAGGCGCUCGAGCUCGGGGGAGGCCAGCUUCAGCAGCCCC----AGGUCG 178
RPS3|5UTR,ExonCD,ExonCD|chr11:75399415-75399677:+ ACUGGGUUCGGAGAACGACGGCGCCGCGCGGGUCGAGGGCUUCUCGGGGU------GCCA 230
381AGAGGGAAAUCACCUACGG--GCAGUGGUUC--------------AACCC-GGCGAACCA-:7934691-3914691:61rhc|DCnoxE|2SPR
.........190.......200.......210.......220.......230........
)).)).)))))).))))))))))))........
JUND|ExonCD|chr19:18281034-18281245:- GGAGAGGCGAGCAGGCCGUCGGGGGGUGCCGCG 211
RPS3|5UTR,ExonCD,ExonCD|chr11:75399415-75399677:+ CC-GCGAGGCCUGCAGCUCCGUGGCCUGCCCUG 262
402CA------------GGACCAGUGACCGCGGAAA-:7934691-3914691:61rhc|DCnoxE|2SPR
.........250.......260.......270.
A
B
C
c
guaa
a
a
a
c
u
a
m
a
uK
K
C
HBR
U G
H
DMA
YC
CW
Cm
rr
cg
u g c a c g c a g c sCAG
SSC
a H H Y G
W
C
K
HM
G
S
B
S
K
C
G
cccu
u
k
m k A
M
Y
Y
V
C
U
B
MH
SSYC
S
C D R
S SMV
C
BWC
SYKu
m
c
y u u m
a
k
m
G
G
V
R
BR S
R
G
V
R
R
Mr
W
K WK
R
K
C
W
S
B
K
Ca
a
a
u
a
u c
c
m
a
g
rRR
MgK
K
R
W
K S U
gW
S
M
H
K
Y
Y
S
g
uuK
G
A
C
Y
R
R
R
Y
K
Vk
S
M
SR
M
ss
w
c
g r
s
s y
c g
s g
sS
DK
KS
B R
RS
KyyD
SY
M
KS
SV
Y u a
a
a
rgGH
S
RVVaGVS
RSSMSYR
VVSMKBcgkggss
u
g
c
c
s
HS
RPS3
RPS2
JUND
A
C
RPS3
G
 142 
4.9 Discussion  
Implementation of iCLIP to discover direct target RNAs of DDX3X 
uncovered a wealth of information that was useful for downstream 
investigation into the biological roles and mechanistic features of this 
helicase in MCF7 breast cancer cells. The results of this chapter provide 
insight into the roles of DDX3X and indicate possible important functions 
for this protein. These possibly include maintaining RNA stability and 
promoting translation of target RNAs. Moreover, I was able to show 
preferential binding of DDX3X to a specific sequence motif within the 
JUND human transcript. 
 
4.9.1 DDX3X regulates expression of its target RNAs and recognizes at 
least one relevant sequence motif. 
DDX3X regulates several aspects of RNA metabolism (Section 1.5). 
Recently, DDX3X CLIP-seq data sets, generated from HEK293T cells over-
expressing either wild-type or medulloblastoma-associated catalytic 
mutants of DDX3X, were published [203]. Interestingly, these data show 
enrichment of DDX3X binding sites in coding sequences of mainly 
translation factor mRNAs, which is in strong agreement with my findings. 
Also, over-expression of DDX3X mutants led to aberrant formation of 
stress granules and caused global translational impairment [203]. 
  
I found that depletion of DDX3X affects the levels of many of its direct 
target RNAs as well as the proteins they encode. This suggests that the 
role of DDX3X may not be solely involved with translational regulation at 
the ribosome level. My findings suggest that the global translational 
impairment of DDX3X mutant expressing cells [203], as observed by 
Valentin-Vega and colleagues, may be caused by lack of DDX3X positive 
regulation of mRNAs encoding translation-related proteins (such as 
ribosomal proteins), which ultimately results in generally defective 
translation. 
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Binding of DDX3X to the 5¢-cap of mRNAs together with other 
translational initiation factors is dependent upon mTOR activity [96]. 
Proteomic studies using m7GTP affinity chromatography showed that 
presence of DDX3X in the 5¢-cap-binding complex is dependent on the 
activation state of mTOR. Specifically, the amount of DDX3X interacting 
with m7GTP increased when mTORC1 signalling was activated by insulin 
treatment, and it was reduced when mTORC1 signalling was inhibited by 
PI3K inhibitors [96]. Based on these published findings, as well as on the 
pathway enrichment in my DDX3X iCLIP gene ontology (Figure 4.7A) 
which highlighted the mTOR pathway term, I used rapamycin to test the 
hypothesis that the activity of DDX3X might be linked to the mTOR 
signalling pathway. Rapamycin inhibits the kinase activity of mTOR 
thereby blocking the signalling cascade that leads to protein synthesis and 
other processes essential for cell growth (Figure 4.7B-C). As such, it is 
widely used to study events downstream of mTOR [105] [88, 107].  
DDX3X binding to target mRNAs encoding RPS2, RPS3 and RPS6 was not 
affected by short time-course inhibition of mTOR by rapamycin (Figure 
4.8), and neither were the expression levels of the ribosomal mRNAs and 
proteins. Conversely, DDX3X's binding to the same mRNAs remained 
fairly constant after 24h of rapamycin treatment (Figure 4.9). At the same 
time, DDX3X target RNAs levels were slightly elevated. This enhanced 
expression appears to be independent of DDX3X since a similar increase is 
seen in DDX3X knock down cells after 24h of rapamycin treatment. On 
the other hand, the protein levels of RPS2, RPS3 and RPS6 were 
differentially affected by rapamycin. In particular, reduction of DDX3X, 
RPS2 and RPS3 protein levels upon rapamycin treatment likely occurs via 
a DDX3X-independent mechanism. 
Taking all of the previous observations into consideration, my results 
indicate that, in conditions that phenocopy metabolic stress, such as the 
inhibition of the mTOR pathway, which also reduce DDX3X levels, the 
helicase binds preferentially to its target RNAs presumably at the 
expenses of other DDX3X functions. The functional role of this binding 
 144 
does not seem to be general translational regulation. In fact, if DDX3X is 
directly part of the translational apparatus that positively responds to the 
mTOR pathway, binding of DDX3X to its target RNAs would likely 
decrease in response to rapamycin.  
 
Ribosomal proteins and other translation factor mRNAs share a specific 
sequence motif called TOP (terminal oligopyrimidines or track of 
pyrimidines) sequence localized at their 5¢-UTR. In these mRNAs, the 7-
methyl G cap is followed by a cytosine residue and a oligopyrimidine tract 
of 7-14 residues that forms the 5¢-TOP motif. It is known that 5¢-TOP-
containing RNAs are translationally regulated by mTOR since they have 
been shown to be among the most sensitive targets of mTOR inhibition. 
The mechanism through which 5¢-TOP mRNAs are translationally co-
regulated by the mTOR pathway remains poorly understood (Section 
1.1.3). I found that most of the ribosomal protein RNAs in the DDX3X 
CLIP dataset bear a pyrimidine rich motif at their DDX3X binding sites ( 
Figure 4.11C-D). However, I did not observe enrichment of DDX3X 
binding at the 5¢-UTRs of target RNAs. Furthermore, the ribosomal 
protein target RNAs showed the presence of different DDX3X binding 
motifs in many different regions of the transcript (Figure 4.12). This 
indicates that DDX3X binding to ribosomal proteins mRNAs and other 
targets may involve a “TOP like” motif in terms of sequence composition, 
but not necessarily in terms of functionality. Infact, this is consistent with 
the lack of evidence for a direct role of DDX3X RNA binding on regulation 
of proteins levels in the mTOR pathway (Section 4.5). 
Interestingly, one of the motifs found in the JUND transcripts coding 
sequence was also a CT (i.e. CU in RNA) rich motif (Figure 4.14A). The 
results from the EMSA assay suggest the presence of a protein complex in 
MCF7 cells that contains and requires DDX3X to bind JUND mRNA at 
that specific sequence. In fact, a band with high mobility is only observed 
when MCF7 cell lysates expressing DDX3X are used together with a 
JUND wild type motif probe.   
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A band with lower mobility very likely represents binding of a protein 
complex to a region of the JUND probe distinct from the motif site. 
However, DDX3X may well be a component of this complex as the band’s 
mobility is increased when extracts from DDX3X depleted cells are used 
with the wild type JUND probe. A band of similarly lower mobility is still 
observed when MCF7 cell lysates are used together with a JUND mutant 
motif probe. The presence of DDX3X in this complex has presumably a co-
operative effect for the binding of other putative factors to the regions 
outside the relevant motif, as the depletion of DDX3X from MCF7 lysates 
results in reduced intensity of the low mobility band when using the 
JUND mutant probe. Unfortunately, I could not validate the presence of 
DDX3X in the complex that binds the JUND probe in my supershift 
EMSA experiments. This could be due to several technical issues such as 
the inefficiency of the antibody to perform supershift or being stable at the 
gel electrophoresis conditions. Also, the DDX3X epitope recognized by the 
antibody could be masked by the protein-probe interaction. In the future, 
the possibility of attempting supershift with an anti-DDX3X antibody that 
recognizes a different epitope, could be explored. 
 
Notably, RPS2 mRNA bears a DDX3X binding motif identical to the one 
found and validated in the JUND sequence (motif SG1 CCTCCGAG –
Figure 4.14A; Figure 4.12). In contrast, RPS3 and RPS6 mRNAs bear 
multiple DDX3X binding sites (mostly CA or GT rich, respectively), with 
low similarity to the ones in JUND and RPS2 sequences (Figure 4.12). 
Like JUND, RPS2 protein was strongly depleted upon DDX3X knock down 
and this effect was more prominent than observed for RPS6 (Figure 4.6A – 
Figure 4.13B). Interestingly, RPS3 mRNA was reduced upon DDX3X 
depletion but the level of RPS3 protein was unaffected.  
These exciting observations suggest that the binding of DDX3X to 
different motifs may affect the translational fate of the relevant mRNAs. 
Although translational studies (i.e. polysome profiling) are necessary to 
define whether DDX3X is effectively regulating the translation of its 
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bound targets through this motif, one can speculate that DDX3X binding 
to specific motifs may dictate recruitment of different factors to its targets 
or, conversely, DDX3X may be recruited to specific sequences by the 
interaction with proteins exerting different functions (such as translation 
rather than degradation). 
My findings indicate that DDX3X preferentially binds stem-loop RNA 
structures. Indeed, in the comparative structural prediction analysis I 
found that DDX3X binding sites on RPS2, RPS3 and JUND mRNAs lie on 
three consecutive stem loops. Importantly, the binding site is predicted to 
localize at the edge between the single strand and the double strand 
portions of the stem loop, which is entirely consistent with the mechanism 
of loading of DEAD box RNA helicases onto their targets: as described in 
the introduction chapter (Section 1.3) these proteins use a single strand 
extension to be loaded on to the target double strands they subsequently 
unwind. 
By combining all the evidence regarding the possible functional role of the 
binding motif and the latter observations on the structural binding 
preferences of DDX3X, the overall results of this chapter suggest that the 
binding of DDX3X may be directed by RNA substructures and could be 
relevant for the stability of the bound mRNAs.  However, the functional 
consequences of binding may depend on the specific sequence bound, 
which could call into action other proteins to exert differential functions on 
the RNA.  
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5 Chapter 5 - DDX54 and DDX3X as cell cycle 
regulators in breast cancer MCF7 cells 
 
 
 
5.1 Introduction 
DDX RNA helicases play essential roles in the biology of cells of very 
different tissues and they have been associated with the onset of several 
different cancers (Section 1.3). As described in Section 1.6, the roles of 
DDX54 and DDX3X in breast cancer in vitro models have been previously 
reported, although detailed investigations of these helicases biological 
function in breast cancer cells was not shown. 
Having studied mechanistic features of DDX3X and DDX54 function via 
their iCLIP RNA binding profile, I next investigated the biological roles of 
these proteins in MCF7 breast cancer cells, as well as in immortalized 
non-tumorigenic MCF10A breast epithelial cells.  
 
5.2 Aims of the chapter 
This chapter had the following aims: 
• To determine the effects of knocking down DDX54 and DDX3X on 
cellular proliferation in MCF7 cells.  
• To determine gene expression changes upon DDX54 or DDX3X 
knock down 
• To analyse cell cycle changes upon DDX54 or DDX3X knock down  
• To provide mechanistic insight into the roles of DDX54 and DDX3X 
through the intersection of iCLIP data with gene expression 
changes upon helicases knock down. 
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5.3 Effects of DDX54 and DDX3X knock down on proliferation of 
immortalized breast epithelial cells and transformed breast 
cancer cells 
To determine whether the roles of DDX54 and DDX3X are essential in 
transformed breast cancer cells, but not in non-tumorigenic immortalized 
breast cells, I performed proliferation assays in MCF7 cells (transformed) 
and MCF10A cells (immortalized) upon knock down of DDX54 or DDX3X 
helicases. Cells were transfected with either scramble siRNA or two 
different siRNAs targeting either DDX54 or DDX3X. 24 h after 
transfection (day 0) cells were seeded for proliferation assays and counted 
at the indicated time-points up to 6 days after seeding (Figure 5.1A-B).  
 
Figure 5.1 shows the sensitivity of MCF7 and MCF10A cells to knock 
down of DDX54 (panel A) and DDX3X (panel C). Panels A and C show the 
number of living cells counted at each indicated time-point, panels B and 
D show depletion of DDX54 and DDX3X upon siRNA-mediated knock 
down, at the indicated time-points. Proliferation of both MCF7 and 
MCF10A cells showed sensitivity to DDX54 knock down (Figure 5.1A). As 
shown by the western blot in Figure 5.1B, the knock down efficiency of 
DDX54 protein was different in the two cell lines. In MCF10A cells, 
virtually no recovery of DDX54 expression occurred up to day 6. At 72h 
after transfection (day 2), when the levels of DDX54 depletion were 
comparable between the two cell lines, the sensitivities of MCF7 and 
MCF10A cells proliferation to DDX54 knock down were similar, with both 
cell lines showing basically no cell growth. In contrast, scramble siRNA-
transfected control cells grew normally. 
 
MCF7 and MCF10A cells show differential sensitivity to DDX3X knock 
down (Figure 5.1C). As can be seen in Figure 5.1D, recovery of DDX3X 
expression during the time course was faster in MCF7 cells. At 72h after 
transfection (day 2), when depletion of DDX3X was virtually complete in 
both cell lines, the depleted MCF7 cells showed no growth compared to 
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scramble control cells. In contrast, DDX3X depleted MCF10A cells 
displayed a growth rate similar to scramble control cells. Indeed, MCF10A 
cells showed almost no difference in proliferation to the scramble control 
cell line at any time-point, irrespective of the expression level of DDX3X 
(Figure 5.1C-D). 
 
Overall, these findings indicate that DDX54 is essential for proliferation of 
transformed breast epithelial cancer (MCF7) and immortalized non-
tumorigenic breast epithelial (MCF10A) cells. Conversely, DDX3X is 
mainly required for the growth of transformed MCF7 cells.  
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Figure 5.1. DDX3X is specifically required for breast cancer cells proliferation. 
(A and C) Cell viability curves for MCF7 (left panels) and MCF10A (right panels) 
cells. Cells were transfected with either scrambled siRNA or two different 
siRNAs targeting either DDX54 (#9 or #12) (A) or DDX3X (#6 or #8) (C) 24h after 
transfection, cells were seeded for proliferation assays and counted at the 
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indicated time-points up to 6 days after seeding. Error bars indicate standard 
deviation. P-values represent statistical significance calculated with unpaired t 
test compared to scramble (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 
0.001;**** ≤ 0.0001). (B and D) Western blots showing the protein levels of 
DDX54 (B), DDX3X (D) and GAPDH (B and D) in MCF7 (left panels) and 
MCF10A (right panels) transfected with either scrambled siRNA or the two 
different siRNAs targeting each helicase. Protein levels were measured at each 
indicated time-point corresponding to counting time-points.  
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5.4 DDX54 and DDX3X regulate MCF7 cell cycle 
To gain further insight into the biological roles of DDX54 and DDX3X in 
MCF7 cells, and the pathways linked to reduced proliferation observed 
upon depletion of these proteins, I performed RNA-seq analysis of MCF7 
cells following knock down of DDX54 and DDX3X. MCF7 cells were 
transfected with either scrambled siRNA or two different siRNAs 
targeting DDX54 or DDX3X. 72h after transfection, RNA was isolated 
from cells and used for Illumina RNA-seq library preparation (Section 
2.11). Knock down of both proteins caused both down-regulation and up-
regulation of genes (Figure 5.2) with good reproducibility between the two 
siRNAs used for each protein (Figure 5.3A- Appendix Figure 3).  
Strikingly, when I cross-compared gene expression changes caused by the 
depletion of DDX54 versus DDX3X, I found overlap of downregulated 
genes between the two datasets (Figure 5.3B). This suggests the two 
proteins might have partially redundant function in gene regulation. 
I then performed a gene ontology search using DAVID functional 
annotation tool to categorize the differentially expressed genes in both 
DDX54 and DDX3X knock down cells. Figure 5.4 shows the GO terms 
related to biological processes (panel A) and cellular components (panel B) 
for genes down-regulated upon DDX3X (left) and DDX54 (right) knock 
down in MCF7 cells. This gene ontology analysis highlights a striking 
resemblance in biological processes and cellular component categories. In 
particular, it indicates that genes encoding proteins involved in cell cycle 
and nuclear components were down-regulated upon knock down of either 
DDX3X or DDX54 in MCF7 cells. 
Following on from the above observation, I next analysed cell cycle 
progression of MCF7 cells when either DDX54 or DDX3X was knocked 
down (Figure 5.5, Figure 5.6). Cells were transfected with scramble siRNA 
or with two different siRNAs against either DDX54 or DDX3X. 24h after 
transfection, cells were seeded for cell cycle analysis. 48h after 
transfection, cells were treated overnight with 50 ng/ml nocodazole and 
tested by propidium iodide (PI) staining in flow cytometric analysis the 
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next day. Nocodazole is a chemical compound that interferes with 
the polymerization of microtubules and therefore with the formation of the 
mitotic spindle.  Nocodazole treatment blocks cells at the G2/M transition 
allowing a comparative analysis of cell cycle from cell populations in 
different conditions equally forced to arrest in G2/M. Figure 5.5A and 
Figure 5.6A show the proportion of cells in each cell cycle phase (G1, S, 
G2/M) normalized to scramble control cell values. Figure 5.5B and Figure 
5.6B show depletion of either DDX54 or DDX3X proteins in the tested cells 
at the time point when the cells were harvested for cell cycle analysis. 
Figure 5.5C and Figure 5.6C show representative flow cytometric images 
of PI staining analysis of the respective graphs (Figure 5.5A and Figure 
5.6A). As shown, both knock down of DDX54 (Figure 5.5) and DDX3X 
(Figure 5.6) caused a dramatic cell cycle arrest in G1. 
These data, together with the changes in gene expression quantified by 
RNA-seq, indicate that both DDX54 and DDX3X exert regulatory activity 
on the cell cycle of MCF7 cells, specifically impairing progression of cells 
through S phase.  
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Figure 5.2. Gene expression changes upon knock down of DDX3X and DDX54. 
Volcano plots for each individual differential expression analysis. Significant 
genes (based on the specified threshold values) are indicated by the red (up-
regulated) and blue (down-regulated) points of the plot. Genes that are not 
changing in either condition are coloured black.  
 
  
#6 DDX3X siRNA vs Scramble siRNA #8 DDX3X siRNA vs Scramble siRNA 
#9 DDX54 siRNA vs Scramble siRNA #12 DDX54 siRNA vs Scramble siRNA 
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Figure 5.3. Correlation of gene expression changes amongst knock down samples. 
Correlation plots between the log-fold change for the various comparisons.  
Scatter plots show the log-fold change for one siRNA versus another targeting 
the same protein (A) or either DDX3X or DDX54 for cross-comparison (B). Colour 
code indicates whether or not they are up-regulated in both conditions (red), 
down-regulated in both conditions (blue), significant in one condition or the other 
(green), or they are not significant (black). The corresponding Pearson correlation 
(“Cor”) and p-value for a linear model (“P val” and thin dotted line) are shown.  
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Figure 5.4. GO term analysis of down-regulated genes upon knock down: DDX3X 
and DDX54 are cell cycle regulators.  
Down-regulated genes in knock down DDX3X or DDX54 MCF7 cells were 
identified as described in Methods (Section 2.11.2) from RNA-seq data (Section 
2.11.1). The GO enrichment of down-regulated genes was obtained using the 
DAVID functional annotation tool with default settings [PMID: 19131956]. The 
p-values were calculated using the “default” method of DAVID. (A) Y-axis shows 
the GO terms related to biological processes in DDX3X knock down MCF7 cells 
(left panel) and in DDX54 knock down MCF7 cells (right panel); (B) Y-axis shows 
the GO terms related to cellular components in DDX3X knock down MCF7 cells 
(left panel) and in DDX54 knock down MCF7 cells (right panel); (A-B) X-axis 
shows –log10 p-values of each GO terms. 
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Figure 5.5. DDX54 knock down arrests MCF7 cell cycle in G1. 
MCF7 cell cell cycle progression flow cytometric analysis based on PI staining of 
MCF7 cells 72h after transfection with either scrambled siRNA or two different 
DDX54 (#9 or #12) targeting siRNAs. (A) Fold change quantification for each 
phase (G1-S-G2M). Results represent the average of two biological replicates. (B) 
Western blots show the protein levels of DDX54 and GAPDH in MCF7 cells 
transfected with scrambled siRNA or with DDX54 (#9 or #12) targeting siRNAs. 
(C) Images from FlowJo analysis of flow cytometric analysis of cell cycle 
progression upon PI staining as quantified in A (images represent one replicate). 
Cells were treated with 50 ng/ml nocodazole overnight. Error bars indicate 
standard deviation. P-values represent statistical significance calculated with 
unpaired t test compared to scramble (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** 
≤ 0.001; **** ≤ 0.0001). 
 
  
Scramble siRNA 9 DDX54 siRNA #12 DDX54 siRNA C
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Figure 5.6. DDX3X knock down arrests MCF7 cell cycle in G1. 
MCF7 cell cell cycle progression flow cytometric analysis based on PI staining in 
MCF7 cells 72h after transfection with either scrambled siRNA or two different 
DDX3X (#6 or #8) targeting siRNAs. (A) Fold change quantification for each 
phase (G1-S-G2M). Results represent the average of two biological replicates. (B) 
Western blots show the protein levels of DDX3X and GAPDH in MCF7 cells 
transfected with scrambled siRNA or with DDX3X (#6 or #8) targeting siRNAs. 
(C) Images from FlowJo analysis of flow cytometric analysis of cell cycle 
progression upon PI staining as quantified in A (images represent one replicate). 
Cells were treated with 50 ng/ml nocodazole overnight. Error bars indicate 
standard deviation. P-values represent statistical significance calculated with 
unpaired t test compared to scramble (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** 
≤ 0.001;**** ≤ 0.0001). 
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5.5 DDX3X affects cell cycle through regulation of KLF4 
transcription factor 
Transcriptome and cell cycle analysis in cells depleted of DDX54 and 
DDX3X highlighted the role of both proteins in cellular proliferation and 
cell cycle progression in breast cancer cells. This function might be 
redundant in these cells, as knock down of either of the two proteins 
results in down regulation of a similar set of genes (Figure 5.3, Figure 5.4). 
However, the activity of DDX3X seems to be specific for transformed 
breast cancer cells, as knock down for DDX3X has a negligible effect on 
proliferation of immortalised non-tumourigenic MCF10A breast epithelial 
cells (Figure 5.1). In contrast to DDX54, this suggests a possible selectivity 
of DDX3X towards a transformed cancer phenotype. For this reason, I 
decided to focus on DDX3X for the following validation of RNA-seq data.  
 
To this purpose, I performed qPCR validation of a number of cell cycle 
relevant target genes whose expression was altered in DDX3X knock down 
MCF7 cells (Figure 5.7). The table in Figure 5.7A includes the genes 
tested and indicates how their expression was changed in the RNA-seq 
analysis upon DDX3X knock down. Figure 5.7B shows the mRNA levels of 
CCNA2, CCNE1, CDK2 and KLF4 genes in normal and DDX3X knock 
down MCF7 cells. Reassuringly, the expression of these genes was altered 
as predicted from the RNA-seq data analysis: upon DDX3X knock down, 
CCNA2 and CDK2 expression was reduced, CCNE1 expression was 
unchanged and KLF4 expression was increased. As further validation, I 
also showed that the protein level of CDK2 was reduced in MCF7 cells 
upon DDX3X knock down (Figure 5.7C). 
Next, I tested whether the cell cycle defects observed in MCF7 cells upon 
DDX3X knock down could be linked to DDX3X RNA binding activity. To 
this end, I intersected the DDX3X knock down RNA-seq dataset with the 
DDX3X iCLIP dataset to search for cell cycle-related common targets that 
would suggest binding of DDX3X is necessary for their expression. As 
shown in Figure 5.8, the overlap between these two datasets was very 
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limited, indicating that the RNA level of most of the direct DDX3X target 
RNAs was not significantly affected by DDX3X knock down. Interestingly 
however, one of the targets common to the two datasets was KLF4. KLF4 
RNA was bound by DDX3X, according to iCLIP, and it was up-regulated 
in DDX3X knock down MCF7 cells, as determined by RNA-seq and 
validated by qPCR (Figure 5.7B). 
 
To further explore the interaction between DDX3X and KLF4 RNA, I 
validated binding of DDX3X to KLF4 mRNA by performing CLIP-qPCR, 
as previously described (Section 2.13.3), with anti-DDX3X antibodies as 
well as anti-DDX24 and anti-IgG antibodies as controls. KLF4 mRNA was 
only precipitated using the anti-DDX3X antibody and was absent in anti-
DDX3X immunoprecipitation performed in DDX3X knock down MCF7 
cells (Figure 5.9A) indicating specificity of DDX3X binding. To investigate 
the function of DDX3X binding on KLF4 mRNA, I tested the KLF4 protein 
levels in DDX3X knock down MCF7 cells and observed up-regulation of 
the protein. This correlates well with up-regulation of KLF4 mRNA upon 
DDX3X knock down (Figure 5.9B). 
 
KLF4 is a transcription factor and a negative regulator of the G1/S 
transition in the cell cycle[248]. Therefore, I tested the hypothesis that 
DDX3X negatively regulates the protein level of KLF4, which in turn 
would promote cell cycle progression. I decided to focus on the link 
between KLF4 up-regulation and down-regulation of cyclins and cyclin-
dependent kinases observed upon DDX3X knock down (Figure 5.7B), 
whose repression would ultimately result in the observed G1 arrest.  
 
If KLF4 and DDX3X actions are linked in determining the phenotype 
observed, then depletion of KLF4 should increase the expression of cyclin 
and cyclin-dependent kinase genes down-regulated upon knock down of 
DDX3X. Conversely, KLF4 over-expression should phenocopy the effects of 
knocking down DDX3X. Therefore, I performed both KLF4 knock down 
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and over-expression experiments in MCF7 cells. Cells were transfected 
with either scramble siRNA or KLF4 specific siRNA. 72h after 
transfection, cells were collected and RNA was isolated in order to analyze 
expression of specific genes. As shown in Figure 5.9C, knock down of KLF4 
enhanced expression of CCNA2 and CDK2, whilst CCNE1 and DDX3X 
gene expression remained unchanged.  
Figure 5.9D and E show how KLF4 over-expression in MCF7 cells affects 
expression of the same genes and MCF7 cell cycle, respectively.  MCF7 
cells were transfected with increasing amounts of a plasmid over-
expressing the human isoform of KLF4 (pPB-CAG-hKLF4-pA-pgk-Hygro). 
24h after transfection, cells were seeded for cell cycle analysis. Cells were 
treated overnight with 50 ng/ml nocodazole and tested for PI staining in 
flow cytometric analysis the next day. At the same time-point, cells were 
harvested for gene expression analysis by qPCR. Over-expression of KLF4 
caused an increase in the fraction of G1 arrested cells proportional to the 
amount of hKLF4 transfected (Figure 5.9E). Consistent with this, 
expression of the genes that were up-regulated upon DDX3X knock down 
(CCNA2, CDK2) was increased proportionally to the extent of hKLF4 
over-expression. Conversely, CCNE1 gene expression, which was 
unchanged in DDX3X knock down, did not show any change upon KLF4 
over-expression (Figure 5.9D). 
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Figure 5.7. Validation of RNA-seq data upon DDX3X knock down in MCF7 cells. 
(A) Table showing genes whose expression was down-regulated (DDX3X, CCNA2, 
CDK2), up-regulated (KLF4) or unchanged (CCNE1) in RNA-seq analysis of 
DDX3X knock down MCF7 cells. (B) mRNA levels of genes in A in MCF7 cells 
transfected with either scrambled siRNA or #6 or #8 DDX3X siRNAs, measured 
by qPCR. Cells were harvested 72h after transfection. Results represent the 
average of three biological replicates. (C) Western blot showing DDX3X, CDK2 
and GAPDH protein levels in MCF7 cells used in B. Error bars indicate standard 
deviation. P-values represent statistical significance calculated with unpaired t 
test compared to scramble (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001; 
**** ≤ 0.0001). 
 
 
 
 
Figure 5.8 Comparison of gene expression changes upon DDX3X knock down and 
DDX3X iCLIP targets in MCF7 cells. 
Venn diagrams show the intersection between DDX3X iCLIP targets and genes 
up-regulated (left) or down-regulated (right) upon DDX3X knock down detected 
by RNA-seq.   
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Figure 5.9. KLF4 mediates DDX3X-dependent regulation of cell cycle. 
(A) CLIP-qPCR was performed as described in Methods (Section 2.13.3) in: (i) 
MCF7 cells, to validate binding of KLF4 mRNA to DDX3X. DDX24 and IgG were 
used as controls (left panel). (ii) MCF7 cells transduced with either scrambled 
shRNA or DDX3X shRNA to validate the binding of KLF4 mRNA to DDX3X. IgG 
was used as a control (right panel). cDNA obtained from each 
immunoprecipitation was analysed by qPCR to determine enrichment of the 
indicated targets. Results represent the average of three biological replicates. (B) 
Western blot shows the protein levels of KLF4, DDX3X and b-tubulin in MCF7 
cells transfected with either scrambled siRNA or two different DDX3X targeting 
siRNAs (#6 or #8). 
(C) mRNA levels of DDX3X, CCNE1, KLF4, CCNA2 and CDK2 in MCF7 cells 
transfected with either scrambled siRNA or KLF4 targeting siRNA, measured by 
qPCR. Cells were harvested 72h after transfection. Results represent the average 
of three biological replicates. 
(D) mRNA levels of DDX3X, CCNE1, KLF4, CCNA2 and CDK2 in MCF7 cells 
transfected with increasing amount of hKLF4 expressing plasmid as described in 
Methods (Section 2.8.3), measured by qPCR. Cells were harvested 48h after 
transfection. Results represent the average of three biological replicates. 
(E) Cell cycle progression flow cytometric analysis in MCF7 cells transfected with 
increasing amount of hKLF4 expressing plasmid as in (D). Shown is the fold 
change quantification for each phase (G1-S-G2M). Cells were harvested 48h after 
transfection. Results represent the average of two biological replicates. Cells 
were treated with 50ng/ml nocodazole overnight.  
Error bars indicate standard deviation. P-values represent statistical significance 
calculated with unpaired t test compared to scramble (C) or 0µg controls (D-E) 
(P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001;**** ≤ 0.0001). 
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5.6 Discussion 
5.6.1 DDX3X and DDX54 show similar potential cell cycle regulation role  
The results presented in this chapter highlight the role of DDX54 and 
DDX3X in regulating MCF7 cell growth through modulation of cell cycle. I 
found that both proteins are required for efficient proliferation of MCF7 
cells and their progression through the cell cycle, specifically through S 
phase (Figure 5.4, Figure 5.5, Figure 5.6). This finding is completely new 
for DDX54, which has not been linked previously to cell cycle control. 
Conversely, DDX3X has previously been shown to regulate the cell cycle in 
different cell types (Section 1.5). 
 
Interestingly, the gene ontology analysis of down-regulated genes in 
DDX54 and DDX3X knock down cells resulted in a very similar outcome. 
This suggests that the two proteins are involved in similar pathways and 
might have partly redundant function. However, when I compared the 
targets of DDX54 and DDX3X identified by iCLIP with the differentially 
expressed genes resulting from the knock down of the relevant helicase, I 
found virtually no overlap, apart from a very small number of candidates 
with no obvious common role (Figure 5.8 – Appendix Figure 4-5). 
 
5.6.2 DDX3X is an upstream regulator of cell cycle 
Notwithstanding the above, the intersection of DDX3X target mRNAs 
identified by iCLIP and down-regulated genes upon DDX3X knock down, 
highlighted one interesting candidate to follow up on: the transcription 
factor KLF4. 
KLF4 is a zinc-finger containing transcription factor associated with 
growth arrest. In fact, the level of expression of KLF4 in actively 
proliferating cells is usually very low and it is lost in many different 
cancers [249-251]. As KLF4 possesses both a transactivation domain and a 
repression domain, its activity could have different outcomes based on the 
interaction with other transcriptional factors. The main function of KLF4 
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in the cell cycle is to induce arrest both at G1/S and G2/M transitions 
[248]. So far, this effect has been reported to be mediated, at least in part, 
by KLF4 dependent repression of CCND1, CCNB1 and CCNE1 [252]. 
KLF4 mRNA was validated as a direct target of DDX3X binding in CLIP-
qPCR experiments and the levels of both KLF4 mRNA and protein were 
strongly up-regulated upon DDX3X knockdown. These observations 
prompted me to investigate the link between DDX3X and KLF4 and to 
test the hypothesis that the cell cycle regulatory activity of DDX3X may be 
exerted through its regulation of KLF4 mRNA and protein levels. 
In agreement with my hypothesis, knock down of KLF4 induced 
expression of CCNA2 and CDK2 genes that were down-regulated by 
DDX3X knock down. No change was observed in CCNE1 levels, consistent 
with what was observed in DDX3X knock down cells. When KLF4 was 
over-expressed, expression of CCNA2 and CDK2 was reduced 
proportionally to the level of expression of KLF4 and consistent with the 
increased G1 arrest.  
Association between cyclin A2 and CDK2 is necessary for progression 
through S phase and it is specifically required for DNA replication [253-
256]. Interestingly, among the genes down-regulated upon DDX3X knock 
down in MCF7 cells, many genes encode replication-related factors such as 
the replication origin recognition complex 1 (ORC1), factors involved in 
DNA replication regulation (CDC6 and CDC45) and chromosome-related 
factors such as minichromosome maintenance proteins (MCM2, 3, 5, 7, 
8,10) that associate with chromatin in G1 (raw data at link in Appendix 
Figure 3). This suggests DDX3X may have a broad role in regulating S 
phase-relevant factors.  
 
DDX3X regulation of CCNE1 mRNA translation is responsible for 
progression of HeLa cells to S phase [202]. In this system, DDX3X is 
required for production of CCNE1 protein but it does not affect CCNE1 
mRNA levels. Consistent with this, my data show that the mRNA level of 
CCNE1 is not affected by DDX3X knock down in MCF7 cells. In the 
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previous chapter, I showed evidence for a potential role of DDX3X in 
positively regulating the levels of proteins translated from its bound 
mRNAs consistent with a positive translation regulatory activity of 
DDX3X (as previously proposed by others [203]).  
In contrast, the findings presented in this chapter suggest a repressive 
role for DDX3X on the expression (at both the mRNA and protein level) of 
one of its target mRNAs, KLF4. It is possible that these represent distinct 
functions of DDX3X, which may be able to regulate different targets using 
different mechanisms. 
 
5.6.3 CDKN1A (p21) involvement in DDX3X-dependent cell cycle 
regulation. 
CDKN1A (p21) is a central regulator of cell cycle arrest in G1/S [257]. P21 
expression change was not detected in RNA-seq. Nevertheless, p21 mRNA 
was found to be an iCLIP target of DDX3X and it harbours a CT (i.e. CU 
in RNA) rich binding motif in its 3’-UTR (CCTCCC –Appendix Figure 6). 
This observation potentially adds another level of complexity to DDX3X's 
regulation of the cell cycle. Certainly, further investigations are necessary 
as these might provide insight into a different mechanism through which 
DDX3X can counteract cell cycle arrest in MCF7 breast cancer cells. 
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6 Chapter 6 - Relevance of DDX54 and DDX3X in 
acute myeloid leukaemia cell lines  
 
 
 
6.1 Introduction  
The RNA-guided endonuclease CRISPR/Cas9 (clustered regularly inter- 
spaced short palindrome repeats/associated nuclease Cas9) system of 
bacterial host defence has recently revealed its powerful potential as a 
genome editing tool for the study of gene functions. In biomedical 
research, CRISPR/Cas9 represents a revolutionary approach to investigate 
disease-causing genes and to help identify new therapeutic targets. 
Cas9 is an endonuclease that induces DNA double-strand breaks (DSB) 
whose activity can be directed to specific genomic sites by the sequence of 
a single guide RNA (sgRNA).  Ectopic expression of Cas9 and a single 
guide RNA (sgRNA) in cells leads to formation of a DNA double-strand 
break (DSB) at specific genomic sites. In the absence of a homology-
directed repair DNA template, DSBs are repaired by the non-homologous 
end-joining (NHEJ) pathway, which generates an assortment of short 
insertions and deletions (indels) in the target sequence. This can result in 
generation of a loss-of-function allele. Numerous studies have used 
CRISPR/Cas9 in mammalian cells that target 5’ coding exons to create 
complete target gene knockouts [258, 259]. CRISPR/Cas9 can be used in 
both positive and negative selection screens.  In the first case, it allows 
identification of tumour suppressors or genes that give growth advantage 
in particular conditions, such as drug resistance genes [258]. Negative 
selection or dropout screens allow identification of genes whose knockout 
confers lethality and determines consequent depletion of targeted cells 
[260]. Therefore, if applied in cancer cell lines, this approach can identify 
potential oncogenes. However, negative selection screens have shown 
limitations in their ability to uncover real oncogenes in cancer cells, 
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because of an enrichment of hits for essential genes such as RNA 
processing and DNA replication factors. Thus, performing negative 
screens in multiple cancer and non-cancer cell lines helps identify real 
oncogenes relevant for a particular cancer type. Another limitation of the 
common CRISPR/Cas9 approach is that it relies upon preferential 
targeting of 5’ exons. Recently, Vakoc and colleagues reported that 
targeting the 5’ exon of candidate genes often generates in-frame 
mutations that retain the functionality of the gene product thereby 
inhibiting identification of candidate oncogenes [261]. In the same work, 
the authors showed that CRISPR/Cas9 targeting of genomic regions 
encoding functional domains of a protein overcomes this limitation, since 
the resulting in-frame and frame-shift mutations within these domains 
results in loss of function alleles. Indeed, in this study the magnitude of 
negative selection obtained by targeting enzymatic domains was higher 
than that obtained when targeting 5¢ exons or other regions. This 
indicates that a domain targeted CRISPR/Cas9 dropout approach can help 
identify functionally important domains within a target protein. 
Results from recent CRISPR/Cas9 dropout screens, performed in various 
cancer cell lines, highlighted the importance of DDX54 and DDX3X in both 
mouse and human acute myeloid leukaemia (AML) cell lines [235]. As 
described in Section 1.6, DDX3X mutations have been identified in various 
blood cancers including T-cell acute lymphoblastic leukaemia, chronic 
lymphoblastic leukaemia and natural killer/T-cell lymphomas but nothing 
is known about the involvement of DDX3X in acute myeloid leukaemia 
(AML). 
In this chapter, I present results from a CRISPR/Cas9 dropout approach 
in which the catalytic activities of DDX54 and DDX3X were targeted in 
mouse AML cells. Moreover, I describe results of a CRISPR/Cas9 dropout 
approach targeting distinct domains of DDX3X in OCI-AML2 and OCI-
AML3 human AML cells. 
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6.2 Aims of this chapter 
The aims of the work described in this chapter were: 
• To determine the effect of targeting the helicase core of DDX54 and 
DDX3X in a mouse AML cell line (MLL-AF9) and in mouse NIH-
3T3 fibroblasts using CRISPR/Cas9 technology 
• To investigate the effect of targeting DDX3X functional domains in 
two humans AML cell lines (OCI-AML2 and OCI-AML3) using 
CRISPR/Cas9 technology 
 
 
6.3 Targeting DDX54 and DDX3X catalytic domains affects MLL-
AF9 mouse AML cell proliferation but not NIH-3T3 mouse 
fibroblast proliferation 
In an attempt to link the function of RNA binders and modifiers to a 
cancer, the Kouzarides laboratory initiated a collaborative project with the 
Vakoc laboratory (Cold Spring Harbor Laboratories, USA) to perform a 
dropout screen in mouse AML cell lines using CRISPR/Cas9 technology. 
Previous work from the Vakoc laboratory showed that CRISPR targeting 
of gene regions encoding important functional domains of chromatin-
associated factors significantly enhanced the efficacy of the dropout 
screens in identifying potential oncogenes [261]. 
In the CRISPR/Cas9 dropout screen we performed, mouse AML MLL-
AF9/Cas9 cells, stably expressing Cas9, were infected with a pooled 
lentiviral sgRNA library to target the catalytic sites of different RNA-
related enzymes. Five different sgRNAs were designed against each 
enzyme. Depletion of individual sgRNAs was measured by deep 
sequencing of the integrated sgRNA cassette in surviving cells over a 12-
day time course. The read number of individual sgRNAs targeting the 
same gene were averaged at day 2 (first measurement point) and at day 12 
(final measuring point) after infection. The ratio between average reads 
measured at day 2 and average reads measured at day 12 is called the 
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CRISPR score and represents one way of quantifying the magnitude of 
negative selection observed in a dropout screen. 
Figure 6.1A graphically displays the CRISPR scores obtained for all the 
RNA hydrolases tested in the screen. In this study, a value of 50 was 
taken as the minimum of average reads considered at the measurement 
taken at day 2. Therefore, a value of CRISPR score above 50 indicates 
overgrowth of the targeted population whereas values of CRISPR score  
equal to or below 50 indicate no growth or depletion of the targeted 
population. To identify a biologically relevant range, a value of CRISPR 
score of 50 was sat as a maximum theoretical score and a value of CRISPR 
score of 10 was sat as a minimum significance threshold. The actual 
numerical CRISPR scores are listed in Figure 6.1B. Both Ddx54 and 
Ddx3x scored significantly highly in the screen yielding CRISPR scores of 
114.9 and 29.1, respectively (Figure 6.1A-B). These data highlight both 
Ddx54 and Ddx3x as potential essential genes in mouse MLL-AF9 /Cas9 
cells. 
 
I validated the above results by performing the same CRISPR/Cas9 
approach in both MLL-AF9/Cas9 cells and NIH-3T3/Cas9 cells. The AML 
cell line used in this study is the MLL-AF9/NRasG12D AML cell line (RN2), 
which has been extensively used to identify genetic dependencies in 
leukaemia [262]. NIH-3T3 is an immortalized mouse fibroblast cell line 
that is used as a control. This cell line was used to discriminate between 
essential genes and genes specifically required for growth of AML cells.  
Genes showing depletion upon CRISPR/Cas9 catalytic targeting in NIH-
3T3 cells are considered generally essential for cell survival and non-
specific for AML cell growth.  Cas9-expressing RN2 cells (MLL-AF9/Cas9 
or RN2c) and NIH-3T3 cells (NIH-3T3/Cas9) were generated by the Vakoc 
laboratory using retroviral transduction with MSCV-hCas9-PGK-Puro, 
followed by puromycin selection and serial dilution to obtain single cell–
derived clones. To validate results from the screen, I used two different 
sgRNAs designed to target the helicase core domain of Ddx3x, two sgRNA 
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against the helicase core domain of Ddx54, one sgRNA to target the 
negative control locus Rosa26 and one sgRNA to target the essential 
(positive control) replication factor gene Rpa3. Rosa26 is a genomic mouse 
locus commonly used for knock-in studies, whereas Rpa3 is an essential 
DNA replication factor whose targeting is lethal. The relevant sgRNA 
sequences were cloned into pLenti-U6-sgRNA-EFS-GFP vector for co-
expression of both the sgRNAs and GFP. These plasmids were used to 
generate lentiviral particles bearing the relevant sgRNA and infect cells 
as described in Section 2.8.7. 
Figure 6.2 shows the results of competition assays performed to measure 
negative selection. The rationale of a competition assay is that by 
performing infection at low viral titre, only a subset of cells will be 
targeted therefore leaving in culture a heterogeneous population of 
infected and non-infected cells. GFP fluorescent cells were monitored over 
time via flow cytometric analysis to measure out-competition of the GFP 
negative (non-infected) cells over the GFP positive (infected) cells. At each 
indicated time-point the percentage of GFP cells in the whole population 
was measured for all conditions.  
The graphs in the left-hand panels of Figure 6.2 (panels A and C) show the 
ratio between the percentage of GFP positive cells observed at each time 
point over the percentage of GFP positive cells observed at the start (day 2 
for MLL-AF9/Cas9 (panels A) and day 4 for NIH3T3/Cas9 (panels C)). 
GFP positive cells were monitored for 8 days. The fold depletion of GFP-
positive cells over the whole period is the ratio of percentage of GFP 
positive cells observed at the starting time point over the percentage of 
GFP positive cells observed at the last time point. The fold depletion value 
was measured for both RN2/Cas9 (Figure 6.2B) and NIH3T3/Cas9 (Figure 
6.2D) cells and is used to summarize the results of GFP progressive 
depletion (Figure 6.2A and C).  
 
In MLL-AF9/Cas9 cells, targeting the region of the Ddx54 gene encoding 
the catalytic domain led to strong depletion of GFP-positive cells with a 
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20- and 33-fold depletion for the two sgRNAs used (Figure 6.2B). 
Targeting of Ddx3x catalytic domain led to 13- and 15-fold depletions of 
GFP-positive cells. This is similar to what observed with Rpa3 targeting 
that led to a 16-fold depletion. Targeting Rosa26 did not cause depletion of 
GFP-positive cells. 
In NIH-3T3/Cas9 cells (Figure 6.2C-D), no GFP-positive cell depletion was 
observed when targeting the gene regions encoding the catalytic domains 
of either Ddx3x or Ddx54. Targeting Rosa26 caused negative depletion due 
to the GFP positive population increasing over time (Figure 6.2C). 
Targeting Rpa3 caused a GFP-positive cell depletion of 2.8 fold (Figure 
6.2D). 
The difference in the magnitude of negative selection caused by targeting 
Rpa3 between the two cell lines may be explained by their different 
growth rates. Indeed, MLL-AF9 cells express NRasG12D that confers 
growth advantage [262]. In any case, targeting Rpa3 in NIH-3T3/Cas9 
showed clear depletion of GFP positive cells after 8 days. In contrast, 
these cells showed no sensitivity to targeting of Ddx54 or Ddx3x.  
Overall, these observations show that growth sensitivity to CRISPR/Cas9 
targeting of the regions of the Ddx54 and Ddx3x genes encoding catalytic 
domains was not pan-lethal. 
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Figure 6.1. CRISPR/Cas9 negative screening against RNA binders and modifiers 
highlights proteins potentially important in MLL-AF9 mouse cells survival. 
(A) The graph shows the CRISPR score obtained from targeting different RNA 
hydrolases in a mouse MLL-AF9/Cas9 cell line.  The CRISPR score equals the 
ratio of the average fold change of reads obtained at day 2 after infection over the 
average fold change of reads obtained at day 12 after infection for individual 
sgRNAs targeting the same gene. Fold change value of 50 threshold indicates the 
maximum theoretical score). Significance threshold was set at 5. 
The screen was performed by Jungwei Shi (C. Vakoc lab) and Isaia Barbieri (T. 
Kouzarides lab). (B) The table shows the numerical CRISPR scores obtained in 
the screen and graphed in A. DDX3X and DDX54 showed significant CRISPR 
scores. 
A
B RNA HELICASE CRISPR Score
DDX1 69.37
DDX10 92.4
DDX18 0.657
DDX21 19.94
DDX23 45.43
DDX24 39.53
DDX27 107.59
DDX28 4.63
DDX31 4.49
DDX3X 29.3
DDX41 14.85
DDX42 2.8
DDX46 88.82
DDX47 20.3
DDX49 43.93
DDX50 0.613
DDX51 9.97
DDX54 114.94
DDX56 24.35
DDX6 3.41
DHX15 2.93
DHX29 4.88
DHX30 1.17
DHX33 18.17
DHX34 0.821
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Figure 6.2. DDX54 and DDX3X targeting shows lethality in the AML MLL-
AF9/Cas9 cell line but not in the control NIH-3T3/Cas9 cell line.  
MLL-AF9/Cas9 (A-B) and NIH-3T3/Cas9 (C-D) cells were transduced with a 
lentivirus expressing Rosa26, Ddx3x #1, #2, Ddx54 #1, #2 and Rpa3 specific 
sgRNAs. Each sgRNA plasmid co-expresses a GFP marker.  
(A-C). Ratio between the percentage of GFP positive cells at each time point and 
the percentage of GFP positive cells at the measurement start time point (day 2 
for MLL-AF9/Cas9 (A) and day 4 for NIH-3T3/Cas9 (C)). 
(B-D) Fold depletion of GFP-positive cells over the whole period, i.e. the ratio of 
percentage of GFP positive cells observed at the start (day 2 for MLL-AF9/Cas9 
(B) and day 4 for NIH-3T3/Cas9 (D)) over the percentage of GFP positive cells 
observed at the last time point (day 8). 
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6.4 DDX3X functional domain targeting affects OCI-AML3 but not 
OCI-AML2 cells. 
Very recently, a CRISPR/Cas9 dropout screen was published by Vassiliou 
and co-workers (Wellcome Trust Sanger Institute, Cambridge) [235]. The 
authors screened various human cancer cell lines, including those derived 
from colorectal adenocarcinoma (HT29), fibrosarcoma (HT1080) and blood 
cancers such as acute promyelocytic leukaemia (HL60), B myelomonocytic 
leukaemia (MV411) and acute myeloid leukaemia (AML: MOLM13, OCI-
AML2, OCI-ALM3) [235]. In this work, the genes of several RNA related 
enzymes, including DDX54 and DDX3X, were targeted at their 5¢ exons in 
order to generate knock out cells. The results from the screen, from 
targeting DDX54 and DDX3X, are summarized in Figure 6.3. Targeting 
DDX54 resulted in significant dropout in all cancer cell lines tested, whilst 
targeting DDX3X resulted in significant dropout in only a subset of cancer 
cell lines. Amongst the leukaemia cell lines tested, acute myeloid 
leukaemia OCI-AML2 cells were resistant to DDX3X targeting whereas 
acute myeloid leukaemia OCI-AML3 cells were sensitive to loss of DDX3X 
[235]. 
 
Based on the above findings, I decided to further analyse the effects of 
targeting DDX3X in AML cells. Specifically, I selected the DDX3X knock 
out resistant OCI-AML2 cell line and the DDX3X knock out sensitive OCI-
AML3 cell line for further analysis.  I decided to use a CRISPR/Cas9 
dropout approach to target regions of the DDX3X gene that encode 
different functional domains of the helicase.  This approach was designed 
to provide insight into the importance of the different functional domains 
of this enzyme for growth of OCI-AML3 cells. In collaboration with the 
Vassiliou laboratory, I designed sgRNAs targeting region of the DDX3X 
locus encoding the different subdomains of DDX3X including the  helicase 
core (RNA binding domain, ATP hydrolysis site and ATP binding loop), the 
N-terminal domain and the RS-like domain in the C-terminal region of 
DDX3X (Figure 6.4). 
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The Vassiliou laboratory generated OCI-AML2 and OCI-AML3 Cas9-
expressing cell lines by lentiviral transduction using pKLV2-
EF1aBsd2ACas9-W and selection in blasticidin (Section 2.8). sgRNAs 
targeting different regions of DDX3X encoding the different functional 
domains of DDX3X, as well as a positive control gene (AURKB), were 
cloned into pKLV2-U6gRNA5 (BbsI)-PKGpuro2ABFP-W vector bearing 
BFP marker and a puromycin resistance cassette. These plasmids were 
used to generate lentiviral particles bearing the relevant sgRNA or the 
empty vector and cells were infected as described in Section 2.8.7. Two 
different sgRNAs were used to target gene sequences encoding DDX3X's 
ATP hydrolysis site, ATP binding loop, N terminal domain and RS-like 
domain. Two sgRNAs were used to target the gene sequences encoding the 
two portions of the DDX3X RNA binding domain (referred to as “RNA 
binding domain A” and “RNA binding domain B”) within the two helicase 
core domains. One sgRNA was used to target DDX3X exon 2 and one to 
target DDX3X exon 3. Two different sgRNAs were used to target the 
essential gene AURKB used as positive control of negative selection. 
AURKB is a key regulator of the mitotic spindle assembly, previously 
identified as essential in all cell lines tested in the published screen [235].  
Competition assays were performed to measure negative selection 
comparing the results obtained with all sgRNAs in OCI-AML2/Cas9 and 
OCI-AML3/Cas9 cells (Figure 6.5). Under all conditions, cells were 
monitored over time via flow cytometric analysis to measure out-
competition of the BFP negative (non-infected) cells over the BFP positive 
(infected) cells. At each indicated time-point the percentage of BFP cells in 
the whole population was measured for all conditions. BFP depletion is 
shown as the ratio of percentage of BFP positive cells observed at each 
time point over the percentage of BFP positive cells observed at the start 
(day 4) (Figure 6.5). BFP positive cells were monitored over 12 days. Fold 
depletion of BFP-positive cells over the 12 days period, was quantified as 
previously described for both OCI-AML3/Cas9 cells (Figure 6.6A) and OCI-
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AML2/Cas9 cells (Figure 6.6B). The fold depletion values (Figure 6.6A-B) 
summarize the results of BFP progressive depletion (Figure 6.5).  
In OCI-AML3/Cas9 cells, targeting of DDX3X 5¢ exons 2 and 3 (which 
leads to DDX3X protein depletion - Figure 6.6C) led to an average 2 fold 
depletion of BFP-positive cells (Figure 6.6A). Targeting of the DDX3X gene 
sequences encoding the ATP hydrolysis site, ATP binding loop, N terminal 
domain or the RS-like domain, caused BFP-positive cells depletion from 
1.4 to 1.8 fold. Interestingly, targeting the gene sequences encoding the 
two regions (A and B) of the DDX3X RNA binding domain led to higher 
depletion of BFP-positive cells ranging from 2.6 to 4.8 fold. When 
targeting the essential gene AURKB, BFP-positive cells depletion was 1.6 
fold. Notably, this is below the value observed when the RNA binding 
domain of DDX3X was targeted (Figure 6.5, Figure 6.6A). 
In OCI-AML2/Cas9 cells, most DDX3X targeting sgRNA, including the 
ones targeting DDX3X exons, caused no depletion of BFP-positive cells 
(Figure 6.6B). Targeting the essential AURKB gene generated an average 
BFP-positive cells depletion of 1.7.  This is a higher fold depletion than 
any of those obtained by targeting DDX3X (Figure 6.6B). Interestingly, 
when targeting the RS-like C-terminal domain and ATP binding loop of 
DDX3X, the BFP-positive cells depletion fold change in OCI-AML2 
reached the highest level observed for DDX3X targeting (~1.3 fold change).  
Infection with empty vector did not cause depletion of BPF-positive cells in 
either of the cell lines (Figure 6.5, Figure 6.6A-B). 
These preliminary results confirm that DDX3X is selectively required for 
growth of OCI-AML3 but not OCI-AML2 leukaemia cells. Moreover, they 
indicate that DDX3X RNA binding function is more important than 
DDX3X enzymatic activity for OCI-AML3 cell survival.   
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Figure 6.3. Sensitivity of human cancer cell lines to DDX3X or DDX54 targeting. 
The table summarizes DDX54 and DDX3X data from a CRISPR/Cas9 dropout 
screen in the indicated cell lines (Tzelepis et al. 2016). Dropout of the BFP-
fluorescence positive population was set at a FDR of 20%. In each box, which 
corresponds to the indicated cancer cell line, the helicase(s) whose targeting gives 
significant depletion of the BFP-fluorescence positive population is indicated. Red 
box highlights result in OCI-AML2 and OCI-AML3 cells.  
Solid tumour cells: colorectal adenocarcinoma (HT29), fibrosarcoma (HT1080); 
blood cancers: acute promyelocytic leukaemia (HL60), B myelomonocytic 
leukaemia (MV411) and acute myeloid leukaemia (MOLM13, OCI-AML2, OCI-
ALM3). Top line lists major cancer driver mutations of each cell line. 
 
 
 
Figure 6.4. Schematic representation of the CRISPR/Cas9 domain targeted 
approach against DDX3X.  
Upper panel: Schematic structure of DDX3X indicating protein functional 
domains (adapted from [146]). Lower panel: Table shows amino acid regions of 
DDX3X targeted by the sgRNAs designed for CRISPR/Cas9 dropout approach.   
sgRNA target region
DDX3X DOMAIN amino acid coordinates
N-terminal domain 2-110 
ATP binding loop 135-166 
ATP binding and hydrolysis 195-232
RNA binding (on first helicase lobe) A 274-330 
RNA binding (on second helicase lobe) B 445-506 
RS-like (C-terminal) 582-632 
Valiente-Echeverría et al., Review In Medical Virology (2015)
A
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Figure 6.5. CRISPR/Cas9 targeting of functional domains of DDX3X in OCI-
AML2/Cas9 and OCI-AML3/Cas9 AML cell lines: BFP-positive cell population 
depletion. 
OCI-AML2/Cas9 and OCI-AML3/Cas9 cells were transduced with a lentivirus 
expressing DDX3X exon 2 and 3, N-terminal domain#1, #2, ATP binding loop#1, 
#2, ATP hydrolysis site #1, #2, RNA binding domain A#1, #2 and B #1, #2, RS-
like C terminal domain #1, #2 and AURKB #1, #2 specific sgRNAs. Each sgRNA 
plasmid expresses a BFP marker and puromycin resistance cassette. All panels 
show the ratio between the percentage of BFP positive cells at each time point 
and the percentage of BFP positive cells at day 4 (the measurement starting time 
point) for both OCI-AML2/Cas9 and OCI-AML3/Cas9 cells infected with the 
indicated sgRNA construct or empty vector. 
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Figure 6.6. CRISPR/Cas9 targeting of functional domains of DDX3X in OCI-
AML2/Cas9 and OCI-AML3/Cas9 AML cell lines:  fold depletion. 
 (A-B) The panels show the fold depletion of BFP-positive cells over the entire 
duration of the experiment, i.e. the ratio of percentage of BFP positive cells 
observed at the starting time point (day4) over the percentage of BFP positive 
cells observed at the last time point (day 12) for both OCI-AML3/Cas9 (A) and 
OCI-AML2/Cas9 (B) cells infected with the indicated sgRNA construct or empty 
vector. (C) Western blot shows the protein levels of DDX3X and GAPDH in OCI-
AML3/Cas9 cells (left panel) and OCI-AML2/Cas9 cells (right panel) infected 
with either empty vector, DDX3X exon 2 or DDX3X exon 3 specific sgRNA 
constructs for CRISPR/Cas9. Cells were harvested 4 days after selection in 1 
µg/ml puromycin (6 days after infection). 
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6.5 Targeting the DDX3X gene sequence encoding the RNA binding 
domain reduces proliferation of OCI-AML3 cells and induces G1 
cell cycle arrest 
Based on the previous results from the domain targeted CRISPR/Cas9 
approach against DDX3X in OCI-AML3/Cas9 and OCI-AML2/Cas9 cells, I 
next characterized the effect of targeting the gene sequences encoding the 
two regions of DDX3X's RNA binding domain on OCI-AML3/Cas9 and 
OCI-AML2/Cas9 cell proliferation. Each cell line was infected in triplicate 
with lentiviral particles bearing the relevant sgRNA, or the empty vector, 
and cells were monitored over time via flow cytometric analysis to 
measure out-competition of the BFP negative (non-infected) cells over the 
BFP positive (infected) cells. I used one sgRNA to target each of the two 
portions of DDX3X RNA binding domain (A and B) and one sgRNA to 
target the essential gene AURKB. 
 
The results I previously obtained from targeting the same sequences were 
initially replicated in both cell lines using just one sgRNA per domain ( 
Figure 6.7A-D). In fact, in OCI-AML3/Cas9 BFP-positive cell depletions 
were 3.5, 3.6 and 2 fold when targeting gene sequences encoding the two 
regions (A and B) of the DDX3X RNA binding domain and the AURKB 
gene, respectively (Figure 6.7 B). Again, no depletion of BFP positive cells 
was observed when targeting the same sequences of DDX3X in OCI-
AML2/Cas9 cells, whereas a 1.6 fold depletion was obtained when 
targeting the AURKB gene (Figure 6.7 D).  
 
Representative images from a flow cytometric analysis of targeted cells (as 
described in Figure 6.7) show the percentage of BFP-positive cells under 
all conditions at 4, 8 and 12 days after infection of OCI-AML3/Cas9 cells 
(Figure 6.8) and OCI-AML2/Cas9 cells (Figure 6.9). Targeting DDX3X's 
RNA binding domain encoding sequences induced a rapid decrease in the 
percentage of OCI-AML3/Cas9 BFP-positive cells over time, whereas the 
percentage of OCI-AML2/Cas9 BFP-positive cells remained constant.    
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Next, the OCI-AML3/Cas9 and OCI-AML2/Cas9 cells described above 
were selected in puromycin to isolate the BFP-positive population. 
Proliferation rates of these cells were then assessed (Figure 6.10A-B). 
Targeting DDX3X RNA binding domain (A and B) encoding sequences in 
OCI-AML3/Cas9 cells significantly reduced their proliferation to a level 
comparable to targeting the essential gene AURKB (Figure 6.10A). 
Specifically, at the last time point (day 6), the number of OCI-AML3/Cas9 
cells in which RNA binding domain portions A and B had been targeted 
was on average about 35% less than the number of OCI-AML3/Cas9 cells 
infected with empty vector. AURKB targeted OCI-AML3/Cas9 cells grew 
about 30% less than OCI-AML3/Cas9 cells infected with empty vector, at 
the same time point (Figure 6.10A). 
 
Conversely, OCI-AML2/Cas9 cells showed no reduced proliferation when 
DDX3X RNA binding domain (portions A or B) encoding sequences were 
targeted (Figure 6.10B). In contrast, when the AURKB gene was targeted, 
the number of cells was reduced by about 45% at the last time point (day 
6) compared to OCI-AML2/Cas9 cells infected with empty vector (Figure 
6.10B).  
 
Since DDX3X knock down caused a cell cycle defect in MCF7 cells (Section 
5.4), I performed a cell cycle analysis of OCI-AML2/Cas9 and OCI-
AML3/Cas9 cells in which DDX3X RNA binding domain encoding 
sequences were targeted. BFP positive cell populations were selected in 
puromycin two days after infection, and grown in selection media for 6 
additional days. Then, cells were treated overnight with 50 ng/ml 
nocodazole and tested the next day by propidium iodide staining in a flow 
cytometric analysis (Figure 6.11). 
 
Targeting DDX3X RNA binding domains caused a dramatic increase of 
cells arrested in G1 phase in OCI-AML3/Cas9 cells compared to cells 
infected with empty vector (Figure 6.11A). Conversely, DDX3X RNA 
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binding domains targeted OCI-AML2/Cas9 cells did not show any 
consistent defect in cell cycle progression, compared to cells infected with 
empty vector (Figure 6.11A). Representative images of the propidium 
iodide staining-based flow cytometric analysis of data quantified in Figure 
6.11 are shown in Figure 6.11B-C. When targeting DDX3X RNA binding 
domain (A and B) encoding sequences, the percentage of OCI-AML3/Cas9 
cells in G1 phase was increased compared to cells infected with empty 
vector (Figure 6.11B). Conversely, the percentage of OCI-AML2/Cas9 cells 
in G1 phase remained unchanged compared to cells infected with empty 
vector (Figure 6.9C). 
 
 
 
Figure 6.7. Validation of the effect of CRISPR/Cas9 targeting of DDX3X RNA 
binding domain in OCI-AML2/Cas9 and OCI-AML3/Cas9 cells. 
(A and D) OCI-AML3/Cas9 (A and B) and OCI-AML2/Cas9 (C and D) cells were 
infected with DDX3X RNA binding domain A and B, AURKB specific sgRNAs or 
empty vector. (A-C) The ratio between the percentage of BFP positive cells at 
each time point and the percentage of BFP positive cells at day 2 (the 
measurement starting time point) was determined. (B and D) Fold depletion of 
BFP-positive cells over the entire experimental duration, i.e. the ratio of 
percentage of BFP positive cells observed at the starting time point (day 2) over 
the percentage of BFP positive cells observed at the last time point (day 16) is 
plotted. All conditions were produced in three biological replicates. Error bars 
indicate standard deviation. P-values represent statistical significance calculated 
with unpaired t test compared to empty control (P-values: ns. > 0.05; * ≤ 0.05; ** 
≤ 0.01; *** ≤ 0.001;**** ≤ 0.0001).  
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Figure 6.8. Flow Jo charts of OCI-AML3/Cas9 cells used in Figure 6.7A-B 
 
 
Figure 6.9. Flow Jo charts of OCI-AML2/Cas9 cells used in Figure 6.7C-D 
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Figure 6.10. Disrupting DDX3X RNA binding domain reduces proliferation of 
OCI-AML3/Cas9 but not OCI-AML2/Cas9 cells.  
Shown is the proliferation curve of OCI-AML3/Cas9 (A) and OCI-AML2/Cas9 (B) 
cells infected with DDX3X RNA binding domain A and B, AURKB specific 
sgRNAs or empty vector. Cells were selected in 1ug/ml puromycin from day 2 
after infection for 4 days and then seeded for proliferation assay (see Section 
2.8.2). Cells were counted at the indicated time-points after infection (red box). 
Result represents the average of three biological replicates. Error bars indicate 
standard deviation. P-values represent statistical significance calculated with 
unpaired t test compared to empty control (P-values: ns. > 0.05; * ≤ 0.05; ** ≤ 
0.01; *** ≤ 0.001;**** ≤ 0.0001). 
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Figure 6.11. Disrupting DDX3X RNA binding domains results in G1 cell cycle 
arrest of OCI-AML3/Cas9 but not OCI-AML2/Cas9 cells. 
Shown is the cell cycle progression flow cytometric analysis based on PI staining 
in OCI-AML3/Cas9 and OCI-AML2/Cas9 cells infected with DDX3X RNA binding 
domain A and B, AURKB specific sgRNAs or empty vector. Cells were selected in 
1ug/ml puromycin from day 2 after infection for 6 days and then seeded for cell 
cycle analysis. Cells were treated overnight with 50ng/ml nocodazole overnight 
and harvested the next day for cell cycle analysis (day 8 after infection). (A) 
Shown is the fold change quantification per each phase (G1-S-G2M): values were 
normalized to empty vector value for both OCI-ALM3/Cas9 and OCI-ALM2/Cas9 
OCI-AML3/Cas9 DDX3X sgRNA
RNA binding domain A
DDX3X sgRNA
RNA binding domain BEmpty Vector sgRNA AURKB
B
OCI-AML2/Cas9 DDX3X sgRNA
RNA binding domain A
DDX3X sgRNA
RNA binding domain BEmpty Vector sgRNA AURKB
C
 188 
cells. Results represent the average of three biological replicates. Error bars 
indicate standard deviation. P-values represent statistical significance calculated 
with unpaired t test compared to empty control (P-values: ns. > 0.05; * ≤ 0.05; ** 
≤ 0.01; *** ≤ 0.001;**** ≤ 0.0001). (B-C) Flow Jo charts for OCI-ALM3/Cas9 (B) 
and OCI-AML2/Cas9 (C) cells referred to experiment in A. 
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6.6 Gene expression changes upon disrupting DDX3X RNA binding 
domain in OCI-AML2 and OCI-AML3 cells 
I next investigated the differential gene expression in OCI-AML2 and 
OCI-AML3 cells when the DDX3X RNA binding domain (A and B) was 
targeted by CRISPR/Cas9. Targeting of DDX3X RNA binding domain 
encoding sequences in OCI-AML2/Cas9 and OCI-AML3/Cas9 cells was 
performed as previously described (Section 6.5) and cells were harvested 8 
days after infection (day 6 after selection in puromycin), which 
corresponded to the highest BFP depletion observed in OCI-AML3/Cas9 
cells (Figure 6.7).  RNA was isolated from cells and used for Illumina 
RNA-seq library preparation (Section 2.11- Appendix Figure 7A-B). 
A DAVID GO term analysis was obtained with the common differentially 
expressed genes resulting from targeting both portions (A and B) of the 
DDX3X RNA binding domain in either cell lines. Gene ontology of down-
regulated genes (Figure 6.12) shows enrichment for nucleosome and 
ribosome related terms in OCI-AML3/Cas9 cells. No significant GO terms 
for down-regulated genes were observed in OCI-AML2/Cas9 cells 
(Appendix Figure 7C), consistent with absence of phenotype shown by 
these cells when DDX3X's RNA binding domain was targeted (Figure 6.10, 
Figure 6.11).  
Interestingly, similar terms were observed for down-regulated genes upon 
DDX3X knock down in MCF7 cells (Figure 5.3). 
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Figure 6.12. Gene expression changes in OCI-AML3/Cas9 cells upon targeting of 
the DDX3X RNA binding domain. 
(A-B) Down-regulated genes in OCI-AML3/Cas9 cells upon targeting of DDX3X 
RNA binding domain were identified as described (Section 2.11.2) from RNAseq 
data (Section 2.11.1). 
The GO enrichment of down-regulated genes was obtained using the DAVID 
functional annotation tool with default settings [PMID: 19131956]. The p-values 
were calculated using the “default” method of DAVID. X-axis shows the GO 
terms related to biological processes (A) or cellular components (B). Y-axis shows 
–log10 p-values of each GO term. 
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6.7 Discussion 
The results of this chapter present evidence, for the first time, of a role for 
DDX54 and DDX3X in AML cells and they highlight a potentially critical 
role for DDX3X RNA binding activity in a particular subtype of AML, 
namely OCI-AML3 cells 
 
6.7.1 AML cells are sensitive to the catalytic disruption of DDX54 and 
DDX3X 
Although preliminary and requiring further replication, results from my 
validation of the two previously performed CRISPR/Cas9 dropout screens 
in both mouse and human cells, confirmed sensitivity of the leukaemia cell 
lines tested, to the catalytic impairment of the two DEAD box RNA 
helicases DDX54 and DDX3X. Specifically, catalytic targeting of both 
proteins resulted in a dramatic depletion of targeted mouse MLL-
AF9/Cas9 cells, but this was not observed in targeted mouse NIH-
3T3/Cas9 fibroblasts. These results indicate that the negative effect of 
targeting Ddx54 and Ddx3x is not due to a general lethality effect and that 
the function of these two proteins could be essential for maintenance of 
the leukaemia phenotype, whereas their functions may be dispensable in 
non-cancer cells, at least in mouse.  
The data from the dropout screens performed by Tzelepis et al. [235] 
suggested a generally lethal effect of knocking out DDX54 in all cancer cell 
lines tested (Figure 6.3). This observation is to some extent consistent 
with what I observed in the mouse AML cells screen. In fact, although the 
targeting of this protein was not lethal in my validation of the screen in 
mouse NIH-3T3 fibroblasts, the CRISPR score obtained for DDX54 was 
considerably above the maximum theoretical score of 50 (Figure 6.1), 
beyond which CRIPSR score values indicate essential gene functions 
considered not specific to the cell line tested. Overall, these findings 
suggest that the role of DDX54 might be generally essential in many 
human cancer cell types.  
 192 
In contrast to DDX54, targeting DDX3X revealed a selective sensitivity 
exhibited by only a subset of cancer cell lines. This prompted me to 
validate the effect of targeting different functional domains of this protein. 
 
6.7.2 Targeting the DDX3X RNA binding domain impairs growth and cell 
cycle progression of OCI-AML3 but not OCI-AML2 AML cells 
Evidence from the domain targeted CRISPR/Cas9 dropout screen I 
performed suggested that OCI-AML3 cells are specifically sensitive to loss 
of the RNA binding function of DDX3X more than loss of its enzymatic 
activity. This result, whilst confirming domain targeted CRISPR/Cas9 
approaches as valid tools to select functionally important protein domains, 
further suggests that the ability of DDX3X to recognize specific RNAs may 
be more important for viability of specific cells than its ability to resolve 
double stranded structures within target RNAs. Furthermore, numerous 
studies have proposed that the hydrolysis activity of DDX proteins may be 
dispensable from their main biological function (Section 1.3). This would 
be consistent with my results obtained using sgRNAs versus DDX3X ATP 
binding loop and ATP hydrolysis site encoding sequences, which caused 
milder depletion of targeted OCI-AML3 cells. 
The differences observed when results from the domain targeted screen in 
OCI-AML2 and OCI-AML3 cell lines are compared, may reflect the 
differential importance of the various functional domains of DDX3X in 
different cell lines. DDX3X may be part of specific protein complexes in 
OCI-AML3 cells distinct from the ones formed in OCI-AML2 cells, which 
could determine its RNA binding selectivity. 
 
Importantly, targeting the RS-like C terminal domain of DDX3X, caused 
mild but similar sensitivity of the growth of both OCI-AML2 and OCI-
AML3 cells. This motif is rich in arginine and serine residues often found 
in SR splicing factors (Section 1.2). Together with the observation that 
many DDX3X iCLIP target RNAs in MCF7 cells were found to contain a 
DDX3X binding motif with homology to the binding motif of splicing 
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factors SRSF1 and SRSF2 (Figure 4.11B), one speculation would be that 
DDX3X may have a splicing function that is required in all cells to some 
extent.   
  
Impairment of DDX3X function in MCF7 cells through transient knock-
down caused reduced proliferation and a G1 cell cycle arrest (Section 5.4). 
Importantly, a very similar phenotype was observed in OCI-AML3 cells 
when DDX3X RNA binding domain encoding regions were targeted by 
CRISPR/Cas9. This result suggests that DDX3X may function as a cell 
cycle regulator in different cancer cells and this role directly involves 
DDX3X RNA binding activity. Although I haven’t investigated the binding 
specificity of DDX3X in OCI-AML3 cells, it seems plausible that inhibiting 
the function of DDX3X in different cancer cell lines, such as breast cancer 
cells and leukaemia cells, leads to cell cycle effects as a consequence of 
secondary effects due to DDX3X directly affecting stabilization or 
translation of mRNAs encoding cell cycle master regulators (such as the 
case of KLF4 in MCF7 cells, Chapter 4).  
 
OCI-AML2 and OCI-AML3 cell lines are both AML cell lines with very 
different cytogenetic backgrounds. However, the main driver of the 
leukaemic phenotype in OCI-AML3 is known to be a type A mutation in 
the Nucleophosmin-1 gene (NPM1), which is not present in the OCI-AML2 
cell line. This mutation consists in a TCTG insertion within exon 12 of the 
NPM1 gene [263]. 
NPM1 is a predominantly nucleolar protein, which possesses structural 
domains allowing both cytoplasmic and nucleoplasmic localization. Under 
normal physiologic conditions, nuclear import predominates over export 
[264]. Translocation of NPM1 to the cytoplasm requires interaction of 
CRM1 and NPM1's nuclear export signal (NES) motifs [265]. Different 
functions of NPM1 have been described, including roles in ribosome 
biogenesis, maintenance of genomic stability and p53-dependent stress 
response [265]. 
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Insertions in exon 12 of the NPM1 gene are among the most common 
driver mutations in AML, found in 20–30% of cases, with type A being the 
most frequent insertion (~80% of cases on NPM1 insertions)[266].  
These mutations cause a frameshift in the C-terminus, which causes the 
generation of an additional NES motif. This results in stronger nuclear 
export than import, which eventually causes higher cytoplasmic 
localization of NPM1. The mutant form is therefore referred to as NPM1c. 
Although NPM1 mutations are always heterozygous, NPM1c can still 
homo-dimerize with wild-type NPM1 and recruit it to the cytoplasm [266]. 
Different mechanisms have been suggested to account for NPM1c driving 
AML. Firstly, reduced nuclear NPM1 causes genomic instability due to 
lack of NPM1-dependent control of centrosome duplication. Secondly, mis-
localization of NPM1c-interacting tumour suppressors (such as ARF) 
antagonizes cell-cycle arrest and apoptosis induction [264, 265]. However, 
transgenic mice studies indicate that NPM1c alone is insufficient to 
generate leukaemia, suggesting there may be a cooperative factor in 
NPM1c-driven AML [267]. 
 
Further studies are needed to investigate whether the presence of the 
NPM1 mutation is a determinant for the sensitivity of the OCI-AML3 cells 
to DDX3X functional knockout. Interestingly, the DDX3X RNA binding 
domain targeting caused down-regulation of nucleosome and ribosome 
related genes. This gene ontology overlaps with the one found for DDX3X 
knock down-dependent down-regulated genes in MCF7 cells (Figure 5.2). 
Moreover, it recalls two of the main functions of Nucleophosmin-1 such as 
nucleosome remodelling, by its histone chaperone activity, and 
involvement in ribosome biogenesis.   
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Chapter 7 - Discussion 
 
 
The aim of my thesis was to investigate the role of two members of the 
DDX RNA helicase family, DDX54 and DDX3X. Specifically, I set out to 
characterize the RNA binding properties of these proteins and to better 
understand their biological roles in two cancer model systems: MCF7 
breast cancer cells and OCI-AML3 AML cells. 
 
Very recently, DDX54 was reported to exert a splicing regulatory function 
in MCF7 cells exposed to DNA damage [183]. Upon exposure to ionising 
radiation, DDX54 relocates from nucleoli to the nucleoplasm where it 
binds pre-mRNAs. By performing PAR-CLIP, the authors reported that 
DDX54 binds mostly to intronic and exonic regions close to the 3¢-ends of 
transcripts. Moreover, gene ontology analysis for DDX54-bound introns 
included chromosome organization and cell cycle factors. Under conditions 
of DNA damage, DDX54 was shown to interact with members of the 
spliceosome (including U2AF1), to be required for expression and splicing 
of its bound DNA damage-responsive RNAs and for survival of MCF7 cells 
[183]. 
Overall, the above observations are in good agreement with the findings 
from my DDX54 iCLIP. Interestingly, amongst the nucleotide 8-mers 
bound by DDX54, I identified enrichment of a motif homologous to the 
recognition sequence of U2AF2 and U2AF50, two other members of the 
spliceosome complex (Figure 3.8C). This motif is also present within 
MTA3, one of the validated iCLIP targets of DDX54. Here, the motif is 
located within an intron close to an exon/intron boundary (Appendix 
Figure 8A). This suggests that DDX54 may have a general function in 
regulating splicing, not only restricted to DNA damage conditions. 
Unfortunately, I could not reproduce DDX54's co-repressive role in ERa-
dependent transcription, previously observed in MCF7 cells [180]. My 
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approach involved measuring the expression of ERa-dependent genes 
upon knock down of DDX54 and in the presence or absence of estrogen, via 
qPCR analysis of the resulting transcripts. Although, no DDX54 
dependent effect was observed, my methodology would not have measured 
post-transcriptional changes to the transcripts, such as alternative 
splicing. It remains possible therefore that DDX54 regulation of ERa-
dependent transcripts occurs, if at all, at this level. Consistent with this 
possibility, I did detect an interaction between DDX54 and ERa via 
immunoprecipitation.  Furthermore, my ChIP-seq analysis failed to detect 
co-localization of the two proteins on chromatin, suggesting they interact 
off chromatin, which is consistent with a post-transcriptional function of 
DDX54. 
 
If DDX54 acts as a general splicing factor, it is reasonable to think that its 
function is essential for cell survival. In support of this idea, knock down 
of DDX54 was lethal in most cell lines tested in this project (MCF7, 
MCF10A and MLL-AF9 mouse leukaemia cells), as well as in many cancer 
cell types screened using a CRISPR/Cas9 dropout approach [235] (Figure 
6.3). Although DDX54 catalytic knockout did not cause lethality in mouse 
fibroblasts, the results from Chapter 5 and those from Tzlepis et al, 
(Figure 6.3) strongly suggest the general essentiality of this protein at 
least in human cell lines. As shown, the biological function of DDX54 is 
ultimately due to its cell cycle regulation activity, at least in MCF7 breast 
cancer cells. 
 
As with DDX3X, the intersection of DDX54 iCLIP targets and DDX54 
knock down-induced gene expression changes, was extremely limited 
(Figure 5.8-Appendix Figure 5). This suggests that these two techniques 
provide very different information. Whereas direct biochemical function of 
RNA binding proteins may be inferred from iCLIP data, differential gene 
expression profiles likely highlight later, and therefore largely indirect 
effects due to depletion of the targeted protein.  
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One robust finding from my analyses is that DDX54 preferentially binds 
to introns. However, this is not in agreement with the strong association of 
DDX54 with NEAT1 lncRNA, which is an intron-less transcript. 
Nevertheless, most of the DDX54 binding motifs found within NEAT1 are 
AT/CT (i.e. AU/CU in RNA)-rich 8-mers (Appendix Figure 8B), which are 
similar to those found in intronic regions of other targets, which would 
suggest a sequence binding preference of DDX54. 
NEAT1 lncRNA is up-regulated upon DNA damage and then forms 
additional paraspeckle structures [268]. Although my DDX54 iCLIP 
profile identified many binding sites within NEAT1 lncRNA, and the 
binding was validated by CLIP-qPCR, I did not observe co-localization of 
DDX54 and NEAT1 lncRNA in paraspeckles in MCF7 cells. Since both 
DDX54 and NEAT1 lncRNA respond to DNA damage caused by different 
sources [183] [269], one explanation for this somewhat contradictory result 
may be linked to the fact that iCLIP and CLIP-qPCR both rely on UV 
irradiation of cells [270].  It is speculative but possible that the DNA 
damage response is triggered in cells exposed to UV light and that this 
induces both NEAT1 lncRNA up-regulation and DDX54 relocation to the 
nucleoplasm, where the interaction occurs. Nevertheless, since it was 
shown that that exposure to UV radiation did not cause increase in H2AX 
phosphorylation in MCF7 cells and therefore does not induce DNA 
damage [183], this possibility is virtually unlikely. 
Other speculations concerning the nuclear activity of DDX54 stem from its 
preferential binding to A-rich triplets and localization at the 3¢ end of 
transcripts.  DDX54 A-rich target sites are located in introns more than in 
3’-UTRs. Therefore, DDX54 could potentially be involved in 
polyadenylation steps as well as in RNA editing steps, for instance in the 
unwinding of the dsRNA, coordinating the action of ADAR proteins 
(Section 1.1.1). As a future perspective, it would be interesting to 
investigate these hypotheses and to clarify the molecular mechanism 
underlying the cell cycle defect observed upon DDX54 knock down.   
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One striking result from my work was the strong overlap of genes down-
regulated by both DDX54 and DDX3X knock down in MCF7 cells. This 
suggests that these two proteins function in very similar pathways. 
However, DDX54 is a nuclear enzyme whereas DDX3X is predominantly 
cytoplasmic in most cell lines tested, making it difficult to understand how 
their activities could be so redundant. It is possible that the nuclear 
fraction of DDX3X exerts much of its biological function. Nevertheless, the 
reason for such a strong overlap in common gene expression changes upon 
knockdown of either helicases remains elusive. 
However, most published evidence so far, has linked DDX3X to 
cytoplasmic RNA processes (Section 1.5). Results from my studies tend to 
confirm this view (Chapter 4). I showed that DDX3X is required for 
maintaining the levels of proteins encoded by validated bound mRNAs 
(Figure 4.6) which could corroborate the hypothesis of a major cytoplasmic 
function in either counteracting degradation or favouring translation. In 
my results, DDX3X is enriched at both 5¢ and 3¢ ends of mRNAs (Figure 
4.2). Taking into account the circularization of mRNAs occurring during 
translation by the interaction of poly-A tails- and cap- binding factors 
(Section 1.1.3), this observation could indicate a role for DDX3X in 
translation. In fact, DDX3X could be relevant for the bridging of 5¢cap- and 
poly A tails- associated factors and therefore for the stability of mRNAs 
during translation. 
A recently published CLIP profile identified binding of DDX3X to exonic 
regions of translation factors mRNAs, in agreement with my findings 
[203]. This work suggested a global role for DDX3X in regulating  
translation, mainly through recruitment of bound mRNAs into stress 
granules [203]. In contrast, my data show evidence for an effect of DDX3X 
activity on the levels of proteins encoded by specific mRNAs. Notably, 
DDX3X specifically binds to the JUND transcript and knockdown of the 
helicase leads to lower levels of JUND mRNA and protein. I identified a 
specific sequence within the JUND transcript to which DDX3X binds. This 
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was confirmed by EMSA experiments and the sequence represents the 
first validated DDX3X specific RNA binding sequence. 
JUND is a member of the AP-1 family of dimeric transcription factors 
which can either activate or repress gene expression. Whereas other 
members of the AP-1 family have mainly oncogenic roles, JUND is 
generally associated with negative regulation of cell proliferation and 
positive regulation of cell differentiation [271]. Nevertheless, it was 
recently shown to be required for proliferation of prostate cancer cells 
[272]. The ultimate role of JUND seems to be highly dependent on the cell 
context as well as on the identity of its dimerization partner in the AP-1 
dimer [273] 
Interestingly, JUND expression has been shown to be regulated post 
transcriptionally: the binding of the DEAH-BOX helicase 9 (DHX9 or 
RHA) to JUND mRNA’s 5’UTR is required for its efficient translation 
[247]. It will be interesting to investigate the biological significance of 
DDX3X binding to its specific recognition motif on the JUND mRNA 
sequence. In fact, it remains to be evaluated whether DDX3X affects 
JUND levels via its binding motif and whether the expression of JUND 
downstream DDX3X is relevant to cell survival. 
Interestingly, the same motif found and validated in the JUND mRNA 
sequence was also found in RPS2 mRNA. Amongst the validated 
ribosomal proteins (RPs) iCLIP targets, RPS2 displayed the highest 
sensitivity to DDX3X levels. In fact, RPS2 protein was almost completely 
depleted upon DDX3X knock down, whereas RPS6 and RPS3 protein 
levels showed little or no reduction, respectively. Notably, these RPs, 
displaying differential sensitivity to DDX3X depletion, harbour distinct 
DDX3X binding motifs within their sequences. Moreover, through 
structural prediction analysis, I found evidence supporting DDX3X 
binding to similar stem loop structures on RPS2, RPS3 and JUND 
mRNAs. These results suggest that DDX3X binding to RPS2, RPS3 and 
JUND mRNAs requires a region extended over the single strand and the 
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double strand portions of a stem loop. Although based on structural 
predictions, this finding represents a validation from in vivo data of the 
DDX proteins loading mechanism on RNA targets previously reported in 
vitro (Section 1.3). Moreover, it suggests that the structure of the binding 
site may be a direct element for recognition by DDX3X. Instead, the 
sequence of the binding motif may be more relevant for the functional 
consequences of DDX3X binding, perhaps by recruiting motif-specific 
effector proteins. 
It is also possible that the mutation in the JUND probe tested in EMSA, 
disrupts the secondary structures necessary for DDX3X and DDX3X–
containing complexes binding to the RNA in vitro. 
 
Previous reports [96], as well as my iCLIP GO terms, have linked DDX3X 
activity to the mTOR pathway.  Interestingly, I observed that the protein 
levels of RPS2, RPS3 and DDX3X itself were reduced upon rapamycin 
dependent mTOR inhibition. This suggests that rapamycin is acting on 
the translation level of these proteins in a DDX3X-independent way. 
Nevertheless, under this growth inhibitory condition, the binding of 
DDX3X to its target mRNAs remained relatively constant. One 
speculation about the functional role of DDX3X binding in conditions of 
growth arrest and translational inhibition such as the ones caused by 
rapamycin, is that the helicase may have a protective role against 
degradation of mRNAs that encode factors essential for cell growth. 
 
The overall biological function of the binding features of DDX3X was not 
immediately evident from the sole analysis of iCLIP data, therefore I also 
evaluated gene expression as well as the cells growth parameters changes 
caused by depletion of DDX3X in cells. Knock-down of DDX3X in MCF7 
cells caused a general reduction of proliferation due to a cell cycle arrest in 
G1. Interestingly, the same phenotype was also observed in OCI-AML3 
leukaemia cells in which the RNA binding activity of DDX3X had been 
disrupted using a CRISPR/Cas9 approach. This result suggests that 
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DDX3X could have a general biological function which is not specific to 
one type of cancer. This was further corroborated by the fact that, in the 
absence of a functional DDX3X RNA binding domain in OCI-AML3 cells, 
many nucleosome-related genes were down-regulated, which was a gene 
expression changes signature very similar to the one observed in MCF7 
cells depleted of DDX3X (Figure 5.4; Figure 6.12). 
In MCF7 cells, the expression of cell cycle regulated genes involved in 
replication and onset of S phase, such as CCNA2 and CDK2 [254], were 
reduced by DDX3X knock down. These findings were surprising because 
none of them were identified in the DDX3X iCLIP dataset (Figure 5.8). On 
the other hand, gene ontology analysis of genes up-regulated by DDX3X 
knock-down mainly highlighted terms related to metabolic processes 
(Appendix Figure 4). Nevertheless, one of the very few targets resulting 
from the overlap of DDX3X iCLIP targets and up-regulated genes upon 
DDX3X knock down was the transcription factor and negative regulator of 
cell cycle, KLF4. 
Further studies are needed to clarify the pathway of cell cycle regulation 
involving DDX3X and KLF4. The fact the DDX3X RNA level does not 
change upon KLF4 knock down, suggests DDX3X may be effectively 
upstream of KLF4 regulation in the proposed pathway. The hypothesised 
model therefore suggests that DDX3X is a key factor in repression of 
KLF4 mRNA and protein, at least in cancer cells, thereby hindering 
transcriptional activation of key cell cycle genes (CCNA2 and CDK2), 
which lie downstream of KLF4. Direct transcriptional regulation of KLF4 
on these genes needs now to be confirmed. The mechanism of DDX3X-
mediated repression of KLF4 has to be clarified. DDX3X may act directly 
on the KLF4 gene to repress its expression. However, this scenario is 
unlikely because of no evidence of DDX3X chromatin binding in my ChIP-
seq data set (data not shown; raw data in Appendix Figure 2). Other 
possibilities concern the destabilization of the mRNA or induction of its 
degradation. DDX3X may even negatively regulate splicing of KLF4 pre-
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mRNA, which would account for a nuclear post-transcriptional function of 
DDX3X distinct from its main cytoplasmic roles reported so far. 
The multifunctional mechanisms by which DDX3X regulates the protein 
levels of its target mRNAs may be explained, at least in part, by the fact 
that DDX3X exists in distinct macromolecular complexes (Section 1.5). 
Interestingly, although it differentially regulates the levels of proteins 
translated from its bound mRNAs, DDX3X activity is consistent with an 
oncogenic function: it favours cellular proliferation by stimulating 
ribosome production (via RPs), and it promotes cell cycle progression by 
impairing expression of cell cycle negative regulators, such as KLF4. 
 
Overall, these observations corroborate the potential of DDX3X as a good 
candidate target for therapy development against certain cancers, 
although additional investigation is needed to understand its specific roles 
in different cell types. In this regard, a key novel finding of my thesis is 
the specificity of DDX3X oncogenic function in breast cancer cells 
compared to non-tumourigenic breast epithelial cells. This observation is 
particularly important when considering DDX3X as a target of onco-
therapeutic intervention. 
 
The essential role of DDX3X in AML cells is also a novel finding from my 
work. Indeed, the preliminary results obtained from studies of the two 
different leukaemia cells lines (OCI-AML2 and OCI-AML3) were 
particularly exciting. As with the breast cancer cell line data, these 
findings indicate a cell type-specific oncogenic role for DDX3X. 
Importantly, my work also identified a critical requirement for DDX3X's 
RNA binding activity, in addition to its ATPase activity, for sustained 
growth of leukaemic cells. This highlights DDX3X's RNA binding domains 
as potential therapeutically targetable regions, in addition to its 
enzymatic domain. 
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It remains to be determined why OCI-AML2 cells are insensitive to 
DDX3X functional knockout. Initially, it would be important to show that 
CRISPR targeting of the DDX3X locus occurred with equal efficiency in 
both cell lines. This will entail analysis of the CRISPR/Cas9 target 
sequences in the DDX3X locus in both cell lines in order to classify the 
percentage of indels induced by CRISPR/Cas9 and the number of in-frame 
or out-of-frame mutations occurring. 
 Since OCI-AML3 cells express a mutant version of the NPM1 gene that 
determines aberrant localization of NPM1 in the cytoplasm (NPM1c), it 
would be interesting to investigate a potential NPM1c-related function of 
DDX3X in these cells that could then be responsible for their sensitivity to 
DDX3X functional targeting. For example, it may be that DDX3X 
cooperates with NPM1c to maintain a leukaemogenic phenotype in OCI-
AML3.  Indeed, this is particularly intriguing since mouse studies have 
shown that NPM1c is an AML-driver mutation but it is not sufficient to 
generate leukaemia on its own [267]. 
Since DDX3X has been shown to interact with CRM1 [193], which is the 
factor that mediates NPM1 and NPM1c export from the nucleus, one 
hypothesis is that DDX3X is required for the export of NPM1c, and 
therefore is necessary for NPM1c oncogenic activity in OCI-AML3. The 
notion of a DDX3X/NPM1 interaction and re-localization of NPM1 upon 
DDX3X knockout remains to be tested. It will also be essential to 
determine where DDX3X is localized within the two cell lines. In fact, 
DDX3X could mediate the potential oncogenic functions of NPM1c in the 
nucleus and/or the cytoplasm.  
 
Overall, although leaving many open questions for experimental follow up, 
my results presented in this thesis have provided new insights into the 
mechanistic and biological functions of two members of the DDX family of 
RNA helicases. In particular, my observations highlight the relevance of 
DDX3X in the biology of a subset of cancer cells and underscore its 
importance as a potential therapeutic target. 
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Many DDX3 inhibitors have already been developed (Figure 7.1). These 
molecules are Ring expanded nucleoside (REN) analogues that mimic 
adenosine nucleosides and are designed to specifically target the ATP- 
binding cleft of DDX3 and impair the helicase activity [168]. 
Some of these compounds have been already tested for anticancer efficacy, 
such as the case of NZ-51. NZ-51 is a REN analogue that was found to 
inhibit viability and motility of breast cancer cells in vitro, but failed to 
show any efficacy in vivo [221].  
A more recent and most studied DDX3 inhibitor is the REN analogue RK-
33. RK-33 has shown specificity in binding DDX3 (whereas it did not bind 
other closely related DEAD-box RNA helicases) [216, 274] and to radio-
sensitize lung and prostate cancer cells. Importantly, mice treatment with 
RK-33 did not cause normal tissue toxicity [216, 275].  
Other DDX3 inhibitors have been produced and tested for antiviral 
therapy (specifically against HCV, HIV-1, West-Nile virus and dengue 
virus) [276-278] and could be evaluated for their anti-cancer potential. 
 
 
Figure 7.1 DDX3 inhibitors. 
The table summarizes the current knowledge about DDX3 inhibitors. Data were 
adapted from Marise R. Heerma van Voss et al., 2017 [168]. (REN analogs NZ51 
[221]; RK-33 [216, 218, 275]; NSC305787 [279]; Ketorolac salt [280]; Rhodanine 
and Triazine derivatives [277]; 16d [278]). 
Compound Mechanism Developmental 
status 
Results
REN analogs (NZ51) Target ATP-binding 
domain of DDX3
Tissue culture Reduces cancer cell 
viability and motility 
RK-33  Targets ATP-binding 
domain of DDX3 
Preclinical animal studies Causes radiosensitization
in several mouse models 
      and has single 
agent activity in a Ewing 
Sarcoma mouse model 
NSC305787 Inhibitor of the DDX3-
Ezrin interaction
Tissue culture Anti-cancer activity not 
tested 
Ketorolac salt 
(ZINC00011012) 
Targets ATP-binding 
domain of DDX3 
Preclinical animal studies Anticancer activity in a 
mouse oral squamous 
cell carcinoma model 
Rhodanine and Triazine
derivatives 
Target DDX3 ATP-binding 
domain 
Tissue culture In vitro anti-viral activity, 
anti-cancer efficacy not 
tested 
16d Inhibitor of RNA helicase 
activity 
Tissue culture in vitro anti-viral activity, 
anti-cancer efficacy not 
tested 
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7 Appendices 
 
 
 
Appendix Figure 1- DDX3X and DDX54 iCLIP in MCF7 cells :reads and quality 
control analysis.  
(A)Number of reads and proportion of reads following mapping and filtering of all 
biological replicates. (B) Quality Control: Principal Component Analysis of iCLIP 
biological replicates. Principal Component Analysis was done with the R function 
prcomp (with scale parameter set to true) on the transposed and log-transformed 
A
B
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matrix of normalised counts. The PCA biplot was realised with the R package 
"ggbiplot". 
 
 
iCLIP raw data are available at the following link 
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6230 
Username:Reviewer_E-MTAB-6230 
Password: edchpurB 
 
 
 
 
Appendix Figure 2-ERa, DDX3X, DDX54 and H3K4me3 ChIP-seq in MCF7 cells: 
reads. 
Number of reads and proportion of reads following mapping and filtering of all 
biological replicates. 
 
 
ChIP-seq raw data are available at the following link  
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6211 
Username:Reviewer_E-MTAB-6211 
Password: kk33morL 
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Appendix Figure 3- MCF7 RNA-seq upon DDX3X and DDX54 knock down: reads 
and quality control analysis. 
(A)Number of reads and proportion of reads following mapping and filtering of all 
biological replicates. (B) Quality Control: Principal Component Analysis of RNA-
seq biological replicates. Principal Component Analysis was done with the R 
function prcomp (with scale parameter set to true) on the transposed and log-
transformed matrix of normalised counts. The PCA biplot was realised with the 
R package "ggbiplot". 
 
RNA-seq raw data are available at the following link 
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6235 
Username:Reviewer_E-MTAB-6235 
Password: C73ooofp 
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Appendix Figure 4 Up-regulated genes in MCF7 cells upon DDX3X and DDX54 
knock down. 
Upregulated genes DAVID GO terms in MCF7 cells knockdown for DDX3X and 
DDX54. The GO enrichment of differentially expressed genes was obtained using 
the DAVID functional annotation tool with default settings [PMID: 19131956 ]. 
The p-values were calculated using the “default” method of DAVID. X-axis shows 
the GO terms related to cellular components. Y-axis shows –log10 p-values of 
each GO terms.  
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Appendix Figure 5 iCLIP-RNA-seq intersection for DDX54. 
Intersection of gene expression changes upon DDX54 knock down and DDX54 
iCLIP targets in MCF7 cells. 
Venn diagrams show the intersection between DDX54 iCLIP targets and genes 
upregulated (left) or downregulated (right) upon DDX54 knockdown detected in 
RNAseq.  
 
 
 
 
 
Appendix Figure 6- DDX3X binding motif on CDKN1A mRNA. 
Visualization of the USCS custom tracks for DDX3X iCLIP truncation sites and 
motif localization on CDKN1A (p21) sequence. 
 
 
 
 
 
 
 
DDX54 iCLIP
437
DDX54 RNA-seq
downregulated
195
2
DDX54 iCLIP
437
DDX54 RNA-seq
upregulated
8 62
 225 
 
 
C 
 
 
 
A
B
OCI-AML3OCI-AML2
 226 
Appendix Figure 7- OCI-AML2/OCI-AML3 RNAseq RNA-seq upon DDX3X RNA 
binding domain (A and B) disruption: reads, quality control analysis and gene 
expression changes. 
(A)Number of reads and proportion of reads following mapping and filtering of all 
biological replicates. (B) Quality Control: Principal Component Analysis. 
Principal Component Analysis was done with the R function prcomp (with scale 
parameter set to true) on the transposed and log-transformed matrix of 
normalised counts. The PCA biplot was realised with the R package "ggbiplot". 
(C) Venn diagrams sowing up- and down- regulated genes upon CRISPR/Cas9-
mediated targeting of RNA binding domain A (RBDA) and B (RBDB) of DDX3X 
in either OCI-AML2 or OCI-AML3 cells. 
 
 
RNA-seq raw data are available at the following link 
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6241 
Username:Reviewer_E-MTAB-6241 
Password: qqsrrhic 
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Appendix Figure 8-DDX54 binding motifs on MTA3 mRNA and NEAT1 lncRNA. 
A.Visualization of the USCS custom tracks for DDX54 iCLIP truncation sites and 
motif localization on MTA3 (p21) sequence. Density plot of the motifs localisation 
within a scaled gene body. The scaled gene body represents three indicative 
regions: 5’-end, middle, and 3’-end. Y axis indicates the frequency (actual count) 
of the motif; X axis = scaled gene body localization. Consensus motifs for the 
clustered 8-mer(s) in each phylogenetic group were found with MATLAB function 
seqlogo (Section 2.13.5). The sequence logo of the phylogenetic group consensus 
motif is shown (Y axis = Bits; X axis =sequence position).  The motif is matched 
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to known RNA binding motif. Table shows the known RNA binding proteins that 
recognize a similar sequence motif and relative p-values.  (B). Visualization of the 
USCS custom tracks for DDX54 iCLIP truncation sites and motif localization on 
NEAT1 lncRNA sequence. 
 
 
